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Background: Whole-body magnetic resonance imaging is advocated as an alternative to standard
pathways for staging cancer.
Objectives: The objectives were to compare diagnostic accuracy, efficiency, patient acceptability, observer
variability and cost-effectiveness of whole-body magnetic resonance imaging and standard pathways in
staging newly diagnosed non-small-cell lung cancer (Streamline L) and colorectal cancer (Streamline C).
Design: The design was a prospective multicentre cohort study.
Setting: The setting was 16 NHS hospitals.
Participants: Consecutive patients aged ≥ 18 years with histologically proven or suspected colorectal
(Streamline C) or non-small-cell lung cancer (Streamline L).
Interventions: Whole-body magnetic resonance imaging. Standard staging investigations (e.g. computed
tomography and positron emission tomography–computed tomography).
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Reference standard: Consensus panel decision using 12-month follow-up data.
Main outcome measures: The primary outcome was per-patient sensitivity difference between
whole-body magnetic resonance imaging and standard staging pathways for metastasis. Secondary
outcomes included differences in specificity, the nature of the first major treatment decision, time and
number of tests to complete staging, patient experience and cost-effectiveness.
Results: Streamline C – 299 participants were included. Per-patient sensitivity for metastatic disease
was 67% (95% confidence interval 56% to 78%) and 63% (95% confidence interval 51% to 74%) for
whole-body magnetic resonance imaging and standard pathways, respectively, a difference in sensitivity
of 4% (95% confidence interval –5% to 13%; p = 0.51). Specificity was 95% (95% confidence interval
92% to 97%) and 93% (95% confidence interval 90% to 96%) respectively, a difference of 2%
(95% confidence interval –2% to 6%). Pathway treatment decisions agreed with the multidisciplinary team
treatment decision in 96% and 95% of cases, respectively, a difference of 1% (95% confidence interval
–2% to 4%). Time for staging was 8 days (95% confidence interval 6 to 9 days) and 13 days (95%
confidence interval 11 to 15 days) for whole-body magnetic resonance imaging and standard pathways,
respectively, a difference of 5 days (95% confidence interval 3 to 7 days). The whole-body magnetic
resonance imaging pathway was cheaper than the standard staging pathway: £216 (95% confidence
interval £211 to £221) versus £285 (95% confidence interval £260 to £310). Streamline L – 187 participants
were included. Per-patient sensitivity for metastatic disease was 50% (95% confidence interval 37% to
63%) and 54% (95% confidence interval 41% to 67%) for whole-body magnetic resonance imaging and
standard pathways, respectively, a difference in sensitivity of 4% (95% confidence interval –7% to 15%;
p = 0.73). Specificity was 93% (95% confidence interval 88% to 96%) and 95% (95% confidence interval
91% to 98%), respectively, a difference of 2% (95% confidence interval –2% to 7%). Pathway treatment
decisions agreed with the multidisciplinary team treatment decision in 98% and 99% of cases, respectively,
a difference of 1% (95% confidence interval –2% to 4%). Time for staging was 13 days (95% confidence
interval 12 to 14 days) and 19 days (95% confidence interval 17 to 21 days) for whole-body magnetic
resonance imaging and standard pathways, respectively, a difference of 6 days (95% confidence interval
4 to 8 days). The whole-body magnetic resonance imaging pathway was cheaper than the standard staging
pathway: £317 (95% confidence interval £273 to £361) versus £620 (95% confidence interval £574 to
£666). Participants generally found whole-body magnetic resonance imaging more burdensome than
standard imaging but most participants preferred the whole-body magnetic resonance imaging staging
pathway if it reduced time to staging and/or number of tests.
Limitations: Whole-body magnetic resonance imaging was interpreted by practitioners blinded to other
clinical data, which may not fully reflect how it is used in clinical practice.
Conclusions: In colorectal and non-small-cell lung cancer, the whole-body magnetic resonance imaging
staging pathway has similar accuracy to standard staging pathways, is generally preferred by patients,
improves staging efficiency and has lower staging costs. Future work should address the utility of
whole-body magnetic resonance imaging for treatment response assessment.
Trial registration: Current Controlled Trials ISRCTN43958015 and ISRCTN50436483.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 23, No. 66. See the NIHR Journals Library website
for further project information.
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Plain English summary
Colorectal and lung cancer are the leading causes of cancer-related deaths in the UK. Optimal treatmentdepends on accurately defining (or ‘staging’) the extent of disease, particularly if it has spread to other
parts of the body such as the liver. Current staging pathways are complex and rely on a variety of tests
that use X-rays, such as computed tomography and positron emission tomography–computed tomography
scans. Patients often undergo multiple tests before starting treatment. Alternatively, it is possible to scan
the whole body using magnetic resonance imaging without X-rays, and this may be more accurate and
reduce the time and number of tests needed before treatment can start. We compared the ability to
detect cancer spread, efficiency, patient experience and cost-effectiveness of staging based on whole-body
magnetic resonance imaging with the standard NHS pathways in participants newly diagnosed with either
lung (187 participants) or colorectal (299 participants) cancer. We found that the whole-body magnetic
resonance imaging pathway was as accurate as standard staging pathways and resulted in very similar
treatment decisions made by the clinical teams. The whole-body magnetic resonance imaging pathway
detected 67% and 50% of participants with cancer spread in colorectal and lung cancer, respectively,
compared with 63% and 54%, respectively, for standard staging. However, staging was quicker using
whole-body magnetic resonance imaging (by 5 days for colorectal cancer and 6 days for lung cancer)
and needed on average one less test to stage colorectal cancer. The whole-body magnetic resonance
imaging pathway was also cheaper (costing on average £216 and £317 for colorectal and lung cancer,
respectively, compared with £285 and £620, respectively, for standard pathways). Participants generally
found whole-body magnetic resonance imaging more burdensome than standard imaging but most
preferred the whole-body magnetic resonance imaging pathway if it reduced the time to staging and/or
the number of tests. Agreement between different radiology doctors interpreting the same whole-body
magnetic resonance imaging scan was moderate for colon cancer and low for lung cancer, emphasising
the need for training.
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Scientific summary
Background
Colorectal and lung cancer are the leading causes of cancer-related deaths in the UK. Accurate staging
is fundamental to the treatment and, in particular, the detection of metastatic disease. Cross-sectional
imaging forms the bedrock of cancer staging in the NHS, notably computed tomography, positron emission
tomography and magnetic resonance imaging. Ultrasonography, plain radiography and scintigraphy are also
widely used. For both cancers, the National Institute for Health and Care Excellence provides guidance on
staging pathways, detailing the sequential deployment of various tests before staging is deemed complete
and treatment can begin. This stepwise deployment of cross-sectional imaging is resource intensive, exposes
patients to ionising radiation and increases their anxiety. Whole-body magnetic resonance imaging has
been proposed as an alternative to multimodality staging pathways and can image the body in 1 hour or
less using magnetic resonance imaging scanners available throughout the NHS. It does not impart ionising
radiation and could reduce the time and number of tests required before staging is complete and treatment
can begin. Meta-analyses suggest that whole-body magnetic resonance imaging is equivalent to or may
surpass the accuracy of standard tests for metastatic disease detection, although the primary literature is
of questionable quality and prospective multicentre comparative data are lacking. High-quality evidence is
needed to guide implementation.
Objectives
The primary objective of the Streamline trials was to compare the per-patient diagnostic accuracy for
metastatic disease of staging pathways utilising initial whole-body magnetic resonance imaging (whole-body
magnetic resonance imaging staging pathway) with those following current National Institute for Health
and Care Excellence recommendations (standard pathway). We conducted two parallel but separate trials in
colorectal cancer (Streamline C) and non-small-cell lung cancer (Streamline L). Additional objectives were a
comparison between alternative pathways for the time and number of tests taken before staging completion
and the nature of the first major treatment decision, accuracy for local tumour staging, cost-effectiveness,
patient experience, interobserver variability of whole-body magnetic resonance imaging interpretation and
diagnostic accuracy of time-efficient whole-body magnetic resonance imaging sequence protocols.
Design
We performed two parallel multicentre prospective cohort trials (Streamline C and Streamline L). For both
trials, participants were recruited from 16 representative NHS teaching and general hospitals in England.
Patients were eligible for Streamline C if they had histologically proven or suspected colorectal cancer
(defined as a mass highly suspicious for cancer on endoscopy or imaging) and were referred for staging
investigations. Polyp cancers were excluded. Patients were eligible for Streamline L if they had histologically
proven non-small-cell lung cancer or this was suspected on chest computed tomography with sufficient
confidence to trigger staging investigations/biopsy and deemed radically treatable (stage IIIB or less). Patients
with unequivocal metastatic or N3 disease on diagnostic chest computed tomography were excluded.
For both trials, patients were excluded if they were aged < 18 years, were pregnant or had contraindications
to magnetic resonance imaging or if the final diagnosis was not lung or colorectal cancer as appropriate.
Consecutive (i.e. unselected) patients underwent whole-body magnetic resonance imaging (including
T1-weighted imaging pre and post gadolinium enhancement and T2- and diffusion-weighted imaging
sequences) in addition to all standard staging investigations. Standard investigations were interpreted
locally by the usual clinical care team blinded to the whole-body magnetic resonance imaging. Whole-body
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magnetic resonance imaging was interpreted by 19 (Streamline C) and 16 (Streamline L) radiologists
blinded to all standard staging investigations and clinical data other than the location of the primary
tumour. Radiologists recorded the local stage of the primary tumour together with the presence, organ
site and size of any metastatic deposits. The whole-body magnetic resonance imaging images and report
were withheld from the multidisciplinary team meeting until all standard investigations had completed such
that the first major treatment decision could be made (which was recorded). The whole-body magnetic
resonance imaging was then revealed to the multidisciplinary team, which stated if additional tests would
have been generated had it been the initial staging investigation. The multidisciplinary team then recorded
its treatment decision, based on the whole-body magnetic resonance imaging and the results of generated
additional tests (if any), the whole-body magnetic resonance imaging staging pathway, and the final
treatment decision based on all available tests. We used the construct reference standard paradigm
(multidisciplinary panel diagnosis). Participants’ clinical courses were followed for 12 months. For each
participant, the panel considered the results of all staging and follow-up imaging investigations and all
additional information including surgical findings, histopathology and clinical course. Based on all available
data, the panel adjudicated on the Tumour Node Metastasis Classification of Malignant Tumors stage
of the participant at the time of recruitment and indicated the optimal retrospective treatment decision.
For Streamline C, we estimated that a sample size of 290 participants would give 80% power to detect a
10% sensitivity difference between the whole-body magnetic resonance imaging pathway and standard
pathways, assuming a 40% prevalence of metastasis. For Streamline L we estimated that a sample size
of 200 participants would give 80% power to detect a 24% sensitivity difference between pathways,
assuming a 25% prevalence of metastasis. Binary comparisons (sensitivity, specificity, treatment decision
agreement) were calculated using paired proportions (population marginal). We calculated the time and
number of tests taken to complete staging for each pathway (by adding times for staging tests [from
request to performance] to median treatment decision multidisciplinary team wait times). The median
difference in time and number of staging tests between pathways was compared for each participant
with 95% confidence interval from 2.5 and 97.5 centiles of 1999 bootstrap samples with replacement.
We compared the nature of the first major treatment decision with that made by the multidisciplinary team
and also with the retrospective optimal treatment decision made by the consensus reference panel. We also
tested interobserver variability in whole-body magnetic resonance imaging interpretation and the impact of
whole-body magnetic resonance imaging sequences on radiologist accuracy (T1- and diffusion-weighted
sequences vs. T1-, diffusion- and T2-weighted sequences vs. T1-, diffusion- and T2-weighted sequences
and contrast-enhanced T1-weighted sequences), investigated participant experience staging pathways using
interviews, questionnaires and a discrete choice experiment, and performed a cost-effectiveness analysis.
Results
Streamline C
A total of 299 participants completed the trial; 68 (23%) had metastasis. The whole-body magnetic
resonance imaging pathway had 67% (95% confidence interval 56% to 78%) sensitivity for participants
with metastasis, not significantly different from standard pathways [63% (95% confidence interval 51% to
74%)], a 4% (95% confidence interval –5% to 13%; p = 0.508) difference in sensitivity. Specificity was not
significantly different [whole-body magnetic resonance imaging pathway 95% (95% confidence interval
92% to 97%) vs. standard pathways 93% (95% confidence interval 90% to 96%)]. The whole-body
magnetic resonance imaging staging pathway had 86% (95% confidence interval 74% to 94%) sensitivity
for participants in whom the largest metastasis was ≥ 1 cm in size, which was not significantly different
from that of standard staging pathways [82% (95% confidence interval 69% to 91%)]. As a stand-alone
investigation, whole-body magnetic resonance imaging had a comparable sensitivity of 70% (95%
confidence interval 59% to 80%) to the standard staging pathway, but a significantly lower specificity [86%
(95% confidence interval 81% to 90%) vs. 94% (95% confidence interval 90% to 96%), respectively].
The whole-body magnetic resonance imaging staging pathway had 54% agreement for T stage compared
with 60% for the standard pathway, a difference of 6% (95% confidence interval 0% to 12%). There was
no significant difference in agreement between the whole-body magnetic resonance imaging and standard
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pathways for N staging (58% vs. 56%, respectively), a difference of 2% (95% confidence interval –4% to
7%). Agreement with the final multidisciplinary team treatment decision was 96% and 95% for whole-body
magnetic resonance imaging and standard pathways, respectively, and 68% with the retrospective optimal
treatment decision for both pathways. Time to complete staging was significantly shorter for whole-body
magnetic resonance imaging [8 days (95% confidence interval 6 to 9 days) vs. 13 days (95% confidence
interval 11 to 15 days)], a 5-day (95% confidence interval 3- to 7-day) difference. Across the cohort, a total
of 558 and 320 investigations were performed as part of standard pathways and the whole-body magnetic
resonance imaging staging pathway, respectively (whole-body magnetic resonance imaging would have
generated an additional 21 tests). The median number of tests in the whole-body magnetic resonance imaging
pathway was significantly lower [1 test (95% confidence interval 1 to 1 test) vs. 2 tests (95% confidence interval
2 to 2 tests)], a difference of 1 test (95% confidence interval 1 to 1 test).
The mean test costs per participant (bootstrapped 95% confidence intervals) were £285 (95% confidence
interval £260 to £310) for standard pathways and £216 (95% confidence interval £211 to £221) for the
whole-body magnetic resonance imaging pathway.
Streamline L
A total of 187 participants completed the trial; 52 (28%) had metastasis. The whole-body magnetic resonance
imaging pathway had 50% (95% confidence interval 37% to 63%) sensitivity for participants with metastasis,
not significantly different from standard pathways [54% (95% confidence interval 41% to 67%)], a 4%
(95% confidence interval –7% to 15%; p = 0.73) difference. Specificity was not significantly different [93%
(95% confidence interval 88% to 96%) vs. 95% (95% confidence interval 91% to 98%), respectively]. The
whole-body magnetic resonance imaging staging pathway had 82% (95% confidence interval 64% to 92%)
sensitivity for participants in whom the largest metastasis was ≥ 1 cm, which was not significantly different
from that of standard staging pathways [75% (95% confidence interval 57% to 87%)]. As a stand-alone
investigation, whole-body magnetic resonance imaging had comparable sensitivity [50% (95% confidence
interval 37% to 63%)] to standard pathways but lower specificity [85% (95% confidence interval 78% to
90%)]. The whole-body magnetic resonance imaging staging pathway had 65% agreement for N stage
compared with 75% for the standard pathway, a statistically significant difference of –10% (95% confidence
interval –3% to –18%). There was no significant difference in agreement between the whole-body magnetic
resonance imaging and standard pathways for T stage (54% vs. 55%, respectively), a difference of 1%
(95% confidence interval –8% to 9%). Agreement with the final multidisciplinary team treatment decision
was 98% and 99% for whole-body magnetic resonance imaging and standard pathways, respectively, and
83% and 82%, respectively, with the retrospective optimal treatment decision. Time to complete staging was
significantly shorter for whole-body magnetic resonance imaging [13 days (95% confidence interval 12 to
14 days) vs. 19 days (95% confidence interval 17 to 21 days)], a 6-day (95% confidence interval 4- to 8-day)
difference. Across the cohort a total of 302 and 232 investigations were performed as part of standard and
whole-body magnetic resonance imaging staging pathways, respectively (whole-body magnetic resonance
imaging would have generated an additional 45 tests). The median number of tests in the whole-body
magnetic resonance imaging pathway were similar [1 test (95% confidence interval 1 to 1 test) vs. 1 test
(95% confidence interval 1 to 2 tests)], a difference of 0 tests (95% confidence interval –1 to 0 tests). Mean
test costs per participant (bootstrapped 95% confidence intervals) were £620 (95% confidence interval
£574 to £666) for standard pathways and £317 (95% confidence interval £273 to £361) for the whole-body
magnetic resonance imaging pathway.
Participant experience
In general, whole-body magnetic resonance imaging presented a greater challenge than standard scans.
Key challenges were the enclosed space, noise and scan duration. Reduced participant tolerance was
associated with claustrophobia, pulmonary symptoms and existing comorbidities. Coping strategies
facilitated scan tolerance. Perceived whole-body magnetic resonance imaging burden was greater than
for computed tomography (mean score 2.09 vs. 1.70, respectively; p < 0.0001) and positron emission
tomography–computed tomography (2.33 vs. 2.05; p = 0.003). However, participants preferred the
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whole-body magnetic resonance imaging-based pathway (probability: lung 0.64, colorectal 0.66) if it was
equivalent in accuracy, total scan number and time to diagnosis to a standard staging pathway. Preference
was stronger if whole-body magnetic resonance imaging reduced time to staging and/or number of tests.
Whole-body magnetic resonance imaging sequence selection
Streamline C
A combination of T1-weighted imaging pre and post gadolinium enhancement and T2- and diffusion-
weighted sequences had significantly greater sensitivity for participants with metastatic disease than T1- and
diffusion-weighted sequences alone [72% (95% confidence interval 60% to 81%) vs. 63% (95% confidence
interval 51% to 73%), respectively], a difference of 9% (95% confidence interval 1% to 17%). Specificity
was not significantly different [85% (95% confidence interval 80% to 89%) vs. 84% (95% confidence
interval 78% to 88%), respectively]. A combination of non-contrast enhanced T1-, T2- and diffusion-
weighted sequences had 70% (95% confidence interval 58% to 80%) sensitivity and specificity of 86%
(81% to 90%).
Streamline L
A combination of T1-weighted imaging pre and post gadolinium enhancement and T2- and diffusion-
weighted sequences had significantly greater sensitivity for participants with metastatic disease than T1- and
diffusion-weighted sequences alone [52% (95% confidence interval 39% to 65%) vs. 42% (95% confidence
interval 29% to 56%), respectively], difference of 10% (95% confidence interval 1% to 19%). Specificity
was not significantly different [86% (95% confidence interval 79% to 81%) vs. 82% (95% confidence interval
74% to 87%), respectively]. A combination of non-contrast enhanced T1-, T2- and diffusion-weighted
sequences had 48% (95% confidence interval 35% to 61%) sensitivity and 84% (95% confidence interval
76% to 89%) specificity.
Whole-body magnetic resonance imaging interobserver agreement
Interobserver agreement for interpretation of whole-body magnetic resonance imaging against the
final reference standard was moderate for Streamline C (80% overall agreement against the consensus
reference standard, κ = 0.6), but poor for Streamline L (44% overall agreement against the consensus
reference standard, κ = –0.12). For the primary outcome, not considering the final participant metastatic
status based on the consensus reference standard, two reads agreed in 35 out of 40 (88%) whole-body
magnetic resonance imaging data sets (Streamline C) and 28 out of 43 (65%) whole-body magnetic
resonance imaging data sets (Streamline L).
Conclusions
For both colorectal and non-small-cell lung cancer, the whole-body magnetic resonance imaging staging
pathway is as accurate as current standard staging pathways for identifying patients with metastatic
disease and results in the same treatment decisions. It is more efficient, reducing time to complete staging,
the number of staging tests (in colorectal cancer) and staging costs.
Implications for health care
In a NHS setting, the whole-body magnetic resonance imaging staging pathway achieves similar accuracy
as standard staging pathways for detecting patients with metastatic disease in both colorectal cancer and
non-small-cell lung cancer. Agreement for local T and N stage is also similar, although in non-small-cell
lung cancer, the whole-body magnetic resonance imaging pathway has lower agreement and sensitivity for
N stage than standard pathways. However, for both cancers, agreement between the primary treatment
decisions based on the whole-body magnetic resonance imaging pathway and both a contemporaneous
multidisciplinary team treatment decision and a retrospective optimal treatment decision is nearly identical
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to that for decisions based on standard staging pathways. For colorectal cancer, the whole-body magnetic
resonance imaging pathway reduces the number of tests required to complete staging, and for both cancers
whole-body magnetic resonance imaging significantly reduces the time to complete staging. Based on NHS
reference costs, the whole-body magnetic resonance imaging staging pathway is cheaper than standard
pathways in both colorectal and non-small-cell lung cancer. Although patients find whole-body magnetic
resonance imaging a more burdensome test than standard staging investigations, in general they prefer the
whole-body magnetic resonance imaging staging pathway if it at least matches the accuracy and efficiency
(time and number of tests) of standard pathways. Time-efficient whole-body magnetic resonance imaging
protocols using just T1- and diffusion-weighted sequences have lower sensitivity than protocols that also
include T2- and post-gadolinium-enhanced T1-weighted sequences. Interobserver variation in whole-body
magnetic resonance imaging interpretation is moderate, and lower for non-small-cell lung cancer than for
colorectal cancer.
Recommendations for future research
Future research should investigate:
1. the diagnostic accuracy, patient acceptability and cost-effectiveness of whole-body magnetic resonance
imaging for staging and treatment follow-up of other primary cancer sites, notably breast, prostate and
myeloma, compared with standard investigations
2. the diagnostic accuracy, patient acceptability and cost-effectiveness of whole-body magnetic resonance
imaging for investigating patients with clinically suspected recurrence of colorectal and non-small-cell
lung cancer compared with standard investigations
3. the diagnostic accuracy, patient acceptability and cost-effectiveness of whole-body magnetic resonance
imaging in routine post-cancer therapy surveillance in comparison with standard investigations
4. the impact on diagnostic accuracy and cost-effectiveness of adding liver-specific contrast agents to
whole-body magnetic resonance imaging protocols
5. the impact of formalised training on radiologist performance and interobserver agreement.
Trial registration
These trials are registered as ISRCTN43958015 and ISRCTN50436483.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background
Accurate staging of cancer is fundamental to optimal treatment. Staging relates to the local tumour extent as
well as the presence or otherwise of disease remote from the primary organ of origin – so-called metastatic
disease. Conventionally, cancer stage is expressed using the Tumour Node Metastasis Classification of
Malignant Tumors (TNM) system, with T denoting the characteristics of the primary tumour, based for
example on size and invasion of local structures, N stage denoting the involvement or otherwise of lymph
nodes and M stage denoting metastatic status.
Colorectal and lung cancer are the third and fourth most common cancers in the UK, accounting for
13% and 12% of all new cancers, respectively, and they are the leading causes of cancer-related deaths.1
In both cancers, detection of metastatic disease is fundamental to treatment strategy. For example, after
surgical removal of the primary tumour, up to 50% of patients with colon cancer relapse with undiagnosed
metastatic disease, usually to the liver and/or lung.2 Upfront detection of this disease would allow informed
clinical decision-making and the appropriate use of chemotherapeutic, surgical and ablative therapies.3
Similarly, prognosis in lung cancer is closely related to stage at diagnosis; correctly identified and surgically
treated non-metastatic early-stage disease is associated with 5-year survival rates of between 54% and
80%, although at least 20% of patients undergoing lung surgery with curative intent relapse with
undiagnosed metastatic disease – so-called futile thoracotomy.4
Cross-sectional imaging forms the bedrock of cancer staging in the NHS. A range of imaging tests are
available including computed tomography (CT), positron emission tomography–computed tomography
(PET-CT) and magnetic resonance imaging (MRI). Ultrasonography (US), plain radiography and scintigraphy
are also widely used. The choice of imaging investigations is governed by the specific cancer type and
predilection for metastatic spread, as imaging modalities differ in their diagnostic accuracy across the
various organ sites.
For both lung and colorectal cancer, the National Institute for Health and Care Excellence (NICE) has
provided guidance on staging pathways,5,6 which details the deployment of imaging tests as part of
standard staging pathways. In the case of colorectal cancer, CT of the chest, abdomen and pelvis is
recommended, supplemented by pelvic MRI for local staging of rectal cancer. Although the NICE does
not currently recommend additional imaging, in routine clinical practice it is not unusual for patients to
undergo PET-CT and/or liver MRI if metastatic disease is suspected. Staging pathways in lung cancer are
more complex, with CT, PET-CT, MRI, US and endobronchial/percutaneous biopsy all recommended at
various points in the staging algorithm.
The stepwise deployment of multimodality cross-sectional imaging as part of the staging pathways in colorectal
and lung cancer is resource intensive and exposes patients to relatively high doses of ionising radiation, which
may increase their risk of subsequent malignancy.7 Furthermore, patients have understandably very high anxiety
levels when being investigated for suspected cancer, and this anxiety increases if the diagnostic and staging
process is protracted.8
Whole-body magnetic resonance imaging (WB-MRI) has been proposed as an alternative to multimodality
staging pathways. Using modern MRI scanners available throughout the NHS, it is possible to acquire
images through the body (skull vertex to mid-thigh) in 60 minutes or less. Importantly, WB-MRI does
not impart diagnostic ionising radiation to patients, and promising data support its ability to stage
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malignancy, particularly in detection of metastatic disease. It could also increase staging efficiency,
reducing the time to complete staging and the number of tests required. Overall, WB-MRI may therefore
be a safer, more efficient and accurate alternative to complex multimodality staging pathways in colorectal
and lung cancer.
Existing literature on the diagnostic accuracy of WB-MRI in cancer staging
We searched PubMed and Embase for articles between 1 January 1990 and 1 October 2018 without
language restriction. We used MeSH (Medical Subject Headings) and a full-text search for ‘cancer’,
‘neoplasm’, ‘staging’, ‘diagnostic accuracy’, ‘magnetic resonance imaging’, ‘whole body imaging’,
‘diffusion magnetic resonance imaging’, ‘colon’, ‘colorectal’, ‘bronchial’ and ‘lung’. Meta-analyses and
systematic reviews were identified using appropriate search limits.
There have been a number of meta-analyses and systematic reviews reporting the accuracy of WB-MRI
for cancer staging.9–20 Many have combined multiple cancer types in one single meta-analysis.9–11,13,14,16,17
Those meta-analyses considering the staging of only lung cancer have limited themselves to the detection
of bone12,15 or nodal18–20 metastasis. No meta-analysis has considered colon cancer in isolation, and the
largest study to date recruited just 20 participants.21
A variety of comparators have been selected but the majority compare WB-MRI with PET-CT and
scintigraphy (in the case of bone metastasis). A summary of the main meta-analyses and systematic
reviews is shown in Table 1.
Those meta-analyses that consider all organ sites (albeit in a range of primary tumour sites) have generally
reported similar performance between WB-MRI and conventional imaging (notably PET-CT) for detection
of metastasis, with sensitivity between 80% and 90% and specificity in excess of 95%. Studies reporting
the accuracy for bone metastasis detection have been inconsistent. Those limited to lung cancer staging
alone have generally reported lower sensitivity for WB-MRI. For example, Qu et al.15 and Liu et al.12
reported the sensitivity of WB-MRI at 77% and 80% compared with 92% and 95%, respectively, for
PET-CT. Conversely, in a more recent meta-analysis of mixed primary tumour sites (for which lung cancer
was the largest contributor), Duo et al.10 estimated the sensitivity of WB-MRI to be 84% compared with
80% for PET-CT. Most studies contributing to the secondary literature are small, including < 50 participants.
In the largest study in lung cancer to date, Ohno et al.22 investigated WB-MRI staging compared with
PET-CT in 203 non-small-cell lung cancer patients referred as potential surgical candidates to a single
university hospital. All imaging was read in consensus by two experienced radiologists or nuclear medicine
physicians. Of the 203 participants, 40 had metastatic disease. The sensitivity and specificity of WB-MRI
for metastatic disease was 70% (95% CI 53% to 83%) and 92% (95% CI 87% to 96%), respectively,
compared with 63% (95% CI 46% to 77%) and 95% (95% CI 90% to 97%), respectively, for PET-CT.
The largest study to date investigating WB-MRI in colon cancer staging included just 20 participants and
compared diagnostic performance to PET-CT.21 WB-MRI detected four more liver metastases than PET-CT
(27 vs. 24, respectively) but fewer lung metastases (19 vs. 25, respectively).
As well as deficiencies in the secondary literature resulting from grouping disparate primary tumour sites
together and/or focusing on one specific organ site of metastatic spread, the majority of contributory
studies are small single-site explanatory studies with imaging interpreted by a small number of experienced
radiologists. Generalisability is also limited because most studies investigate single modality comparisons
(e.g. WB-MRI vs. PET-CT) rather than comparing ‘real-life’ complex multimodality staging pathways.23
Most studies also use a single optimised MRI platform, rather than a range of platforms that typifies
NHS practice. Finally, there has been no study on the influence of alternative staging pathways on actual
treatment decisions, which is crucial to the evaluation of any new technology.24 Overall, the current
evidence base is insufficiently mature to guide the implementation or otherwise of WB-MRI in colorectal
and/or non-small-cell lung staging pathways within the NHS.
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TABLE 1 Summary of recent meta-analyses and systematic reviews reporting the diagnostic accuracy of WB-MRI in cancer staging
Study Year
Modalities
considered Cancer type
Number of
included studies
(number of
participants)
Number of
participants in
largest contributing
WB-MRI study Main outcome Main findings
Xu et al.9 2013 PET-CT, WB-MRI Mixed (melanoma,
lung, breast,
naso/oropharynx,
colorectal)
13 (1239) 203 (lung) Diagnostic accuracy
for all site metastatic
disease
Per-patient sensitivity: WB-MRI 86%
(95% CI 70% to 94%); PET-CT 85%
(95% CI 68% to 94%)
Per-patient specificity: WB-MRI 97%
(95% CI 94% to 99%); PET-CT 96%
(95% CI 95% to 97%)
Per-lesion sensitivity: WB-MRI 89%
(95% CI 81% to 94%); PET-CT 85%
(95% CI 79% to 90%)
Per-lesion specificity: WB-MRI 89%
(95% CI 81% to 94%); PET-CT 90%
(95% CI 82% to 94%)
Duo et al.10 2013 PET-CT, gadolinium-
enhanced WB-MRI
Mixed (melanoma,
lung, breast,
naso/oropharynx)
9 (1116) 203 (lung) Diagnostic accuracy
for bone metastasis
Per-patient sensitivity: WB-MRI 84%
(95% CI 63% to 94%); PET-CT 80%
(95% CI 64% to 90%)
Per-patient specificity: WB-MRI 98%
(95% CI 95% to 99%); PET-CT 99%
(95% CI 97% to 94%)
Li et al.11 2014 PET-CT, diffusion-
weighted WB-MRI
Mixed (colorectal,
myeloma, breast,
lymphoma, lung,
kidney, thyroid,
prostate, liver)
8 (584) 203 (lung) Diagnostic accuracy
for primary lesion and
metastatic disease
Per-patient/-lesion sensitivity: WB-MRI
90% (95% CI 88% to 92%); PET-CT
90% (95% CI 87% to 92%)
Per-patient/-lesion specificity: WB-MRI
95% (95% CI 94% to 96%); PET-CT
98% (95% CI 97% to 98%)
continued
D
O
I:10.3310/hta23660
H
EA
LTH
TECH
N
O
LO
G
Y
A
SSESSM
EN
T
2019
VO
L.23
N
O
.66
©
Q
ueen
’s
Printer
and
C
ontroller
of
H
M
SO
2019.
This
w
ork
w
as
produced
by
Taylor
et
al.
under
the
term
s
of
a
com
m
issioning
contract
issued
by
the
Secretary
of
State
for
H
ealth
and
SocialC
are.
This
issue
m
ay
be
freely
reproduced
for
the
purposes
of
private
research
and
study
and
extracts
(or
indeed,
the
fullreport)
m
ay
be
included
in
professional
journals
provided
that
suitable
acknow
ledgem
ent
is
m
ade
and
the
reproduction
is
not
associated
w
ith
any
form
of
advertising.
A
pplications
for
com
m
ercialreproduction
should
be
addressed
to:
N
IH
R
Journals
Library,
N
ationalInstitute
for
H
ealth
Research,
Evaluation,
Trials
and
Studies
C
oordinating
C
entre,
A
lpha
H
ouse,
U
niversity
of
Southam
pton
Science
Park,
Southam
pton
SO
16
7N
S,
U
K
.
3
TABLE 1 Summary of recent meta-analyses and systematic reviews reporting the diagnostic accuracy of WB-MRI in cancer staging (continued )
Study Year
Modalities
considered Cancer type
Number of
included studies
(number of
participants)
Number of
participants in
largest contributing
WB-MRI study Main outcome Main findings
Liu et al.12 2011 PET-CT, PET,
WB-MRI, bone
scintigraphy
Lung 14 [4241
(PET, 2446;
WB-MRI 258;
scintigraphy,
1537)]
115 Diagnostic accuracy
for bone metastasis
Per-patient sensitivity: WB-MRI 80%
(95% CI 67% to 90%); PET 87%
(95% CI 81% to 92%); PET-CT 95%
(95% CI 91% to 97%); scintigraphy
92% (95% CI 89% to 94%)
Per-patient specificity: WB-MRI 91%
(95% CI 86% to 94%); PET 95%
(95% CI 93% to 97%); PET-CT 98%
(95% CI 97% to 98%); scintigraphy
69% (95% CI 66% to 72%)
Wu et al.13 2011 WB-MRI Mixed (breast,
lung, renal,
prostate)
11 (495) 115 Diagnostic accuracy
for bone metastasis
Per-patient sensitivity: WB-MRI 90%
(95% CI 85% to 94%)
Per-patient specificity: WB-MRI 92%
(95% CI 88% to 95%)
Yang et al.14 2011 PET-CT, CT,
WB-MRI, bone
scintigraphy
Mixed 67 (10,760 [PET,
4367; CT, 723;
WB-MRI, 1032;
scintigraphy,
4638])
115 Diagnostic accuracy
for bone metastasis
Per-patient sensitivity: PET 87%
(95% CI 84% to 90%); CT 73%
(95% CI 67% to 79%); PET-CT 94%
(95% CI 91% to 96%); MRI 91%
(95% CI 87% to 94%); scintigraphy
86% (95% CI 84% to 88%)
Per-patient specificity: PET 96%
(95% CI 96% to 97%); CT 95%
(95% CI 94% to 97%); PET-CT 97%
(95% CI 96% to 98%); MRI 95%
(95% CI 94% to 97%); scintigraphy
81% (95% CI 80% to 83%)
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Study Year
Modalities
considered Cancer type
Number of
included studies
(number of
participants)
Number of
participants in
largest contributing
WB-MRI study Main outcome Main findings
Qu et al.15 2012 PET-CT, PET,
WB-MRI, bone
scintigraphy
Lung 17 (2940
[WB-MRI, 252])
115 Diagnostic accuracy
for bone metastasis
Per-patient sensitivity: WB-MRI 77%
(95% CI 65% to 87%); PET 87%
(95% CI 81% to 92%); PET-CT 92%
(95% CI 88% to 95%); scintigraphy
86% (95% CI 82% to 89%)
Per-patient specificity: WB-MRI 92%
(95% CI 88% to 95%); PET 94%
(95% CI 92% to 96%); PET-CT 98%
(95% CI 97% to 98%); scintigraphy
88% (95% CI 86% to 89%)
Wu et al.16 2013 WB-MRI, bone
scintigraphy
Mixed (lung,
breast, renal,
prostate)
7 (328) 115 Diagnostic accuracy
for bone metastasis
Per-patient sensitivity: WB-MRI 84%
(95% CI 72% to 91%); scintigraphy
83% (95% CI 73% to 89%)
Per-patient specificity: WB-MRI 96%
(95% CI 81% to 99%); scintigraphy
94% (95% CI 68% to 99%)
Smets et al.17 2018 WB-MRI Paediatric solid
tumours
(neuroblastoma,
sarcoma,
hepatoblastoma,
renal)
5 (132) 39 Diagnostic accuracy
for bone metastasis
Per-lesion sensitivity: MRI range
82%–100%
Peerlings
et al.18
2016 MRI Lung 12 (1122) 250 Diagnostic accuracy
for lymph node status
Per-patient sensitivity: MRI 87%
(95% CI 78% to 92%)
Per-patient specificity: MRI 88%
(95% CI 77% to 94%)
Per-nodal sensitivity: MRI 88%
(95% CI 78% to 94%)
Per-nodal specificity: MRI 95%
(95% CI 87% to 98%)
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TABLE 1 Summary of recent meta-analyses and systematic reviews reporting the diagnostic accuracy of WB-MRI in cancer staging (continued )
Study Year
Modalities
considered Cancer type
Number of
included studies
(number of
participants)
Number of
participants in
largest contributing
WB-MRI study Main outcome Main findings
Shen et al.19 2016 MRI Lung 18 (1116) 250 Diagnostic accuracy
for lymph node status
Per-patient sensitivity: MRI 68%
(95% CI 63% to 73%)
Per-patient specificity: MRI 92%
(95% CI 90% to 94%)
Per-nodal sensitivity: MRI 72%
(95% CI 69% to 75%)
Per-nodal specificity: MRI 96%
(95% CI 96% to 96%)
Wu et al.20 2012 MRI, PET-CT Lung 19 (2845) 250 Diagnostic accuracy
for lymph node status
Per-patient sensitivity: MRI 72%
(95% CI 63% to 80%); PET-CT 75%
(95% CI 68% to 81%)
Per-patient specificity: MRI 95%
(95% CI 85% to 98%); PET-CT 89%
(95% CI 85% to 91%)
CI, confidence interval.
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Objectives of the Streamline studies
The primary aim of the Streamline studies was to compare the per-patient diagnostic accuracy for metastatic
disease of staging pathways utilising initial WB-MRI with those following the current NICE recommendations
(the ‘standard pathway’).23 We conducted two parallel but separate trials in colorectal cancer (Streamline C)
and non-small-cell lung cancer (Streamline L). Secondary objectives were the time and number of tests
taken to complete staging and the nature of the first major treatment decision based on WB-MRI or
standard pathway, diagnostic accuracy for local tumour staging, cost-effectiveness of staging pathway,
patients’ experiences of staging using WB-MRI compared with standard staging pathways, the interobserver
variability of WB-MRI diagnosis of metastatic disease by different radiologists and the diagnostic accuracy of
WB-MRI protocols limited to certain sequence combinations. Additional objectives included the diagnostic
accuracy of standard pathways with WB-MRI as an additional test and of WB-MRI as a single stand-alone
replacement test.
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Chapter 2 Methods
Parts of this chapter are reproduced from Taylor et al.25 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Parts of this chapter are reproduced from Taylor et al.26 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
The trial protocol has been previously published.23
Study design
The Streamlines studies were multicentred, non-randomised, single-arm, prospective cohort studies
comparing the diagnostic accuracy for metastatic disease of staging pathways based on initial WB-MRI
with NICE-recommended standard staging pathways in colorectal cancer (Streamline C) and non-small-cell
lung cancer (Streamline L). Ethics permission was granted by Camden and King’s Cross Research Ethics
Committee [Streamline C: Research Ethics Committee (REC) reference number 12/LO/1176; Streamline L: REC
reference number 12/LO/1177] in October 2012 and the trials were conducted in accordance with the
principles of Good Clinical Practice. The trial was co-ordinated by Cancer Research UK, University College
London Cancer Trials Centre (UCL CTC) and an independent Data Monitoring Committee and Trial Steering
Committee (TSC). All participants gave written informed consent prior to participation.
The two trials (Streamline C and Streamline L) were separate but conducted in parallel. Consecutive
(i.e. unselected) eligible patients with known or highly suspected colorectal or lung cancer underwent
WB-MRI in addition to standard staging investigations performed as part of their usual care. Multidisciplinary
team (MDT) treatment decisions based on the standard staging investigations were documented prior to
the revelation of the WB-MRI findings, after which the MDT documented its theoretical treatment decision
based on the WB-MRI (and any additional tests it generated). A final treatment decision was then made
based on all available tests, including WB-MRI. Participants’ clinical course was followed for a period of
12 months. A multidisciplinary consensus panel derived the reference standard for the tumour TNM stage,
including the sites of metastatic disease (if present) using all available clinical, imaging, biochemical and
histological data over the 12-month follow-up period. A summary of patient flow in the main trial is shown
in Figures 1 and 2.
Agreement between radiologists’ interpretation of WB-MRI was tested in a sample of participants and the
contribution of specific MRE sequences on radiologists’ accuracy investigated. Participants’ experiences of
staging using WB-MRI compared with standard staging pathways, and the priorities placed on differing
pathway attributes, was investigated using interviews, structured questionnaires and a discrete choice
experiment (DCE). The cost-effectiveness of WBI-MRI and standard pathways was assessed in an economic
evaluation. The full study protocols for Streamline C and Streamline L are available on the project web
page [URL: www.journalslibrary.nihr.ac.uk/programmes/hta/106801 (accessed 12 September 2019)].
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
9
Patient and public involvement
The Streamline studies were developed in collaboration with patient representatives who joined the trial
team at the inception of the project. The patient representatives helped refine the research questions, devise
the protocol and successfully apply for the funding. By way of example, their advice and guidance was
fundamental to the assessment of patient experience. All patient-facing materials were designed with the
patient representatives (and were in general very well received by participants). The representative sat on
the trial management and steering committees, providing ongoing guidance throughout the running of
the trial and subsequent write-up, for example helping to refine recruitment strategies and advising on
dissemination. This collaboration has been very productive and patient representatives will aid dissemination
of the work via patient forums.
Final MDT treatment decision and
treatment instigated 
Polyp cancer
Exclude
WB-MRI
12-month follow-up
Standard staging algorithm complete  
Clinical/radiological
diagnosis of colorectal
cancer  
Standard staging pathway
WB-MRI result
revealed to MDT
Multidisciplinary consensus
committee derivation of
TNM stage at diagnosis 
• Chest, abdomen and pelvis CT
• Pelvis MRI (rectal cancer)
• Additional standard investigations
   (e.g. MRI, PET-CT, US) as indicated
   by MDT
• MDT review and first major treatment decision.
   Time, test number and treatment decision
   recorded (based on standard pathway)
• Additional tests generated by WB-MRI. Time,
   test number and treatment decision recorded
   (based on WB-MRI pathway)   
FIGURE 1 Participant flow through the main study: Streamline C.
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Recruitment sites
Streamline L recruited participants from 16 NHS hospitals in England and Streamline C also recruited from
16 NHS hospitals in England. Participants were recruited to both trials from 11 hospitals. Recruitment sites
were a mixture of district general hospitals and teaching hospitals. Recruited participants from sites without
the infrastructure to perform WB-MRI locally underwent WB-MRI at nearby imaging hubs (in total eight
and 11 imaging hubs for Streamline C and L, respectively). Some sites acted as both recruitment sites and
imaging hubs. A summary of recruitment sites and their associated imaging hub is shown in Table 2.
Inclusion criteria: Streamline C
l Adult patients (aged ≥ 18 years) with histologically proven or suspected colorectal cancer referred
for staging.
l Suspicion of colorectal cancer defined as presence of a mass highly suspicious for colorectal cancer
on endoscopy, barium enema, CT colonography or other imaging that triggers staging investigations.
l Patient must have given written informed consent and be willing to comply with the protocol
intervention and follow-up.
Final MDT treatment decision and
treatment instigated 
No cancer or
unequivocal N3 or
extranodal metastatic
disease
Exclude
WB-MRI
12-month follow-up
Standard staging algorithm complete
Clinical/radiological
diagnosis of non-small-
cell cancer on diagnostic
chest CT
Standard staging pathwaya 
WB-MRI result
revealed to MDT
Multidisciplinary consensus
committee derivation of
TNM stage at diagnosis 
• PET/CT/EBUS/TBNA/neck US
• Additional standard investigations
   (e.g. head MRI) as indicated by MDT
• MDT review and first major treatment decision. 
   Time, test number and treatment decision recorded 
   (based on standard pathway)
• Additional tests generated by WB-MRI. Time, test
   number and treatment decision recorded (based on
   WB-MRI pathway)   
FIGURE 2 Participant flow through the main study: Streamline L. a, Specific choice of investigations dependent
on CT findings (notably tumour location and mediastinal nodal size). EBUS, endobronchial ultrasonography;
TBNA, transbronchial needle aspiration; VATS, video-assisted thoracoscopic surgery.
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Exclusion criteria: Streamline C
l Any psychiatric or other disorder likely to have an impact on informed consent.
l Evidence of severe or uncontrolled systemic disease that makes it undesirable for the patient to
participate in the trial.
l Pregnancy.
l Contraindications to MRI (e.g. cardiac pacemaker, severe claustrophobia, inability to lie flat).
l Polyp cancer.
TABLE 2 Recruitment sites and imaging hubs
Streamline C Streamline L
Recruitment site Imaging hub Recruitment site Imaging hub
UCLH UCLH UCLH UCLH
Barnet and Chase Farm NHS
Hospitals Trusta
Barnet and Chase Farm
NHS Hospitals Trust
Princess Alexandra Hospital Princess Alexandra
Hospital
North Middlesex University
Hospital
North Middlesex
University Hospital
St Mark’s Hospital Whittington Hospital
West Middlesex University
Hospital
Queen’s Hospital
Whittington Hospital Lister Hospital Paul Strickland Scanner Centre,
Mount Vernon Hospital
Queen’s Hospital Croydon University
Hospital
Royal Marsden Hospital
Homerton University
Hospitalb
Homerton University
Hospital
Kingston Hospital
St Bartholomew’s Hospital/
Royal London Hospital
St Bartholomew’s Hospital/
Royal London Hospital
Charing Cross Hospital Charing Cross Hospital
Charing Cross Hospital Charing Cross Hospital Homerton Hospitalc Homerton Hospital
University Hospital
Southampton NHS
Foundation Trust
University Hospital
Southampton NHS
Foundation Trust
Guy’s and St Thomas’
NHS Foundation Trust
Guy’s and St Thomas’ Hospital
NHS Foundation Trust
Queen Alexandra Hospital Queen Alexandra Hospital Lewisham Hospital
Guy’s and St Thomas’ NHS
Foundation Trust
Guy’s and St Thomas’ NHS
Foundation Trust
St Bartholomew’s Hospital St Bartholomew’s Hospital/
Royal London Hospital
Lewisham Hospital Whipps Cross University
Hospital
Bradford Royal Infirmary Bradford Royal Infirmary Newham University
Hospital
UCLH, University College London Hospital.
a One participant underwent WB-MRI at the Paul Strickland Scanner Centre, Mount Vernon Hospital.
b 10 participants underwent WB-MRI at St Bartholomew’s Hospital.
c One participant underwent WB-MRI at St Bartholomew’s Hospital and one at UCLH.
METHODS
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Inclusion criteria: Streamline L
l Adult patients (aged ≥ 18 years) with suspected primary non-small-cell lung cancer on chest CT with
sufficient confidence to trigger staging investigations/biopsy or with already histologically proven
primary non-small-cell lung cancer.
l Disease is potentially radically treatable as defined as stage IIIB or less on diagnostic chest CT (i.e. T1–4,
N0–2, M0).
l Performance status 0–2 (fit to undergo radical treatment if indicated).
l Patient must have given written informed consent and be willing to comply with the protocol
intervention and follow-up.
Exclusion criteria: Streamline L
l Unequivocal metastatic or N3 disease on diagnostic chest and abdomen CT (including M1a disease,
malignant pleural effusion).
l Further staging work-up not indicated in the opinion of the MDT or clinician owing to poor
performance status or patient choice.
l Histologies other than non-small-cell lung cancer.
l Any psychiatric or other disorder likely to have an impact on informed consent.
l Evidence of severe or uncontrolled systemic disease that makes it undesirable for the patient to
participate in the trial.
l Pregnancy.
l Contraindications to MRI (e.g. cardiac pacemaker, severe claustrophobia, inability to lie flat).
Test methods
WB-MRI
In both trials, recruited participants underwent WB-MRI performed at their recruitment site/designated
imaging hub in addition to all standard staging investigations performed as part of their usual clinical
care. The choice of MRI platform (i.e. manufacturer and tesla strength) was decided by the local hub lead
radiologist according to scanner availability and their usual practice. A minimum data set of sequences
was acquired including whole-body axial diffusion-weighted imaging (DWI), whole-body axial T2-weighted
imaging, whole-body axial or coronal pre-contrast T1-weighted imaging and axial T1-weighted imaging
post intravenous gadolinium contrast through at least the liver, lungs and head. It was stipulated that, in
general, scan acquisition should not take longer than 1 hour. A full description of the WB-MRI acquisition
minimum data set is given in Appendix 1. The WB-MRI was performed concurrently with the standard
staging investigations and no later than 3 weeks after the final standard staging investigation.
WB-MRI blinding
To maintain the integrity of the trial, WB-MRI scans were reported by radiologists blinded to the standard
imaging tests and other clinical information (other than the cancer diagnosis and anatomical location – either
colonic segment for Streamline C or lung lobe for Streamline L). In addition, to ensure that radiologists
reporting the standard staging investigations and other MDT members were not unblinded to the WB-MRI
images and/or report until the designated time of revelation in the MDT (see Revelation of WB-MRI findings
and MDT treatment decisions), unanonymised WB-MRI images were not immediately sent to the picture
archiving and communications system (PACS) at either the imaging hub or the recruitment sites. Instead,
images were uploaded to a secure central imaging server, 3Dnet™ (Biotronics3D, London, UK). This solution
allowed easy upload of MRI data sets via a standard internet connection. A personal computer (PC)-based
internet gateway was installed in each imaging hub to facilitate automated transfer of WB-MRI from the
scanner or workstation to 3Dnet, and thereafter automatically back to PACS at the appropriate time point
after MDT revelation (see Revelation of WB-MRI findings and MDT treatment decisions).
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WB-MRI reporting and radiologist competence/training
Whole-body magnetic resonance imaging was interpreted by designated radiologists at each imaging
hub who were experienced in interpretation based on previous experience of reporting WB-MRI in cancer
staging and were post fellowship of the Royal College of Radiologists. Specifically, all had interpreted at
least 20 validated WB-MRI cases in patients with lung or colorectal cancer. Thereafter, radiologists with
experience of < 100 WB-MRI data sets underwent a period of ‘buddy’ reporting with a more experienced
radiologist (experience of > 100 WB-MRI data sets) and were only permitted to report alone once deemed
competent by the more experienced radiologist.25,26 This process was specifically designed to mirror how
WB-MRI would be reported in standard NHS practice were it to become disseminated. We specifically
avoided using a small number of highly experienced subspecialty radiologists who would not be representative
of the NHS radiological workforce. As noted above, the radiologists were blinded to the standard staging
investigations performed on recruited participants. In total, 19 radiologists interpreted WB-MRI for Streamline C
and 16 radiologists interpreted WB-MRI for Streamline L.
Interpretation was performed using the 3Dnet visualisation software, or a stand-alone workstation after
data set download, according to the preference of the radiologist.
Images were analysed in three blocks in the following order:
1. diffusion-weighted and non-contrast-enhanced T1-weighted images
2. diffusion-weighted and non-contrast-enhanced T1- and T2-weighted images
3. diffusion-weighted, non-contrast enhanced T1- and T2-weighted images and gadolinium-enhanced
T1-weighted images.
After viewing each sequence block (and before reviewing the next block) the radiologist completed a
WB-MRI imaging booklet case report form (CRF) – available on the project web page [URL: www.journals
library.nihr.ac.uk/programmes/hta/106801 (accessed 12 September 2019)] – documenting their findings.
Items recorded on the CRFs included the availability of WB-MRI sequences, location and T and N stage
of the local tumour (TNM 7th edition)27 and the presence, location and size of metastatic disease. The
presence of metastatic disease was recorded for a range of soft tissue and bony anatomical sites using six
confidence levels grouped into normal (levels 1 and 2), equivocal (levels 3 and 4) and abnormal (levels 5
and 6). If disease presence was recorded as equivocal or abnormal (i.e. confidence level 3 or above), the
size of the largest two metastatic deposits per organ was recoded, along with the additional number of
deposits < 6 mm, 6–9 mm and ≥ 10 mm. Reporting radiologists were instructed to interpret the WB-MRI as
they would in their routine clinical practice, taking into account the known morphology and characteristics
of potential metastatic disease across the various sequences.22,25,26 Following completion of the CRF, the
reporting radiologist produced a free-text clinical report as per their usual clinical practice (using all available
sequences and based on the TNM 7th edition)27 for subsequent release to the clinical team. This report
contained information relating to the local T and N stage of the tumour, together with the presence, location,
number and size of metastatic deposits as well as important ‘incidental’ findings, for example a second
malignancy. The radiologists were instructed to express their level of confidence in their report as they would
in their normal clinical practice and to reflect their confidence scores entered on the CRF. If the radiologist
would usually recommend additional tests for equivocal findings, this was included in the report to also mirror
routine clinical practice and guide the MDT. The free-text report was uploaded onto the 3Dnet software.
Quality assurance
Whole-body magnetic resonance imaging scans were scored centrally by a radiographer with 8 years of
experience in WB-MRI using a predefined scoring system based on technical quality (1 to 5) and anatomical
coverage (1 to 4) (see Appendix 2, Table 41). Scans were then classified as optimal (maximum score for
both technical quality and anatomical coverage), suboptimal but fully diagnostic (technical quality score ≥ 3,
anatomical coverage score ≥ 2) or degraded (one or more sequences substantially degraded, technical quality
score < 3, anatomical coverage score < 2). The radiographer visited all imaging hubs during the first months
of their opening to feedback on their WB-MRI imaging quality and advise on improvements (if required).
METHODS
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Standard investigations
Recruited participants underwent all the standard staging investigations employed at their recruiting institution
according to local protocols and the requirements of their clinical care team. All standard investigations were
performed and interpreted by the usual radiologists and clinicians employed at the site where they were performed
[at the local recruitment site or usual tertiary referral site for more complex investigations such as PET-CT and
endobronchial ultrasonography (EBUS)] as per usual clinical care. The images and findings of theWB-MRI were
not available to the local clinical care teams until the point of revelation to theMDT. The date of the first staging
investigation and all subsequent investigations was recorded. Clinical reports for the standard investigations (and
their results) were freely available on hospital PACSs, radiology information systems and Clinical Data Repositories
as per usual clinical practice. The type and date of all standard investigations (e.g. CT, PET-CT, organ-specific MRI,
biopsy) was recorded on CRFs, along with the presence and location of metastatic disease based on the
radiological reports. Standard imaging and standard imaging disease CRFs are available on the project web page
[URL: www.journalslibrary.nihr.ac.uk/programmes/hta/106801 (accessed 12 September 2019)].
Revelation of WB-MRI findings and multidisciplinary team
treatment decisions
Whole-body magnetic resonance images and reports were withheld from clinical care teams until
participants had completed all their standard staging investigations such that their recruitment site MDT
was able to make the first major treatment decision. Each MDT compromised key personnel from a range
of hospital specialties and as a minimum included a radiologist, oncologist, histopathologist and respiratory
physician and/or surgeon (Streamline L) or colorectal surgeon (Streamline C). The first major treatment
decision was defined as:
l referral for surgical excision of the primary tumour and/or a metastatic site
l instigation of definitive treatment using chemotherapy, radiotherapy or a combination of the two
l decision to offer palliative/supportive care only
l request for a highly invasive surgical staging procedure such as surgical mediastinal lymph node
sampling (mediastinoscopy), video-assisted thoracoscopic surgery (VATS) or laparoscopy.
Recruited participants were discussed in the relevant MDT as per their usual care pathways. After reviewing
all standard imaging and all available clinical data, the MDT stated if it had sufficient information to make
the first major treatment decision. If not, and the participant needed further investigations, these were
performed and the participant rediscussed at the next available MDT. Once sufficient staging information
was available to make the first major treatment decision, the MDT documented this, along with the TNM
stage (based on the standard imaging performed) on a dedicated MDT CRF – available on the project
web page [URL: www.journalslibrary.nihr.ac.uk/programmes/hta/106801 (accessed 12 September 2019)].
The MDT then recorded the first major treatment decision based on the standard imaging pathway from
a range of options on the CRF. If the participant was referred to another MDT for the final treatment
decision (for example to a specialised liver MDT), the CRF was transferred to and completed by this MDT.
The WB-MRI report was then revealed to the same MDT. Usually this was by electronically accessing 3Dnet
in the MDT room via internet-enabled computer such that the WB-MRI report and key images (saved
by the reporting radiologist) could be projected to the whole MDT. Presentation of a paper copy of the
report was permissible in cases of information technology (IT) failure. The MDT reviewed the WB-MRI
report (and key images) and stated whether or not WB-MRI would have generated additional tests before
the first major treatment decision if it had been the initial stand-alone staging investigation, for example a
bone scan for equivocal bone lesion or PET-CT for an indeterminant lymph node. If additional tests would
have been generated but these had already been performed as part of the standard care pathway, the
nature and results of these additional tests was recorded on the MDT CRF. However, if these had not
already been performed and the MDT considered them essential for patient care (e.g. if WB-MRI identified
a new potentially important site of disease or incidental abnormality), these were requested and performed
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and the participant rediscussed in the next available MDT once complete. The MDT then recorded the
TNM stage (and sites and number of metastasis) based on the WB-MRI and the results of additional tests it
generated (if any) – the ‘WB-MRI staging pathway’ – and stated what its theoretical first major treatment
decision would have been had only the investigations in the WB-MRI staging pathway been available to
them. The MDT then stated its final treatment decision based on all available tests (i.e. standard pathway,
WB-MRI and generated tests). In this way (and to assuage ethics concerns), the findings of WB-MRI could
be considered when deciding the final patient treatment. Occasionally, and for logistical reasons, the
treatment decision based on the WB-MRI pathway was documented after the MDT. In summary, the
following were therefore recorded:
l stage and treatment decision based on standard investigations (and the number, timing, nature and
findings of these investigations)
l stage and theoretical treatment decision based on the WB-MRI staging pathway (and the number,
timing, nature and findings of any additional tests generated)
l final treatment decision incorporating all available tests
l a summary flow chart of the MDT’s first major treatment decision-making process (see Appendix 3,
Figure 11).
Finally, the MDT recorded on the CRF if any pathway would have resulted in short-interval follow-up
imaging, for example for indeterminate findings such as small lung nodules.
If a participant was on an accelerated treatment pathway such that they were due to commence treatment
before a MDT where the WB-MRI could be revealed, an ad hoc MDT was convened consisting of all
specialties relevant to the participant’s clinical care and the MDT process followed as described above.23
Early release of WB-MRI findings
The WB-MRI report and images were released in an unanonymised form to the hospital PACS and electronic
patient record after revelation during the MDT process as described in Revelation of WB-MRI findings and
multidisciplinary team treatment decisions. However, it was permitted to release the WB-MRI findings to
the clinical teams before this time point if WB-MRI revealed a serious finding that could have an immediate
impact on direct patient care, for example impending spinal cord compression, deep-vein thrombosis,
pulmonary embolism or brain metastasis with significant mass effect requiring immediate treatment.
Reporting radiologists were instructed to contact the participant’s clinician to discuss the finding and a
decision was made about whether or not the results should be revealed early to all members of the clinical
team (based on review of standard tests already performed that may also have detected the finding).
Recruitment
Suitable patients were identified from outpatient clinics, MDT meetings, inpatient wards, imaging requests
and endoscopy lists by members of the local research team, who established whether or not the patient
met the trial entry criteria (for Streamline C or L as appropriate). A screening log recorded the details of
all patients approached to take part in the trials and reasons for non-participation if applicable. All patients
were handed or posted a participant information sheet detailing the study (applicable to Streamline C or L
as appropriate) – available on the project web page [URL: www.journalslibrary.nihr.ac.uk/programmes/hta/
106801 (accessed 12 September 2019)] – and the contact details of study team. The study purpose and
requirements were also explained face to face to patients by an appropriately trained member of the research
team. All participants gave written consent prior to participation in the Streamline trials. Participants gave
additional written consent if they agreed to participate in the patient experience studies (see Chapter 6).
Participants retained a copy of their consent form and participant information sheet and were informed that
they could withdraw from the study at any time.
METHODS
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Data collection and follow-up
Data collation was co-ordinated by UCL CTC. Participant age, performance status and sex were collected,
together with the request date of the first staging investigation [defined as the date of request of the first
staging investigation following a proven or assumed diagnosis of colorectal (Streamline C) or non-small-
cell lung (Streamline L) cancer, for example the date of request for chest, abdomen and pelvis CT after
colonoscopic diagnosis of probable malignant tumour or PET-CT following chest CT diagnosis of probable
lung tumour]. The completion date of staging was also recorded (defined as the date of the final staging
investigation). The time between this and the MDT’s first major treatment decision was also recorded,
as was the date of WB-MRI. The type and date of all standard investigations performed prior to the first
major treatment decision (e.g. CT, PET-CT, organ-specific MRI, biopsy) were recorded on CRFs, along with
the presence and location of metastatic disease based on the radiological reports – available on the project
web page [URL: www.journalslibrary.nihr.ac.uk/programmes/hta/106801 (accessed 12 September 2019)].
Complications related to the WB-MRI were recorded on a specific CRF.
Recruited participants were followed for a period of 12 months (or until the date of death if sooner) to
inform the consensus panel review process (see Reference standard) and collate data for the health economic
analysis (see Chapter 5). During this time, details of any imaging investigations, surgical interventions (and
biopsies) and cancer treatments were recorded on CRFs, along with outpatient visits, hospital day visits and
inpatient stays. Histological findings from any surgical resections or biopsies were also recorded on CRFs.
All CRFs were collated by local site research nurses/practitioners and sent to the clinical trial unit by post or
fax. Forms were entered on to a bespoke study database and any missing fields or apparent data inaccuracies
queried with the centre to optimise data collection.
Reference standard
Multidisciplinary consensus panel review is the standard methodology for diagnostic test accuracy studies
where an independent reference standard does not exist or is impossible because of incorporation
bias.23,25,26,28 The Streamline trials applied this methodology. Specifically, each recruitment site convened a
series of consensus panels to derive the reference standard for the cancer TNM stage at recruitment for
their participants. The panel consisted of one radiologist external to the recruitment site and at least one
radiologist internal to the recruitment site or associated imaging hub. A second internal radiologist attended
if required to ensure sufficient expertise in cross-sectional imaging and nuclear medicine techniques such as
PET-CT was available to the panel. In addition, an oncologist and/or a colorectal surgeon (Streamline C) or
respiratory physician/thoracic surgeon (Streamline L) attended the vast majority of meetings. Occasionally,
such an individual was not available to attend and reviewed the panel decisions after the meeting. The
panel had access to a histopathologist if required. A member of the UCL CTC attended each meeting to
ensure full data collection and uniformity of the consensus process. Typically, each consensus meeting
considered around 10–20 participants in a 2- to 3-hour session. The panel considered all available clinical
information over the 12 months follow-up period, including the images and results of staging investigations
(including WB-MRI, CT, PET-CT, MRI), surgical findings (if applicable), histopathology (surgical resection
and biopsies), all follow-up imaging and the participants’ clinical course. Panels were given a summary of
pertinent data extracted from trial CRFs and had full access to clinical results, records and letters via the
patient notes and/or electronic patient record. Panels also had access to the hospital PACS so that they
could review all imaging during the meeting.
Based on all available data, the panel adjudicated on the TNM stage of the participant at the time of
recruitment. Emphasis was placed on the available histological data, for example following surgical resections
of the primary tumour and/or biopsy data of remote disease sites. In the absence of histological proof of
metastasis, metastatic disease was assumed if new lesions appeared during the 12-month follow-up period
with imaging characteristics compatible with metastasis and no alternative explanation, or if already present
lesions with characteristics compatible with metastasis either grew or shrank (on therapy). Lesions that
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remained stable over the 12-month follow-up period were assumed not to be metastatic unless there were
specific circumstances considered by the panel that indicated malignancy (e.g. change in lesion morphology
with treatment).
Given the variable follow-up period (e.g. owing to participant death) and the potential for primary tumours
left in situ to seed new metastatic disease after cancer diagnosis (which would unfairly penalise diagnostic
accuracy estimates of initial staging investigations), the following criteria were applied by the panel when
opining on metastatic status (defined upfront as part of the trial protocols):25,26
l For participants in whom the primary tumour was completely removed within 3 months of diagnosis,
all new metastatic sites identified over the follow-up period were be assumed to have been present
at diagnosis.
l If the primary tumour was left in situ for > 3 months after diagnosis (or there was incomplete removal),
new metastatic sites were assumed to have been present at diagnosis if they were identified within
6 months of diagnosis. If new metastatic sites were diagnosed > 6 months after diagnosis, and there
was no evidence of their presence on retrospective review of all staging investigations, they were
assumed to be new disease and not present at diagnosis.
l If participants with tumours left in situ did not undergo any imaging capable of detecting metastatic
disease within 6 months of diagnosis of the primary tumour, and new metastatic sites were apparent
beyond 6 months but not visible in retrospect on any trial imaging, the consensus panel decided if the
disease was probably present at diagnosis based on its location, size and imaging characteristics.
l If a participant died before the 12-month follow-up, the panel reviewed all available imaging, histopathology
and clinical course prior to death and in consensus decided if a confident diagnosis of the presence or
absence of metastatic disease could be made [e.g. the presence of imaging characteristics compatible
with metastasis and no alternative explanation or if lesions with characteristics compatible with
metastasis either grew or shrank (on therapy)]. If this judgement could not be made with confidence
(e.g. if the participant had equivocal lesions on staging investigations and no further follow-up), the
participant was excluded.
Using a specific CRF – available on the project web page [URL: www.journalslibrary.nihr.ac.uk/programmes/
hta/106801 (accessed 12 September 2019)] – the panel recorded for each participant the location of the
primary tumour, TNM stage and the availability of histopathological proof for T and N stage. For colorectal
cancer (Streamline C), the panel also recorded whether or not the circumferential resection margin was
involved and whether or not there was presence of extra mural vascular invasion. For non-small-cell lung
cancer (Streamline L), a detailed breakdown of nodal involvement across the 14 TNM stations was recorded.
The presence of metastatic disease was recorded overall, and then on a per-organ basis. For each involved
organ the rational for the diagnosis of metastatic disease was given (histological proof, characteristic imaging
appearances, growth on follow-up and/or response to therapy). The size of the largest two organ deposits at
the time of staging was recorded, measured using the most appropriate staging investigation if pathological
measurement from a surgical resection was not available, together with the number of deposits in the organ
as a whole (split into < 6 mm, 6–9 mm and ≥ 10mm). If the metastatic deposit had appeared after the initial
staging investigation and was not visible in retrospect on any staging investigation yet still fulfilled the panel
criteria for presence at diagnosis, it was marked as not visible. Diffuse metastatic disease such as peritoneal
or pleural disease was marked as non-measurable as appropriate. In addition, the consensus panel reviewed
all imaging tests (including WB-MRI) performed during staging and indicated if there were perceptual errors
(i.e. unreported metastatic disease visible on retrospective review of the standard staging pathway or WB-MRI
alone or the WB-MRI staging pathway).
Finally, the panel considered the final allocated TNM stage, all follow-up data (including the WB-MRI) and
the patient outcomes and indicated the optimal retrospective treatment decision using the same options as
those provided to the initial staging MDT.
METHODS
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Outcomes
A summary of the primary and secondary outcomes is shown in Appendix 4, Table 42. The primary outcome
was the difference in per-patient sensitivity for metastatic disease between standard staging pathways and
the WB-MRI staging pathway against the consensus reference standard, that is the ability of the pathways to
identify patients with metastatic disease at the time of diagnosis. Differences in specificity was a secondary
outcome. Disease reported as equivocal was generally treated as positive for disease presence given the
potential clinical implications of an equivocal result on patient management and the need for further
investigations. However, for rectal cancer only, on advice of the Independent Data Monitoring Committee
(IDMC), disease reported as equivocal was treated as disease negative (rectal cancer patients often undergo
chemoradiation treatment prior to surgery, allowing additional time for equivocal lesion characterisation). A
sensitivity analysis was also performed, treating equivocal results as negative for disease presence (or positive
for rectal cancer). Subanalyses divided participants into those whose largest metastatic deposit was ≥ 1 cm
and those for whom it was < 1 cm to assess the impact of lesion size on diagnostic accuracy based on a size
cut-off commonly reported in the literature and pathway differences in sensitivity and specificity according to
specific organ sites of metastatic disease. The number of participants equivocal for metastatic disease and
those with radiologist perceptual errors was also noted.
Secondary outcomes also included the difference in per-patient sensitivity and specificity for metastatic
disease between standard staging pathways and WB-MRI as a stand-alone test (based on the radiologist
WB-MRI report alone and to allow comparison with the existing literature, which usually considers WB-MRI
as a stand-alone examination),and between standard staging pathways and the combination of standard
tests with WB-MRI in addition, both against the consensus reference standard. Additional secondary outcomes
were differences between standard staging pathways and the WB-MRI staging pathway for the nature of
the first major treatment decision (compared with the final MDT treatment decision and consensus panel
retrospective optimal treatment decision), time taken to complete staging and the number of tests needed to
complete staging. Secondary outcomes also included differences in per-patient agreement for local T and N
stage disease between standard staging pathways and the WB-MRI staging pathway, WB-MRI as a stand-alone
test and the combination of standard tests with WB-MRI, all against the consensus reference standard, and as
an exploratory outcome against a histopathological standard of reference when available.
Additional secondary outcomes pertaining to the lifetime incremental cost and cost-effectiveness of standard
staging pathways and the WB-MRI staging pathway, comparative patient experience of staging pathways,
diagnostic impact of WB-MRI sequence blocks and interobserver variation in the evaluation WB-MRI are
described in the relevant chapters (see Chapters 5–8).
Sample size
Primary outcome
The sample-size calculation was based on the primary outcome stipulated by the Health Technology
Assessment (HTA) commissioning brief: diagnostic accuracy for metastatic disease.
Streamline C
Based on the available literature at the time of study design (see Report Supplementary Material 1) it was
assumed that WB-MRI would achieve 84.8% sensitivity for liver metastasis (by far the most common site
for metastatic disease) compared with 74.9% for contrast-enhanced CT. Using methods for comparative
studies,29 a sample size of 290 participants would give 80% power to detect this 10% sensitivity difference
between the WB-MRI pathway and standard pathways, assuming a 40% prevalence of metastasis, and
73% concordance between pathways. Allowing for a 10% drop-out rate (loss to follow-up) at 1 year gave
a target sample size of 322 participants. This was revised by the IDMC to 360 participants owing to a
higher than expected withdrawal rate of 19%.
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Streamline L
Based on the available literature at the time of study design (see Report Supplementary Material 1) it was
assumed that WB-MRI would achieve greater sensitivity, particularly for bone and brain metastasis, than
standard pathways, notably PET-CT. Overall it was assumed that WB-MRI would have 79% per-patient
sensitivity for metastatic disease compared with 55% per-patient sensitivity for conventional staging (PET-CT).
Using methods for comparative studies,29 a sample size of 200 participants would give 80% power to detect
this 24% sensitivity difference between the WB-MRI pathway and standard pathways assuming a 25%
prevalence of metastasis (12% isolated brain, 5% isolated bone and 8% at other sites) and 53% concordance
between pathways. Allowing for a 20% drop-out rate (loss to follow-up) at 1 year gave a target sample size
of 250 participants. This was revised by the IDMC to 353 participants owing to a higher than expected
withdrawal rate of 43%.
Analysis
We report our prespecified primary and secondary outcomes and additional sensitivity analyses. Sensitivity
(per patient) for each imaging pathway was defined as the percentage of participants identified as having
metastasis by the reference standard who had a positive finding for metastasis in the imaging pathway.
Binary comparisons (sensitivity, specificity, treatment decision agreement) were calculated using paired
proportions (population marginal) in Stata® 14.2 [StataCorp LP, College Station, TX, USA]. For the Streamline L
primary outcome, equivocal disease was considered positive for metastasis. Sensitivity analysis treated
equivocal results as negative. For the Streamline C primary outcome, disease reported as equivocal for rectal
cancer was considered disease-negative. Sensitivity analysis treated equivocal results as all negative or all
positive. There were no missing data for the primary outcome so imputation was not required. Statistical
significance was based on 95% confidence intervals (CIs) using the Newcombe paired proportion method30
(McNemar’s test p-values are reported). Pathway treatment decisions were grouped for analysis (see Tables 3
and 4) and compared with the final MDT and consensus panel treatment decisions (as a sensitivity analysis).
TABLE 3 Streamline C: grouping of treatment decisions for analysis
Summary treatment decision category Component treatment decisions
Surgery for the primary tumour but no chemotherapy Surgical removal of primary tumour alone
Surgery for the primary tumour and chemotherapy
(and/or radiotherapy)
Surgery for primary tumour followed by planned adjuvant
chemotherapy
Neoadjuvant chemotherapy (and/or radiotherapy) alone followed
by anticipated planned surgical removal of primary tumour
Chemotherapy (and/or radiotherapy) without surgery Neoadjuvant chemotherapy (and/or radiotherapy) alone
Palliative care
Surgical metastectomy with or without chemotherapy Surgery for primary tumour followed by planned chemotherapy
followed by surgical removal of metastasis
Surgical removal of primary tumour and metastatic site(s) alone
Surgery for primary tumour and metastatic site(s) followed by
anticipated planned adjuvant chemotherapy
Neoadjuvant chemotherapy (and/or radiotherapy) alone followed
by anticipated planned surgical removal of primary tumour and
metastatic site(s)
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Time to complete staging pathways (excluding initial diagnostic tests) was calculated in days by adding times
for staging tests (from request to performance) to median treatment decision MDT wait times, calculated
across all participants. In the case of missing data, median times from the same or similar tests were used.
The median difference in time and number of staging tests between pathways was compared for each
participant with 95% CI from the 2.5th and 97.5th percentiles of 1999 bootstrap samples with replacement.
TABLE 4 Streamline L: grouping of treatment decisions for analysis
Summary treatment decision category Component treatment decisions
Treatment with curative intent Surgical removal of primary tumour alone
Radical radiotherapy alone
Combination chemoradiotherapy
Treatment with non-curative intent Chemotherapy alone
Non-radical dose radiotherapy alone
Supportive/palliative care
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative
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Chapter 3 Results: Streamline C
Parts of this chapter are reproduced from Taylor et al.25 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Participants
Recruitment commenced in March 2013 and was completed in August 2016. Overall, 1020 patients were
assessed for eligibility, of whom 650 were excluded (Figure 3 and Appendix 5, Table 43).
Screened patients
(n = 1020)
• Patients did not want extra visit,
   n = 91
• Patients did not want WB-MRI
   scan, n = 77
• Patients felt it would delay
   potential treatment, n = 70
• Contraindications to WB-MRI,
   n = 66
• Polyp cancer, n = 65
• No WB-MRI slot available within
   3 weeks of final staging, n = 37
• Evidence of severe or
   uncontrolled systematic disease,
   n = 31
• Not primary colorectal cancer,
   n = 31
• Too frail/not fit enough, n = 24
• Psychiatric or other condition
   likely to impact on informed
   consent, n = 22
• Language barrier, n = 14
• Other, n = 122
Recruited participants
(n = 370) 
Included participants
(n = 299)
• Participant withdrawal due to
   failure to undergo WB-MRI,
   n = 45
• Participant withdrawal due
   to non-primary colorectal
   cancer diagnosis, n = 18
• Participant withdrew consent
   from trial, n = 3
• Participant lost to follow-up,
   n = 3
• Participant withdrawn by
   consensus: not enough
   follow-up data, n = 1
• Participant had no consensus
   owing to administrative error,
   n = 1       
WB-MRI pathway
(n = 299)
WB-MRI and additional tests as
required 
Standard pathway
(n = 299)
CT and additional tests as required
Reference standard
(n = 299)
Consensus panel at 12 months
Excluded
(n = 650)
Withdrawals
(n = 71)
FIGURE 3 Streamline C participant flow diagram. Reproduced from Taylor et al.25 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions and
formatting changes to the original text.
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Of the 370 participants entering the trial, 71 were withdrawn, mainly owing to a final diagnosis other than
colorectal cancer (n = 18) or failure to undergo MRI, usually due to scheduling issues (n = 45) (see Figure 3
and Appendix 6, Table 44). The final cohort consisted of 299 participants, including 106 (35%) women
(Table 5 and see Figure 3). There we no reported series adverse reactions.
Overall, 17 participants (6%) died within the 12-month follow-up period with enough collected data for
the consensus panels to be confident in assigning a TNM stage.
The status of the primary tumour and follow-up imaging available to the panels is shown in Appendix 7,
Table 45.
Of the 299-participant cohort, as defined by the consensus panel, 288 participants (96%) were stage T2 or
above and 166 participants (56%) were node positive (See Appendix 8, Table 46).
In total, 24 participants (8%) had a threatened resection margin and 118 participants (40%) had extra
mural venous invasion (See Appendix 9, Table 47).
Overall, 68 participants (23%) had metastatic disease and 231 participants (77%) did not. The organ
location of the metastatic disease and the basis for diagnosis is shown in Table 6. A more detailed
TABLE 5 Demographics of the final study cohort
Characteristic n (%)
Sex
Male 193 (65)
Female 106 (35)
Age (years)
Mean (SD) 64 (12)
Range 30–90
Performance status
Fully active 199 (67)
Ambulatory (able to work) 31 (10)
Ambulatory (not able to work) 3 (1)
Not recorded 66 (22)
Tumour locationa
Rectum 130 (43)
Sigmoid 86 (29)
Descending 11 (4)
Transverseb 24 (8)
Ascending 29 (10)
Caecum 43 (14)
SD, standard deviation.
a By consensus reference standard. Some participants have multiple tumour locations.
b Flexures tumours were combined and categorised as transverse colon.
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breakdown is shown in Appendix 10, Table 48. The majority of participants with metastatic disease had
liver and/or lung metastasis, with three having metastatic spread to the bone.
The number of deposits per organ site is shown in Appendix 11, Table 49. The maximum size of the
metastasis at the time of staging is shown in Appendix 12, Table 50. Of the 48 participants with liver
metastasis, 37 participants’ largest deposit was ≥ 1 cm, and of the 20 participants with lung metastasis,
only five participants’ largest deposit was ≥ 1 cm. There were six participants in whom metastasis was not
visible on any staging investigation, even in retrospect, and became apparent only during the follow-up
period (but fulfilled the a priori definitions for metastatic disease at the time of staging).
A total of 10 participants had a second malignancy reported.
Equivocal results
The number of equivocal results according to the two staging pathways and WB-MRI alone is shown in
Appendix 13, Table 51. On a per-participant basis, four of the 68 participants with metastatic disease had
equivocal results based on the WB-MRI pathway, compared with seven participants based on the standard
pathway and nine participants based on WB-MRI alone. Of the 231 participants without metastases, seven
participants had equivocal results based on the WB-MRI pathway, compared with 14 participants based on
the standard pathway and 25 participants based on WB-MRI alone.
Streamline C: staging pathway tests
The type and number of standard staging tests performed prior to the first major treatment decision across
the whole cohort is shown in Table 7.
TABLE 6 Streamline C: organ sites of metastatic disease
Organ site
Number with
metastatic
diseasea
Histological
proof, n (%)
Imaging diagnosis without histological proof,b n (%)
Characteristic
imaging
appearances
Growth on
follow-up
Response
to therapy
Liver 48 12 (25) 33 (92) 26 (72) 19 (53)
Lung 20 0 (0) 19 (95) 13 (65) 11 (55)
Bone 3 0 (0) 3 (100) 2 (67) 1 (33)
Mesentery/peritoneum 7 2 (29) 4 (80) 4 (80) 1 (20)
Nodal (metastatic) 11 2 (28) 8 (89) 7 (78) 3 (33)
Otherc 2 1 (33) 2 (100) 2 (100) 0 (0)
a Participants may have more than one site of metastatic disease.
b Metastases may fulfil more than one criterion.
c Two participants with metastasis in three other sites (skin, ovary and vagina).
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The additional tests the MDT stated would have been generated by the WB-MRI is shown in Table 8.
The number of short-interval follow-up scans generated for equivocal findings by the alternative staging
pathways is shown in Appendix 14, Table 52. Overall, the standard imaging pathway generated 13 short-
interval follow-up tests and the WB-MRI staging pathway generated 16 short-interval follow-up tests.
Pathway results and outcomes
Primary outcome
The per-participant sensitivity and specificity for metastatic disease according to staging pathway is shown
in Table 9. The sensitivity analysis treating all equivocal results as either all positive or all negative is also
shown.
Overall, there was no significant difference in sensitivity for participants with metastasis between the
standard staging pathway [63% (95% CI 51% to 74%)] and the WB-MRI staging pathway [67% (95% CI
56% to 78%)], a difference in sensitivity of 4% (95% CI –5% to 13%; p = 0.508).
TABLE 7 Streamline C: constituent tests of the standard staging pathway
Test Number of tests, n (%)a
Chest, abdomen and pelvis CT 243 (81)
Pelvis/rectum MRIb 120 (40)
Chest CT 44 (15)
Abdomen and pelvis CT 27 (9)
Liver MRI 35 (12)
Colonography CT 10 (3)
PET-CT 43 (14)
Radiographyc 9 (3)
USd 12 (4)
Bone scan 2 (1)
Liver CT 3 (1)
Abdomen and pelvis MRI 4 (1)
Rectal US 4 (1)
Othere 2 (1)
a Participants may undergo more than one imaging test.
b One participant with two pelvis/rectum MRI.
c Two participants had two types of radiography (abdominal and chest).
d One participant had two types of US (abdominal and liver).
e Other tests include sigmoidoscopy and non-specified CT.
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TABLE 9 Streamline C: per-participant sensitivity and specificity for metastatic disease – standard staging pathway
vs. WB-MRI staging pathway against the consensus reference standard
Outcome
Sensitivity, % (95% CI; p-value) Specificity, % (95% CI; p-value)
Number
with
metastatic
diseasea
WB-MRI
staging
pathwayb
Standard
staging
pathway
Difference:
WB-MRIb vs.
standard
Number
without
metastatic
diseasea
WB-MRI
staging
pathwayb
Standard
staging
pathway
Difference:
WB-MRIb vs.
standard
Diagnostic
accuracyc
68 67
(56 to 78)
63
(51 to 74)
4 (–5 to 13;
0.508)
231 95
(92 to 97)
93
(90 to 96)
2 (–2 to 6;
0.481)
Equivocal
lesions
considered
positived
68 71
(59 to 80)
68
(56 to 78)
3 (–6 to 12;
0.727)
231 95
(91 to 97)
92
(88 to 95)
3 (–2 to 7;
0.286)
Equivocal
lesions
considered
negatived
68 65
(53 to 75)
58
(46 to 68)
7 (–2 to 17;
0.227)
231 98
(94 to 99)
98
(95 to 99)
0 (–3 to 2;
> 0.999)
a Participants by consensus reference standard.
b WB-MRI plus additional generated tests.
c Equivocal results considered positive for colonic tumours and negative for rectal tumours.
d Sensitivity analysis for imaging findings reported as equivocal.
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TABLE 8 Streamline C: MDT-stated additional staging tests generated by WB-MRI
Test Number of tests, n (%)a
Chest, abdomen and pelvis CT 5 (2)
Pelvis/rectum MRI 6 (2)
Chest CT 1 (1)
Abdomen and pelvis CT 0 (0)
Liver MRI 0 (0)
Colonography CT 0 (0)
PET-CT 0 (0)
Radiography 0 (0)
US 2 (1)
Bone scan 1 (1)
Liver CT 1 (1)
Abdomen and pelvis MRI 0 (0)
Rectal US 0 (0)
US-guided biopsy 1 (1)
Otherb 4 (1)
a Participants may undergo more than one imaging test.
b Four other tests include one spine MRI and three brain MRIs (two in same participant).
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Secondary outcomes
There was also no significant difference in specificity between the standard pathway and WB-MRI pathway
[93% (95% CI 90% to 96%) vs. 95% (95% CI 92% to 97%), respectively], a difference of 2% (95% CI
–2% to 6%). As would be expected, the sensitivity of both pathways increased if all equivocal findings
were assumed positive and decreased if all equivocal findings were considered negative, but there
remained no significant difference in sensitivity or specificity between the pathways (see Table 9).
Results in context
To place the results in context, in a hypothetical population of 1000 patients with newly diagnosed colon
cancer with a prevalence of 23% for metastatic disease, the number of patients with metastases correctly
identified with metastatic disease does not differ between the WB-MRI pathway and the standard staging
pathway. Of the 227 patients with metastatic disease, the results suggest that 10 more patients would be
identified with disease using the WB-MRI pathway (with 73 missed) compared with the standard pathway
(with 84 missed). However, this number could vary from 14 fewer patients to 36 more patients identified
with the WB-MRI pathway. On average, 154 and 144 patients with metastatic disease would be identified
correctly using the WB-MRI pathway and the standard pathway, respectively.
The number of patients without metastases diagnosed correctly is also not different in patients staged
using the WB-MRI pathway and standard pathway. In 773 patients without metastatic disease, 14 more
patients would be identified without metastatic disease using the WB-MRI pathway than using the
standard pathway, but this number could vary from 18 fewer to 44 more patients. On average, 736 and
722 patients without metastatic disease would be identified correctly using the WB-MRI pathway and the
standard pathway, respectively, with metastatic spread overdiagnosed in an average of 37 and 50 patients,
respectively.
Figure 4 presents these data graphically.
The per-participant sensitivity and specificity for metastatic disease according to staging pathway and size
of the largest metastatic deposit is shown in Table 10.
Sensitivity of both pathways was much higher when the largest metastasis was ≥ 1 cm than when it was
< 1 cm. There was no significant difference between pathways when analysed according to the size of the
largest metastatic deposit.
The per-participant sensitivity and specificity for metastatic disease in individual organ sites according to
staging pathway is shown in Appendix 15, Table 53. Overall, there were no significant differences
between pathways according to the site of metastatic deposit. Sensitivity in the liver was almost identical
[72% (95% CI 57% to 83%) for standard imaging and 74% (95% CI 60 %to 84%) for the WB-MRI
staging pathway]. The standard staging pathway detected 65% (95% CI 43% to 82%) of participants
with lung metastasis compared with 55% (95% CI 34% to 74%) for the WB-MRI staging pathway.
Local staging
The agreement of the staging pathways for local T stage based on the consensus reference standard is
shown in Table 11 and in participants with histological confirmation in Appendix 16, Table 54.
Overall, the WB-MRI staging pathway had 54% agreement for T stage compared with 60% for the
standard pathway, a non-significant difference of 6% (95% CI 0% to 12%). However, the differences
were statistically significant for both T3 and T4 stage, with the WB-MRI pathway achieving lower
agreement. When restricted to participants with histological proof of T stage, there was no overall
significant difference between the standard pathway and the WB-MRI pathway (51% vs. 47%),
a difference of 4% (95% CI –3% to 10%) (see Appendix 16, Table 54). However, agreement for
RESULTS: STREAMLINE C
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WB-MRI/standard
pathway result True diagnosis
Average number affected based a cohort of
1000 patients
Pathway
is correct for
disease presence
Pathway
is incorrect for
disease presence
• Pathway is correct
• Patient has
   metastatic disease
• True positive
• Pathway is correct
• Patient does not
   have metastatic
   disease
• True negative
n = 154 n = 144
WB-MRI pathway Standard pathway
Difference between WB-MRI pathway
and standard pathway
No statistical difference in the number
correctly diagnosed with metastatic
disease
10 more patients (could vary from
14 fewer patients to 36 more patients) for
WB-MRI compared with standard pathways
n = 722n = 736
n = 37 n = 50
n = 73 n = 84
Colorectal cancer
diagnosis referred
for staging
(example based on
1000 patients)
• Pathway is
   incorrect
• Patient does not
   have metastatic
   disease
• False positive
• Pathway is
   incorrect
• Patient does have
   metastatic disease
• False negative
No statistical difference in the number
correctly diagnosed without metastatic
disease
14 more patients (could vary from
18 fewer patients to 44 more patients) for
WB-MRI compared with standard pathways
FIGURE 4 Potential impact of staging colorectal cancer with WB-MRI staging pathway or standard staging pathway in a theoretical 1000-patient cohort.
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histologically confirmed T3 stage was significantly lower for the WB-MRI staging pathway (52%) than for
the standard staging pathway (62%), a difference of 10% (95% CI 1% to 20%). Conversely, the WB-MRI
pathway had higher agreement for T2 stage than standard staging [69% vs 52%, a difference of 17%
(95% CI 3% to 31%)].
The agreement of the staging pathways for local N stage based on the consensus reference standard is
shown in Table 12, and in participants with histological confirmation in Appendix 17, Table 55. Sensitivity
to detect nodal disease was 76% (95% CI 69% to 82%) for the WB-MRI staging pathway and 76%
(95% CI 69% to 82%) for the standard staging pathway, not significantly different. Specificity was 60%
and 61%, respectively, also not significantly different. Overall, there were no significant differences between
N staging across the whole cohort against the consensus reference standard or when the analysis was
restricted to participants with histological confirmation.
TABLE 10 Streamline C: per-participant sensitivity and specificity for metastatic disease according to the size of
metastasis – standard staging pathway vs. WB-MRI staging pathway against the consensus reference standard
Maximum
metastatic
deposit
size
Sensitivity, % (95% CI; p-value) Specificity, % (95% CI; p-value)
Number
with
metastatic
diseasea
WB-MRI
staging
pathwayb
Standard
staging
pathway
Difference:
WB-MRIb vs.
standard
Number
without
metastatic
diseasea
WB-MRI
staging
pathwayb
Standard
staging
pathway
Difference:
WB-MRIb vs.
standard
≥ 1cm 45 86
(74 to 94)
82
(69 to 91)
4 (–8 to 17;
0.688)
231 95
(92 to 97)
93
(90 to 96)
2 (–2 to 6;
0.481)
< 1cm 20 35
(18 to 57)
30
(15 to 52)
5 (–13 to 23;
> 0.999)
a Participants by consensus reference standard. Three participants had missing metastatic disease size.
b WB-MRI plus additional generated tests.
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TABLE 11 Streamline C: per-participant agreement for tumour T stage – standard staging pathway vs. WB-MRI
staging pathway against the consensus reference standard
T stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb
vs. standard, n (95% CI)WB-MRIb,c Standardc
T1 11 3 (27) 3 (27) 0 (–19 to 19)
T2 52 37 (71) 29 (56) 15 (2 to 29)
T3 174 100 (58) 120 (69) –11 (–20 to –3)
T4 58 19 (33) 25 (43) –10 (–20 to –1)
Total 295 159 (54) 177 (60) –6 (–12 to 0)
a Four participants had missing data.
b WB-MRI plus additional generated tests.
c 11 and six participants staged at Tx by WB-MRI staging pathway and standard staging pathway, respectively.
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Impact of staging pathways on primary treatment decision
The groupings of treatment decisions for analysis are shown in Table 3. The agreement between the
primary treatment decision based on the two staging pathways and the final MDT decision is shown in
Table 13, and agreement compared with the retrospective optimal treatment decision made by the
consensus reference standard panel is shown in Table 14.
TABLE 12 Streamline C: per-participant agreement for N stage – standard staging pathway vs. WB-MRI staging
pathway against the consensus reference standard
N stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb
vs. standard, n (95% CI)WB-MRIb Standard
N0 132 80 (60) 81 (61) –1 (–9 to 7)
N1 88 45 (51) 45 (51) 0 (–10 to 10)
N2 74 46 (62) 40 (54) 8 (–3 to 19)
Total 294 171 (58) 166 (56) 2 (–4 to 7)
a Five participants were missing data.
b WB-MRI plus additional generated tests.
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Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
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below includes minor additions and formatting changes to the original text.
TABLE 13 Streamline C: primary treatment decision according to the WB-MRI staging pathway and standard
staging pathway compared with the final MDT treatment decision
Participant group Total, nb
Staging pathway, n (%) Difference in
agreement:
WB-MRIb vs.
standard,
% (95% CI)
WB-MRIa Standard
Agreement Disagreement Agreement Disagreement
Colorectal cancer
All participants 296 284 (96) 12 (4) 282 (95) 14 (5) 1 (–2 to 4)
Colon cancer
All participants 168 166 (99) 2 (1) 165 (98) 3 (2) 1 (–3 to 4)
Participants with
metastatic disease
33 33 (100) 0 (0) 32 (97) 1 (3) 3 (–6 to 12)
Participants without
metastatic disease
135 133 (99) 2 (1) 133 (99) 2 (1) 0 (–4 to 4)
Rectal cancer
All participants 128 118 (92) 10 (8) 117 (91) 11 (9) 1 (–5 to 7)
Participants with
metastatic disease
32 28 (88) 4 (12) 28 (88) 4 (12) 0 (–10 to 10)
Participants without
metastatic disease
96 90 (94) 6 (6) 89 (93) 7 (7) 1 (–7 to 9)
a Three participants were missing at least one type of participant management decision.
b WB-MRI plus additional generated tests.
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There was no significant difference between the WB-MRI and standard pathways in terms of primary
treatment decision compared with the MDT final decision or with the retrospective consensus panel
decision for either rectal or non-rectal colon cancer. For both pathways, agreement with the optimal
retrospective treatment decision (which considered 12 months of participant follow-up) was lower
than with the contemporaneous final MDT treatment decision. A more detailed breakdown of
agreement between staging pathways and the retrospective consensus panel decision for rectal and
non-rectal colon cancer for specific treatment decision categories is shown in Appendices 18–21,
Tables 56–59.
Time to complete staging
The time taken to complete staging for the standard pathway and that modelled for the WB-MRI pathway
is shown in Table 15 and Appendix 22, Table 60.
Overall, the WB-MRI staging pathway was significantly shorter than the standard staging pathway
[by 5 days (95% CI 3 to 7 days)], and in participants with [10 days (95% CI 3 to 17 days)] and without
[4 days (95% CI 2 to 7 days)] metastatic disease. For the WB-MRI staging pathway the interquartile
range was 4–13 days, compared with 8–25 days for the standard staging pathway.
TABLE 14 Streamline C: primary treatment decision according to the WB-MRI staging pathway and standard
staging pathway compared with the retrospective optimal consensus panel treatment decision
Participant group Total nb
Staging pathway, n (%) Difference in
agreement:
WB-MRIb vs.
standard,
% (95% CI)
WB-MRIa Standard
Agreement Disagreement Agreement Disagreement
Colorectal cancer
All participants 296 201 (68) 95 (32) 201 (68) 95 (32) 0 (–3 to 3)
Colon cancer
All participants 168 120 (71) 48 (29) 119 (70) 49 (30) 1 (–2 to 3)
Participants with
metastatic disease
33 18 (55) 15 (45) 17 (52) 16 (48) 3 (–5 to 11)
Participants without
metastatic disease
135 102 (76) 33 (24) 102 (76) 33 (24) 0 (–3 to 3)
Rectal cancer
All participants 128 81 (63) 47 (37) 82 (64) 46 (36) –1 (–6 to 5)
Participants with
metastatic disease
32 11 (34) 21 (66) 11 (34) 21 (66) 0 (–7 to 7)
Participants without
metastatic disease
96 70 (73) 26 (27) 71 (74) 25 (26) –1 (–8 to 6)
a WB-MRI plus additional generated tests.
b Three participants missing at least one type of participant management decision.
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Number of tests in staging pathways
The median number of imaging or endoscopic tests in the staging pathways until the MDT was able to
make the first major treatment decision is shown in Table 16. Across the whole cohort, the standard
pathway utilised 558 tests (see Table 7) and the WB-MRI pathway 320 tests (including the 21 additional
tests generated by the 299 WB-MRI scans; see Table 8). WB-MRI pathways required significantly fewer
tests that standard pathways (median 1 [1 to 1]).
WB-MRI as a stand-alone investigation
The diagnostic accuracy of WB-MRI as a stand-alone investigation (based on the original radiologist report)
is shown in Appendix 23, Table 61.
As a stand-alone investigation, WB-MRI had a sensitivity of 70% (95% CI 59% to 80%) for participants
with metastasis, compared with 63% (95% CI 51% to 74%) for standard pathways, a difference of 7%
(95% CI –3% to 18%), which was not statistically significant.
The per-participant sensitivity and specificity for metastatic disease in individual organ sites for WB-MRI as
a stand-alone investigation is shown in Appendix 24, Table 62. There was no significant individual organ
difference between pathways.
TABLE 15 Streamline C: time to complete staging according to treatment pathway
Participant group
Staging pathway, median days
(95% CI)
Difference: WB-MRIa
vs. standard (95% CI)WB-MRIa Standard
All participants 8 (6 to 9) 13 (11 to 15) –5 (–7 to –3)
Participants with metastatic disease 8 (6 to 11) 18 (12 to 25) –10 (–17 to –3)
Participants without metastatic disease 8 (6 to 9) 12 (11 to 14) –4 (–7 to –2)
a WB-MRI plus additional generated tests.
Reproduced from Taylor et al.25 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
TABLE 16 Streamline C: total number of imaging/endoscopic tests before the first major treatment decision
according to staging pathway
Participant group
Staging pathway, median number
of tests (95% CI)
Difference: WB-MRIa
vs. standard (95% CI)WB-MRIa Standard
All participants 1 (1 to 1) 2 (2 to 2) –1 (–1 to –1)
Participants with metastatic disease 1 (1 to 1) 2 (2 to 3) –1 (–2 to –1)
Participants without metastatic disease 1 (1 to 1) 2 (2 to 2) –1 (–1 to –1)
a WB-MRI plus additional generated tests.
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The agreement of WB-MRI alone for local T stage based on the consensus reference standard is shown in
Appendix 25, Table 63 and in participants with histological confirmation in Appendix 26, Table 64.
Overall, and against the consensus, WB-MRI alone had lower agreement than the standard pathway for
T stage (46% vs. 64%, respectively), a difference of 18% (95% CI 10% to 25%). The differences were
also statistically significant for T3-stage tumours. When restricted to participants with histological proof of
T stage, there remained an overall significant difference between WB-MRI alone and the standard pathway
(40% vs. 56%, respectively), a difference of 16% (95% CI 7% to 25%) (see Appendix 26, Table 64).
The agreement of WB-MRI alone for local N stage based on the consensus reference standard is shown in
Appendix 27, Table 65 and in participants with histological confirmation in Appendix 28, Table 66.
Overall, WB-MRI alone had significantly less agreement for overall N stage than the standard pathway
(45% vs. 55%, respectively), a difference of 10% (95% CI 4% to 17%). This was also the case when the
analysis was restricted to participants with histological proof of N stage (41% vs. 51%, respectively), a
difference of 10% (95% CI 3% to 17%) (see Appendix 28, Table 66). WB-MRI had 64% (95% CI 56% to
71%) sensitivity for nodal disease, compared with 75% (95% CI 68% to 81%) for the standard pathway,
a significant difference of 11% (95% CI –19% to –3%). Specificity of WB-MRI alone was also significantly
lower than the standard pathway [47% (95% CI 39% to 56%) vs. 60% (95% CI 51% to 69%),
respectively, a difference of 13% (95% CI –22% to –4%)].
The per-participant sensitivity and specificity for metastatic disease of WB-MRI alone compared with
standard chest, abdomen and pelvis CT is shown in Appendix 29, Table 67. WB-MRI had a significantly
higher sensitivity than the standard pathway [76% (95% CI 63% to 86%) vs. 50% (95% CI 37% to
63%), respectively, a difference of 26% (95% CI 13 to 39)], but lower specificity [86% (95% CI 81% to
91%) vs. 99% (95% CI 97% to 100%), respectively, a difference of 13% (95% CI 9% to 18%)].
WB-MRI as an additional investigation
The diagnostic accuracy of WB-MRI when added as an additional test to the standard staging pathway is
shown in Appendix 30, Table 68.
When WB-MRI was added to the standard staging pathway, sensitivity increased from 63% (95% CI 51%
to 73%) to 71% (95% CI 59% to 80%), a difference of 7% (95% CI 0% to 14%). Specificity was almost
identical [94% (95% CI 90% to 96%) for standard staging and 95% (95% CI 91% to 97%) for standard
staging plus WB-MRI].
Perceptual errors
The number of participants with metastases for whom radiologists made at least one perceptual error
(i.e. seen in retrospect by the consensus panel) according to the staging pathways is shown in Appendix 31,
Table 69 and per organ in Appendix 32, Table 70.
The number of participants with at least one perceptual error was very similar for the WB-MRI staging
pathway (16 participants), standard staging pathway (15 participants) and WB-MRI as a stand-alone
investigation (16 participants). In many of these participants at least one metastatic deposit was also
correctly detected. Overall, for the primary outcome (i.e. per-participant detection of metastasis) there were
three perceptual errors in the WB-MRI pathway and six in the standard pathway.
RESULTS: STREAMLINE C
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WB-MRI quality assurance: Streamline C
The quality assurance scoring system is described in Chapter 2 (see Appendix 2, Table 41). The summary
WB-MRI quality assurance scores for Streamline C participants is shown in Appendix 33, Table 71,
including Streamline L scores for comparison. A more detailed breakdown of scores for those scans judged
as suboptimal or degraded is shown in Appendix 34, Table 72, and Appendix 35, Table 73. This includes
some participants ultimately excluded from the final trial cohorts. Overall, 36 Streamline C WB-MRI scans
were scored as degraded (including those of two participants ultimately withdrawn from the trial). Of the
remaining 34 WB-MRI scans, just four attracted a technical quality score of 1 (more than one sequence
with substantial degradation of the images). Of the 17 WB-MRI scans attracting an anatomical coverage
score of 1, 10 received this score because gadolinium was not administered.
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Chapter 4 Results: Streamline L
Parts of this chapter are reproduced from Taylor et al.26 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Participants
Recruitment commenced in March 2013 and was completed in August 2016. Overall, 976 patients were
screened for eligibility, of whom 623 were excluded (Figure 5 and Appendix 36, Table 74). Of the 353
participants entering the trial, 166 were withdrawn, mainly owing to a final diagnosis other than
Screened patients
(n = 976)
Excluded
(n = 623)
• Evidence of severe or
   uncontrolled systematic
   disease, n = 113
• Unequivocal metastatic or
   N3 disease, n = 110
• Patient did not want extra
   visit, n = 86
• Patient felt it would delay
   potential treatment, n = 62
• Histology other than NSCLC,
   n = 53
• Patient did not want
   WB-MRI scan, n = 52
• Contraindications to WB-MRI,
   n = 47
• Site error/missed opportunity,
   n = 29
• Further staging work-up not
   indicated, n = 27
• Too frail/not fit enough, n = 20
• Language barrier, n = 14
• Psychiatric or other condition
   likely to impact on informed
   consent, n = 10
Recruited participants
(n = 353)
Included participants
(n = 187)
• Participant withdrawal due to
   NSCLC diagnosis, n = 84
• Participant withdrawal due to
   failure to undergo WB-MRI,
   n = 75
• Participant withdrew consent
   to follow-up, n = 4
• Participant lost to follow-up,
   n = 1
• Participant withdrawal due to
   early release of WB-MRI
   findings, n = 1
• Participant died after
   registration, n = 1
WB-MRI pathway
(n = 187)
WB-MRI and additional tests
as required
Reference standard
(n = 187)
Consensus panel at 12 months
Standard pathway
(n = 187)
CT and additional tests as
required
Withdrawals
(n = 166)
FIGURE 5 Streamline L: participant flow diagram. NSCLC, non-small-cell lung cancer. Reproduced from Taylor et al.26
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non-small-cell lung cancer (n = 84) or failure to undergo MRI, usually owing to scheduling issues (n = 75)
(see Appendix 37, Table 75). The final cohort consisted of 187 participants, including 70 women (37%)
(Table 17 and see Figure 5). There were no reported series adverse reactions.
Overall, 31 (17%) participants died within the 12-month follow-up period with enough collected data for
the consensus panels to be confident in assigning a TNM stage.
The status of the primary tumour and follow-up imaging available to the panels is shown in Appendix 38,
Table 76.
TABLE 17 Demographics of the final study: Streamline L cohort
Characteristic n (%)
Sex
Male 117 (63)
Female 70 (37)
Age (years)
Mean (SD) 68 (10)
Range 37 to 96
Performance status
Fully active 86 (46)
Ambulatory (able to work) 75 (40)
Ambulatory (not able to work) 8 (4)
Not recorded 18 (10)
Tumour locationa
Right upper lobe 73 (39)
Right middle lobe 14 (7)
Right lower lobe 24 (13)
Left upper lobe (including lingula) 54 (29)
Left lower lobe 28 (15)
Histological subtype
Adenocarcinoma 115 (62)
Large cell 4 (2)
Squamous 42 (22)
Adenosquamous 1 (1)
Other 13 (7)
No histology (clinical diagnosis of NSCLC)/missing 12 (6)
NSCLC, non-small-cell lung cancer; SD, standard deviation.
a By consensus reference standard. Some participants have multiple tumour locations.
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Of the 187 participants in the cohort, as defined by the consensus panel, 137 participants (73%) were
stage T2a or above and 77 participants (41%) were node positive (see Appendix 39, Table 77). The
detailed sites of nodal involvement are shown in Appendix 40, Table 78.
Overall, 52 participants (28%) had metastatic disease [8 M1a (7%) and 44 M1b (24%)] and 135 participants
did not have metastasis. The organ location of the metastatic disease and the basis for diagnosis is shown
in Table 18 and a more detailed breakdown in Appendix 41, Table 79. The majority of participants with
metastasis had at least liver (n = 9), bone (n = 15), brain (n = 14) and/or lung (n = 14) metastasis.
The number of deposits per organ site is shown in Appendix 42, Table 80. The maximum size of the
metastasis at the time of staging is shown in Appendix 43, Table 81. In eight participants, the metastasis
was not visible on any staging investigation, even in retrospect, and only became apparent during the
12-month follow-up period.
A total of seven participants had a second malignancy reported.
Equivocal results
The number of equivocal results according to the two staging pathways and WB-MRI alone is shown in
Appendix 44, Table 82.
On a per-participant basis, one of the 52 participants with metastatic disease had equivocal results based
on the WB-MRI pathway, compared with four participants based on the standard pathway and two
participants based on WB-MRI alone. Of the 135 participants without metastases, one participant had
equivocal results based on the WB-MRI pathway, compared with two participants based on the standard
pathway and 17 participants based on WB-MRI alone.
TABLE 18 Streamline L: organ sites of metastatic disease
Site
Number of
participantsa
Histological
proof, n (%)
If imaging diagnosis if no histology,b n (%)
Characteristic imaging
appearances
Growth on
follow-up
Response
to therapy
Liver 9 2 (22) 6 (86) 4 (57) 1 (14)
Lung 14 0 (0) 14 (100) 11 (79) 3 (21)
Pleura 5 1 (20) 4 (100) 2 (50) 1 (25)
Brain 14 1 (7) 13 (100) 8 (62) 4 (31)
Adrenal 7 0 (0) 6 (86) 5 (71) 1 (14)
Bone 15 1 (7) 14 (100) 7 (50) 2 (14)
Otherc 9 2 (15) 11 (100) 5 (45) 0 (0)
a Participants may have more than one site of metastatic disease.
b Metastasis may fulfil more than one criterion for imaging diagnosis.
c Nine participants with metastasis in 11 other sites (pancreas, limbs soft tissue, para-aortic node, abdomen/pelvis soft
tissue, right thyroid, left axilla, neck/chest soft tissue, right kidney, leptomeningeal, right axillary node and
mesenteric node).
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Streamline L: staging pathway tests
The type and number of standard staging tests performed prior to the first major treatment decision across
the whole cohort is shown in Table 19.
The additional tests the MDT stated would have been generated by the WB-MRI are shown in Table 20.
TABLE 19 Streamline L: constituent tests of the standard staging pathway
Test Number of tests (%)a
Neck chest and abdomen CT 3 (2)
Chest CTb 8 (4)
Abdomen and pelvis CT 11 (6)
Chest and abdomen CT 5 (3)
Chest abdomen and pelvis CT 2 (1)
PET-CTc 181 (97)
Head CTd 25 (13)
Head MRIe 16 (9)
TBNA 0 (0)
EBUS 6 (3)
EUS 2 (1)
Bone scan 0 (0)
CT-guided biopsy 5 (3)
Liver CTf 6 (3)
US-guided biopsy 6 (3)
USg 8 (4)
Adrenal MRI 2 (1)
MSK-MRI 2 (1)
Other MRI 1 (1)
Radiographyh 9 (5)
Otheri 4 (2)
EUS, endoscopic ultrasonography; MSK-MRI, musculoskeletal magnetic resonance imaging; TBNA, transbronchial
needle aspiration.
a Participants may undergo more than one imaging test.
b One participant had two chest CTs.
c Two participants had two PET-CTs.
d One participant had two head CTs.
e One participant had two head MRIs.
f One participant had two liver CTs.
g One participant had two ultrasounds (transvaginal and abdominal and renal tract).
h One participant had three radiographs.
i Other tests include three bronchial washings and one surgical biopsy.
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The number of short-interval follow-up scans generated for equivocal findings by the alternative staging
pathways is shown in Appendix 45, Table 83. Overall, the standard imaging pathway generated four
short-interval follow-up tests and the WB-MRI staging pathway generated two.
Pathway results and outcomes
Primary outcome
The per-participant sensitivity and specificity for metastatic disease according to staging pathway is shown
in Table 21. The sensitivity analysis treating all equivocal results as positive or negative is also shown.
Overall, there was no significant difference in sensitivity for participants with metastasis between the
standard staging pathway [54% (95% CI 41% to 67%)] and the WB-MRI staging pathway [50% (95% CI
37% to 63%)], a difference of 4% (95% CI –7% to 15%; p = 0.727).
TABLE 20 Streamline L: MDT-stated additional staging tests generated by the WB-MRI
Test Number of tests (%)a
Neck chest and abdomen CT 0 (0)
Chest CT 0 (0)
Abdomen and pelvis CT 0 (0)
Chest and abdomen CT 0 (0)
Chest abdomen and pelvis CT 1 (1)
PET-CT 26 (14)
Head CT 0 (0)
Head MRI 6 (3)
TBNA 0 (0)
EBUS/TBNA 4 (2)
EUS 1 (1)
Bone scan 0 (0)
CT-guided biopsy 0 (0)
Liver CT 0 (0)
US-guided biopsy 1 (1)
US 4 (2)
Adrenal MRI 0 (0)
MSK-MRI 0 (0)
Other MRI 2 (1)
Radiography 0 (0)
Other 0 (0)
EUS, endoscopic ultrasonography; MSK-MRI, musculoskeletal magnetic resonance imaging; TBNA, transbronchial
needle aspiration.
a Participants may undergo more than one imaging test.
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Secondary outcomes
There was no significant difference in specificity between the standard and WB-MRI pathways [95%
(95% CI 91% to 98%) vs. 93% [95% CI 88% to 96%], respectively, a difference of 2% (95% CI –2% to 7%)].
As expected, sensitivity of both pathways decreased if equivocal lesions were considered negative, but there
remained no significant difference in sensitivity or specificity between the pathways (see Table 21).
Results in context
To place the results in context, in a hypothetical population of 1000 patients with newly diagnosed
non-small lung cancer with a prevalence of 28% for metastatic disease, the number of patients with
metastases diagnosed correctly does not differ between the WB-MRI pathway and the standard staging
pathway. Of the 278 patients with metastatic disease, the results suggest that 11 more patients would be
identified with metastatic disease using the standard staging pathway (with 128 patients missed) than
using the WB-MRI pathway (with 139 patients missed). However, this number could vary from 20 fewer
patients to 42 more patients.
The number of patients without metastases diagnosed correctly is also not different in patients staged
using the WB-MRI and standard pathways. In 722 patients without metastatic disease, 16 more patients
would be identified without metastatic disease using the standard pathway than using the WB-MRI pathway,
but this number could vary from 16 fewer patients to 48 more patients. On average, 674 and 690 patients
without metastatic disease would be identified correctly using the WB-MRI pathway and standard pathway,
respectively, with metastatic spread overdiagnosed in an average of 48 and 32 patients, respectively. Figure 6
presents these data graphically.
The per-participant sensitivity and specificity for metastatic disease according to staging pathway and size
of the largest metastatic deposit is shown in Table 22.
Sensitivity of both pathways was much higher when the largest metastasis was ≥ 1 cm than when it was
< 1 cm. There was no significant difference between pathways when analysed according to the size of the
largest metastatic deposit.
The per-participant sensitivity and specificity for metastatic disease in individual organ sites according to
staging pathway is shown in Appendix 46, Table 84.
TABLE 21 Streamline L: per-participant sensitivity and specificity for metastatic disease – standard staging pathway
vs. WB-MRI staging pathway against the consensus reference standard
Outcome
Sensitivity, % (95% CI; p-value) Specificity, % (95% CI; p-value)
Number
with
metastatic
diseasea
WB-MRI
staging
pathwayb
Standard
staging
pathway
Difference:
WB-MRI vs.
standard
Number
without
metastatic
diseasea
WB-MRI
staging
pathwayb
Standard
staging
pathway
Difference:
WB-MRI vs.
standard
pathway
Diagnostic
accuracyc
52 50
(37 to 63)
54
(41 to 67)
–4 (–15 to 7;
0.727)
135 93
(88 to 96)
95
(91 to 98)
–2 (–7 to 2;
0.453)
Sensitivity
analysisd
52 48
(35 to 61)
46
(33 to 59)
2 (–11 to 14;
> 0.999)
135 94
(89 to 97)
97
(93 to 99)
–3 (–6 to 1;
0.125)
a Participants by consensus reference standard.
b WB-MRI plus additional generated tests.
c Equivocal lesions considered positive.
d Equivocal lesions considered negative.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
RESULTS: STREAMLINE L
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
WB-MRI/standard
pathway result True diagnosis
Average number affected based a cohort of
1000 patients
Pathway
is correct for
disease presence
Pathway
is incorrect for
disease presence
• Pathway is correct
• Patient has
   metastatic disease
• True positive
• Pathway is correct
• Patient does not
    have metastatic
    disease
• True negative
n = 139 n = 150
WB-MRI pathway Standard pathway
Difference between WB-MRI pathway
and standard pathway
No statistical difference in the number
of patients correctly diagnosed with
metastatic disease
11 more patients (could vary from
20 fewer patients to 42 more
patients) for standard compared
with WB-MRI pathways
n = 690n = 674
n = 48 n = 32
n = 139 n = 128
Non-small lung
 cancer diagnosis
referred for
staging
(example based on
1000 patients)
• Pathway is
   incorrect
• Patient does not
   have metastatic
   disease
• False positive
• Pathway is
   incorrect
• Patient does have
   metastatic disease
• False negative
No statistical difference in the number
of patients correctly diagnosed without
metastatic disease
16 more patients (could vary from
16 fewer patients to 48 more
patients) for standard compared
with WB-MRI pathways
FIGURE 6 Potential impact of staging non-small-cell lung cancer with WB-MRI or standard staging pathway in a theoretical 1000-patient cohort.
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Overall, there were no significant differences between pathways according to the site of metastasis
deposit. Sensitivity in the lung was identical [36% (95% CI 16% to 61%)]. The standard staging pathway
detected six (44% [95% CI 21 to 67]) out of 14 participants with brain metastasis compared with eight
[57% (95% CI 33% to 79%)] participants with brain metastasis for the WB-MRI staging pathway.
Local staging
The agreement of the staging pathways for local T stage based on the consensus reference standard is
shown in Table 23 and in participants with histological confirmation in Appendix 47, Table 85.
TABLE 22 Streamline L: per-participant sensitivity and specificity for metastatic disease according to the size of
metastasis – standard staging pathway vs. WB-MRI staging pathway against the consensus reference standard
Maximum metastatic
deposit size
Number with
metastatic diseasea,b
Sensitivity, % (95% CI; p-value)
Staging pathway
Difference: WB-MRIc
vs. standardWB-MRIc Standard
≥ 1cm 22 82 (64 to 92) 75 (57 to 87) 7 (–9 to 23; 0.625)
< 1cm 28 9 (3 to 28) 27 (13 to 48) –18 (–37 to 1; 0.125)
Number without metastatic diseasea,b
Specificity, % (95% CI; p-value)
Staging pathway
Difference: WB-MRIc
vs. standardWB-MRIc Standard
135 93 (88 to 96) 95 (91 to 98) –2 (–7 to 2; 0.453)
a Participants by consensus reference standard.
b Two participants were missing the largest metastatic disease size.
c WB-MRI plus additional generated tests.
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TABLE 23 Streamline L: per-participant agreement for tumour T stage – standard staging pathway vs. WB-MRI
staging pathway against the consensus reference standard
T stage
Number of
participantsa
Staging pathway, n (%) Difference in
agreement: WB-MRIb
vs. standard pathway,
% (95% CI; p-value)WB-MRIb,c Standardc
T1a 29 28 (97) 26 (90) 7 (–9 to 22)
T1b 18 9 (50) 8 (44) 6 (–18 to 29)
T2a 51 20 (39) 23 (45) –6 (–20 to 8)
T2b 23 8 (35) 9 (39) –4 (–30 to 21)
T3 33 21 (64) 17 (52) 12 (–9 to 33)
T4 29 13 (45) 17 (59) –14 (–39 to 11)
Overall T stage 183 99 (54) 100 (55) –1 (–9 to 8; 1.00)
a Four participants were missing data.
b WB-MRI plus additional generated tests.
c One participant each staged Tx by WB-MRI and standard staging pathways.
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Overall, and against the consensus, there was no significant difference in T stage agreement between
pathways. When restricted to participants with histological proof of T stage, there remained no significant
difference between the two pathways.
The sensitivity of the agreement pathways for local N stage based on the consensus reference standard is
shown in Table 24 and in participants with histological confirmation in Appendix 48, Table 86. A more
detailed nodal-site breakdown is shown in Appendix 49, Table 87.
Overall, the WB-MRI staging pathway had lower agreement for N stage (65%) than the standard staging
pathway (75%), a difference of 10% (95% CI 3% to 18%). When restricted to participants with histological
proof of N stage, there remained a statistically significant 10% (95% CI 1% to 19%) difference between
the WB-MRI staging pathway and the standard staging pathway (72% vs. 62%, respectively). Sensitivity to
detect nodal disease was 71% (95% CI 61% to 80%) for WB-MRI staging pathway and 84% (95% CI 75%
to 91%) for the standard staging pathway, a significant difference of 13% (95% CI 3% to 22%). Specificity
was 80% (95% CI 72% to 87%) and 86% (95% CI 78% to 91%), respectively, not significantly different.
Impact of staging pathways on primary treatment decision
The groupings of treatment decisions for analysis are shown in Table 4. The agreement between the
primary treatment decision based on the two staging pathways and the final MDT decision is shown in
Table 25, and agreement compared with the retrospective optimal treatment decision made by the
consensus reference standard panel is shown in Table 26.
There was no significant difference between the WB-MRI pathway and standard pathway in terms of
primary treatment decision compared with either the MDT final decision or retrospective consensus panel
decision. For both pathways, agreement with the optimal retrospective treatment decision was lower than
with the contemporaneous final MDT treatment decision. A more detailed breakdown of agreement
between staging pathways is shown in Appendix 50, Table 88, and agreement with the retrospective
consensus panel decision in Appendix 51, Table 89.
TABLE 24 Streamline L: per-participant agreement for N stage – standard staging pathway vs. WB-MRI staging
pathway against the consensus reference standard
N stage
Number of
participantsa
Staging pathway, n (%) Difference in agreement:
WB-MRIb vs. standard pathway,
% (95% CI)WB-MRIb Standardc
N0 107 86 (80) 92 (86) –6 (–14 to 3)
N1 21 3 (14) 8 (38) –24 (–49 to 2)
N2 36 20 (56) 26 (73) –17 (–39 to 5)
N3 20 10 (50) 12 (60) –10 (–34 to 14)
Overall N stage 184 119 (65) 138 (75) –10 (–18 to –3)
a Three participants were missing data.
b WB-MRI plus additional generated tests.
c One participant staged Nx by standard staging pathway.
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Time to complete staging
The time taken to complete staging for the standard pathway and that modelled for the WB-MRI pathway
is show in Table 27 and in Appendix 52, Table 90.
The time taken to stage the participant was significantly less with the WB-MRI pathway than with the
standard pathway, with a median difference of 6 days (95% CI 4 to 8 days), increasing to 7 days (95% CI
3 to 11 days) in those with metastatic disease. For the WB-MRI staging pathway the interquartile range
was 7–19 days, compared with 13–31 days for the standard staging pathway.
TABLE 25 Streamline L: primary treatment decision according to the WB-MRI staging pathway and standard
staging pathway compared with the final MDT treatment decision
Participant group Total, nb
Staging pathway, n (%) Difference in
agreement:
WB-MRIb vs.
standard pathway,
% (95% CI)
WB-MRIa Standard
Agreement Disagreement Agreement Disagreement
All participants 183 180 (98) 3 (2) 181 (99) 2 (1) –1 (–4 to 2)
Participants with
metastatic disease
52 51 (98) 1 (2) 50 (96) 2 (4) 2 (–7 to 11)
Participants
without metastatic
disease
131 129 (98) 2 (2) 131 (100) 0 (0) –2 (–4 to 1)
a WB-MRI plus additional generated tests.
b Four participants were missing at least one type of participant treatment decision.
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TABLE 26 Streamline L: primary treatment decision according to the WB-MRI staging pathway and standard
staging pathway compared with the retrospective optimal consensus panel treatment decision
Participant group Total, nb
Staging pathway, n (%) Difference in
agreement:
WB-MRIb vs.
standard pathway,
% (95% CI)
WB-MRIa Standard
Agreement Disagreement Agreement Disagreement
All participants 183 152 (83) 31 (17) 151 (82) 32 (17) 1 (–2 to 3)
Participants with
metastatic disease
52 29 (56) 23 (44) 28 (54) 24 (46) 2 (–5 to 9)
Participants
without metastatic
disease
131 123 (94) 8 (6) 123 (94) 8 (6) 0 (–4 to 4)
a WB-MRI plus additional generated tests.
b Four participants were missing at least one type of participant management decision.
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Number of tests in staging pathways
The median number of imaging or endoscopic tests in the staging pathways prior to the first major
treatment decision is shown in Table 28. Across the whole cohort the standard pathway utilised 302 tests
(see Table 19) and the WB-MRI pathway utilised 232 tests (including the 45 additional tests generated by
the 187 WB-MRI scans; see Table 20). Overall, however, there was no significant difference in the number
of tests in each pathway.
WB-MRI as a stand-alone investigation
The diagnostic accuracy of WB-MRI as a stand-alone investigation (based on the original radiologist report)
is shown in Appendix 53, Table 91.
As a stand-alone investigation, WB-MRI had a sensitivity of 50% (95% CI 37% to 63%) for participants
with metastasis, compared with 54% (95% CI 41% to 67%) for standard pathways, a difference of 4%
(95% CI –16% to 8%), which was not statistically significant. However, WB-MRI had lower specificity
compared with the standard pathway [85% (95% CI 78% to 90%) vs. 95% (95% CI 91% to 98%),
a difference of –10% (95% CI –17% to –4%)].
The per-participant sensitivity and specificity for metastatic disease in individual organ sites for WB-MRI as
a stand-alone investigation is shown in Appendix 54, Table 92. There was no significant individual organ
differences between pathways.
TABLE 27 Streamline L: time to complete staging according to treatment pathway
Participant group
Staging pathway, days (95% CI) Difference: WB-MRI
vs. standard pathway,
days (95% CI)WB-MRI Standard
All participants 13 (12 to 14) 19 (17 to 21) –6 (–8 to –4)
Participants with metastatic disease 13 (11 to 15) 20 (16 to 23) –7 (–11 to –3)
Participants without metastatic disease 13 (11 to 14) 19 (16 to 21) –6 (–9 to –3)
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TABLE 28 Streamline L: total number of imaging/endoscopic tests before the first major treatment decision
according to staging pathway
Participant group
Staging pathway, number of tests
(95% CI) Difference: WB-MRI
vs. standard pathway,
number of tests (95% CI)WB-MRI Standard
All participants 1 (1 to 1) 1 (1 to 2) 0 (–1 to 0)
Participants with metastatic disease 1 (1 to 1) 2 (1 to 2) –1 (–1 to 0)
Participants without metastatic disease 1 (1 to 1) 1 (1 to 1) 0 (0 to 0)
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The agreement of WB-MRI alone for local T stage based on the consensus reference standard is shown
in Appendix 55, Table 93 and in participants with histological confirmation in Appendix 56, Table 94.
There was no significant difference between WB-MRI alone and standard staging pathways for T stage
agreement against the consensus reference standard [9% difference (95% CI 0% to 17%)]. However,
in those with histological proof, standard pathways had significantly higher agreement than WB-MRI alone
[55% vs. 42%, respectively, a 13% (95% CI 3% to 23%) difference].
The agreement of WB-MRI alone for local N stage based on the consensus reference standard is shown
in Appendix 57, Table 95 and in participants with histological confirmation in Appendix 58, Table 96.
WB-MRI alone had significantly lower agreement for overall N stage compared with standard pathways
[60% vs. 74%, respectively, a difference of –14% (95% CI –22% to –6%)]. However, when the analysis
was restricted to participants with histological proof, there was a non-significant difference of 10% (95% CI
0% to 20%) (see Appendix 58, Table 96). The sensitivity of WB-MRI alone for nodal disease was 67% (95% CI
56% to 77%), which was significantly lower than for standard pathways [84% (95% CI 75% to 91%),
a difference of –17% (95% CI –29% to –5%)]. Specificity was 76% (95% CI 67% to 83%) for WB-MRI
alone and 85% (95% CI 76% to 90%) for standard pathways, a difference of –9% (95% CI –17% to 0%).
The per-participant sensitivity and specificity for metastatic disease of WB-MRI alone compared with standard
PET-CT is shown in Appendix 59, Table 97. There was no significant difference in sensitivity between WB-MRI
and PET-CT [47% (95% CI 33% to 61%) vs. 53% (95% CI 39% to 67%), respectively]. Specificity was also
not significantly different [85% (95% CI 78% to 91%) vs. 90% (95% CI 84% to 94%), respectively].
WB-MRI as an additional investigation
The diagnostic accuracy of WB-MRI when added as an additional test to the standard staging pathway is
shown in Appendix 60, Table 98. When WB-MRI was added to the standard staging pathway, sensitivity
increased from 54% (95% CI 41% to 67%) to 60% (95% CI 46% to 72%), a difference of 6% (95% CI
–3 to 14%). Specificity was identical 96% (95% CI 91% to 98%).
Perceptual errors
The number of participants with metastases in whom radiologists made at least one perceptual error
(i.e. seen in retrospect by the consensus panel) according to the staging pathways is shown in Appendix 61,
Table 99, and per organ in Appendix 62, Table 100.
The number of participants with at least one perceptual error was greater for the WB-MRI staging pathway
(18 participants) compared with the standard staging pathway (seven participants). For WB-MRI as a
stand-alone test there was perpetual errors for 19 participants. In many of these participants at least one
metastatic deposit was also correctly detected. Overall, for the primary outcome (i.e. per-participant detection
of metastasis) there were seven perceptual errors in the WB-MRI pathway and three in the standard pathway.
WB-MRI quality assurance: Streamline L
The summary WB-MRI quality assurance scores for Streamline L participants are shown in Appendix 33,
Table 71, including Streamline C scores for comparison. A more detailed breakdown of scores for those
scans judged as suboptimal or degraded is shown in Appendix 34, Table 72, and Appendix 35, Table 73.
This includes some participants ultimately excluded from the final trial cohorts. Overall, 33 of Streamline L
WB-MRI scans were scored as degraded (including those of 13 participants ultimately withdrawn from the
trial). Of the remaining 20 WB-MRI scans, just four attracted a technical quality score of 1 (more than one
sequence with substantial degradation of the images). Of 11 scans attracting an anatomical coverage score
of 1, seven received this score because gadolinium was not administered.
RESULTS: STREAMLINE L
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Chapter 5 Economic analysis of WB-MRI staging
pathway versus standard staging pathways in
non-small-cell lung cancer and colorectal cancer
Introduction
The aim of this substudy was to examine the cost-effectiveness of WB-MRI compared with standard
pathways for staging of non-small-cell lung cancer and colorectal cancer in the UK. There have been
no previous studies in this area. Huppertz et al.31 examined the cost of WB-MRI versus a sequential
multimodal diagnostic algorithm for staging participants with rectal cancer in Germany and found that
substantial savings were achievable with WB-MRI, but this study did not consider cost-effectiveness and
was not UK based.
Overview of economic analysis
We undertook two separate cost analyses to compare the costs of WB-MRI versus standard staging
pathways for non-small-cell lung cancer and colorectal cancer based on data collected in Streamline L
and C, respectively. We did not undertake lifetime horizon cost-effectiveness analysis because of the
concordance between WB-MRI and standard staging pathways in informing treatment decisions for both
types of cancer (see Chapter 5, Concordance in treatment decisions in Streamline C and L). This meant that
we only needed to compare costs during the decision timeline, so did not consider costs or effects past
that point. The cost analyses took a UK NHS perspective. Costs were calculated in 2016–17 Great British
pounds (£) and inflated where necessary. The time horizon was the time from initial diagnosis to treatment
decision by the MDT, reflecting the fact that beyond this point costs and outcomes would have been the
same for both standard staging and WB-MRI given the concordance in treatment decisions (see Chapter 5,
Concordance in treatment decisions in Streamline C and L). Given the time horizon for the cost analyses
that we have performed, which was < 1 year, discounting was not applied. We completed a Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) statement – available on the project web page
[URL: www.journalslibrary.nihr.ac.uk/programmes/hta/106801 (accessed 12 September 2019)].
Treatment decision-making processes in Streamline
All participants in each of the two Streamline trials followed the standard staging pathway, consisting of a
battery of standard tests to stage their disease, according to local interpretations of the standard pathways
for the two cancer types as recommended by the NICE and according to their particular presentation.
As described in Chapter 1, in the case of colorectal cancer, CT of the chest, abdomen and pelvis is
recommended, supplemented by pelvic MRI for local staging of rectal cancer. Although the NICE does not
currently recommend additional imaging, in routine clinical practice it is not unusual for participants to
undergo PET-CT and/or liver MRI if metastatic disease is suspected. Staging pathways in lung cancer are
more complex, with CT, PET-CT, MRI, US and endobronchial/percutaneous biopsy all recommended at
various points in the staging algorithm. All participants underwent a WB-MRI scan, followed by other
indicated tests when requested by the clinician on the basis of the results of the WB-MRI. (Hypothetical)
treatment decisions were subsequently made and recorded on the basis of these two staging methods
(standard staging pathway and WB-MRI staging pathway; see Chapter 2). The two decisions could be the
same or different.
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A third treatment decision was then made by the MDT using all of the available evidence from the two
staging pathways (i.e. based on all available information from both the standard staging pathway and the
WB-MRI staging pathway combined) and participants were treated empirically on the basis of this third
decision. The treatment decision made by the MDT could be the same or different from the decisions
made on the basis of standard staging alone or WB-MRI staging pathway alone.
As described in Chapter 2, participants were followed for a period of 12 months, or until death if sooner,
and a consensus panel adjudicated on the TNM stage at diagnosis based on all the available clinical,
pathological and imaging data. A fourth theoretical optimal treatment decision was made by the panel
on the basis of all the previous evidence, including the three previous decisions plus all of the follow-up
data over the previous year. The four decisions made in both of the Streamline trials were therefore as
follows.
d1: standard pathway treatment decision, based on standard battery of tests alone
d2: WB-MRI pathway treatment decision, based on WB-MRI alone (plus generated extra tests)
d3: MDT treatment decision, based on the above information combined, as decided by the MDT – study
participants were treated empirically according to this decision
d4: final reference decision, after 12-month follow-up at the consensus meeting – the final reference
decision is the optimal treatment decision based on the ultimate participant outcome at 12 months.
Effect of decision concordance on the economic analysis
The care pathway for Streamline participants can be divided into two stages: the treatment decision
pathway and the subsequent disease management pathway. The former includes the time from initial
diagnosis to treatment decision by the MDT; the latter includes the time period following the treatment
decision.
If there is no difference in treatment decisions made with the two different staging pathways (d1 and d2),
the only difference in costs assigned to the two staging pathways is the differential costs of the two sets
of staging tests (‘standard’ vs. ‘WB-MRI plus generated tests’), and there will be no difference in treatment
pathways or outcomes on the basis of the experimental staging tests used. If there is no difference between
the treatment decisions made with the two different staging pathways (d1 and d2) and the MDT/consensus
reference standard treatment decisions (d3 and d4), then, as well as there being concordance between
the two staging pathways, the agreement with d4 suggests that both d1 and d2 are perfect decisions.
Alternatively, if there is no difference between the treatment decisions made with the two different staging
pathways (d1 and d2) but the MDT/consensus reference standard treatment decisions (d3 and d4) are
different, this suggests that there is concordance between standard staging and WB-MRI pathways but that
both pathways are imperfect.
As detailed in the study protocol,23 concordance between the standard staging pathway and the WB-MRI
staging pathway was defined as > 90% of treatment decisions being the same, or < 10% of treatment
decisions being different, using both pathways. Discordance was defined as > 10% of treatment decisions
being different, or < 90% of treatment decisions being the same, using both pathways. In the case of
concordance, the economic analysis can focus on the cost of the treatment decision pathways only,
because the disease management pathways will be no different. In this case the cost-effectiveness of
WB-MRI versus standard staging pathways depends only on the incremental cost (positive or negative) of
WB-MRI versus standard staging pathways in the treatment decision pathway.
Conversely, if there is discordance between the treatment decisions, suggesting that participants would
have received different treatment depending on which of the two staging pathways was used, then the
economic analysis ought to include both the treatment decision pathways and the subsequent disease
management pathways because both of these will vary between the WB-MRI and the standard staging
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pathway. In this case the cost-effectiveness of the WB-MRI pathway depends on the incremental cost of
the WB-MRI versus standard staging algorithms in the treatment decision pathway plus the incremental
costs and health benefits of the disease management pathway.
The precise nature of the economic analysis therefore depends on the degree of concordance between
treatment decisions provoked by WB-MRI versus standard staging pathways.
Available treatment decisions in Streamline C and L
For colorectal cancer participants, the four available decisions are the following summary treatment
decision categories (see Table 3):
(A) chemotherapy (and/or radiotherapy) without surgery
(B) surgery for the primary tumour and chemotherapy (and/or radiotherapy)
(C) surgery for the primary tumour but no chemotherapy
(D) surgical metastectomy with or without chemotherapy.
For lung cancer participants, the two available treatment decisions are the following summary treatment
decision categories (see Table 4):
(X) treatments with curative intent
(Y) treatments with non-curative intent.
Concordance in treatment decisions in Streamline C and L
As can be seen from Table 13, Table 25 and Appendix 63, Table 101, and Appendix 64, Table 102,
there is > 90% agreement (i.e. concordance) between d1 and d2 in both Streamline trials. Specifically, in
Appendix 62, Table 101, and Appendix 63, Table 102, the sums of the off-diagonal elements are < 10%
(1.69 + 0.34 + 3.04 = 5.07 and 2.19 + 0.55 = 2.74 for Streamline C and L, respectively). Appendix 65,
Table 103, and Appendix 67, Table 104, as well as Appendix 67, Table 105, and Appendix 68, Table 106,
show that there is discordance between d1 and d2 and the panel consensus optimal treatment decision
(d4), but with similar patterns in the magnitude of the off-diagonal elements seen for each of d1 and d2,
in each cancer. These results suggest, first, that the two staging pathways are concordant in terms of
treatment decisions made. Second, the results suggest that d1 and d2 are imperfect, that is, the optimal
treatment decisions that were made with the benefit of 12 months of follow-up and clinical outcomes are
similarly different for each pathway. Overall, d1 and d2 are equivalently imperfect when considering the
subsequent 12 months of participant follow-up.
As the decision based on standard staging pathways (d1) and that based on the WB-MRI staging pathway
(d2) have been shown to be equivalent in both cancers (non-small-cell lung and colorectal), the economic
analyses presented here therefore focuses only on the incremental costs of the two staging pathways for
each cancer; this means that a cost-effectiveness analysis using a lifetime time horizon was not required,
because the only difference between the two options was the cost of obtaining the treatment decision.
Cost of the treatment decision pathways
We calculated the mean cost per participant of investigations performed when undergoing standard staging
pathways only and when undergoing the WB-MRI staging pathway (including additional staging tests
generated as a result of the WB-MRI) for Streamline L and Streamline C. We only included the cost of the
investigations performed; the costs of the MDT were not included, as this cost was incurred irrespective
of the type of staging investigation performed. The analysis plan also required inclusion of costs for any
adverse events related to imaging, but there were no such events reported in either trial. The type and
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number of investigations performed were recorded for every participant in Streamline L and Streamline C.
Unit costs for each test were taken from NHS Reference Costs 2016/1732 and are summarised in Table 29.
Decisions about which reference costs should be assigned to each investigation were taken by clinical
colleagues in consultation with the health economists. We report the total number of each type of
investigation in each trial, the mean number of each type of investigation per participant and the mean cost
of that test per participant. For the mean cost of test per participant, 95% CIs are reported, derived from
1000 bootstrapped replications of the mean.
TABLE 29 Unit costs from NHS Reference Costs 2016/1732 used for Streamline C and L
Currency
code Currency description
Investigations applied
in Streamline C
Investigations applied
in Streamline L
Mean unit
cost (£)
RD03Z MRI scan of one area, with pre and post
contrast
Liver MRI, spine MRI,
brain MRI
Adrenal MRI, head MRI 180.35
RD01A MRI scan of one area, without contrast,
≥ 19 years of age
Pelvis MRI, pelvis/rectum
MRI
Other MRI, MSK-MRI 139.30
RD05Z MRI scan of two or three areas, with
contrast
WB-MRI, abdomen and
pelvis MRI
WB-MRI 206.51
RN03A PET-CT of more than three areas,
≥ 19 years of age
PET-CT PET-CT 484.17
RD21A CT scan of one area, post contrast only,
≥ 19 years of age
chest CT, other CT n/a 97.39
RD26Z CT scan of three areas, with contrast Colonography CT n/a 122.51
YD03Z Percutaneous biopsy of lesion of lung or
mediastinum
Surgical biopsy CT-guided biopsy 791.50
RD22Z CT scan of one area, pre and post contrast n/a Head CT 120.07
RD21A CT scan of one area, post contrast only,
≥ 19 years of age
n/a Liver CT 97.39
RD24Z CT scan of two areas, with contrast Abdomen and pelvis CT Abdomen and pelvis CT,
chest and abdomen CT
112.33
RD26Z CT scan of three areas, with contrast Chest, abdomen and
pelvis CT
Chest, abdomen and
pelvis CT, neck, chest
and abdomen CT
122.51
RN15A Nuclear bone scan of two or three
phases, ≥ 19 years of age
n/a Bone scan 292.40
EBUS Endobronchial ultrasound examination of
mediastinum and percutaneous biopsy
of lesion of lung or mediastinum
n/a EBUS and EBUS/TBNA 1441.17
RD40Z Ultrasound scan with duration of
< 20 minutes, without contrast
n/a US 51.78
YJ04Z Core needle biopsy of axillary lymph nodes n/a US-guided biopsy 92.43
RD97Z Admission or attendance for diagnostic
imaging
n/a Radiography 18.71
FE35Z Diagnostic flexible sigmoidoscopy,
≥ 19 years of age
n/a Sigmoidoscopy 169.43
RD42Z Ultrasound scan with duration of
≥ 20 minutes, without contrast
n/a Rectal US 64.95
DZ70Z Endobronchial ultrasound examination of
mediastinum
n/a EUS 649.67
DZ69A Diagnostic bronchoscopy, ≥ 19 years of age n/a Bronchial washing 686.15
EUS, endoscopic ultrasonography; MSK-MRI, musculoskeletal magnetic resonance imaging; n/a, not applicable;
TBNA, transbronchial needle aspiration.
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Results
Streamline C
The most frequent investigations in the standard staging pathway were chest, abdomen and pelvis CT,
pelvis/rectum MRI and chest CT (Table 30). Twenty-one additional staging tests were generated following
WB-MRI across all 299 participants (mean 0.07 extra tests per participant).
Mean test costs per participant (bootstrapped 95% CIs) were £285 (95% CI £260 to £310) for standard
pathways and £216 (95% CI £211 to £221) for the WB-MRI pathway.
TABLE 30 Mean per-participant staging cost (n= 299 participants) according to staging pathway: Streamline C
Investigation
Frequency (n)
Mean number of
tests per participant
Unit
cost (£)
Mean cost per participant,
£ (95% CI)
Standard
staging
pathway
WB-MRI
staging
pathway
Standard
staging
pathway
WB-MRI
staging
pathway
Standard
staging
pathway
WB-MRI
staging
pathway
WB-MRI 0 299 0.00 1.00 207 0 (0 to 0) 207 (207 to 207)
Chest, abdomen
and pelvis CT
243 5 0.81 0.02 123 100 (94 to 105) 2 (0 to 4)
Pelvis/rectum MRI 120 6 0.40 0.02 139 56 (48 to 64) 3 (1 to 5)
Chest CT 44 1 0.15 0.00 97 14 (10 to 18) 0 (0 to 1)
PET-CT 43 0 0.14 0.00 484 70 (51 to 88) 0 (0 to 0)
Liver MRI 35 0 0.12 0.00 180 21 (15 to 28) 0 (0 to 0)
Abdomen and
pelvis CT
27 0 0.09 0.00 112 10 (6 to 14) 0 (0 to 0)
US 12 2 0.04 0.01 52 2 (1 to 3) 0 (0 to 1)
Colonography CT 10 0 0.03 0.00 123 4 (2 to 7) 0 (0 to 0)
Radiography 9 0 0.03 0.00 19 1 (0 to 1) 0 (0 to 0)
Rectal US 4 0 0.01 0.00 52 1 (0 to 2) 0 (0 to 0)
Liver CT 3 1 0.01 0.00 97 1 (0 to 2) 0 (0 to 1)
Abdomen and
pelvis MRI
4 0 0.01 0.00 207 3 (0 to 5) 0 (0 to 0)
Bone scan 2 1 0.01 0.00 292 2 (0 to 5) 1 (0 to 3)
Brain MRI 0 3 0.00 0.01 180 0 (0 to 0) 2 (0 to 4)
Other CT 1 0 0.00 0.00 123 0 (0 to 1) 0 (0 to 0)
Sigmoidoscopy 1 0 0.00 0.00 169 1 (0 to 2) 0 (0 to 0)
US-guided biopsy 0 1 0.00 0.00 92 0 (0 to 0) 0 (0 to 1)
Spine MRI 0 1 0.00 0.00 180 0 (0 to 0) 1 (0 to 2)
Total 1.87 1.07 285 (260 to 310) 216 (211 to 221)
Participants may undergo more than one of the same imaging test. Tests ranked by the most frequent across both arms.
All costs are 2016/17 Great British pounds, 95% CIs are derived from 1000 bootstrapped replications of the mean.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
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Streamline L
The most frequent tests with conventional imaging were PET-CT followed by head MRI and head
CT (Table 31). WB-MRI generated 45 additional investigations overall across all 187 participants
(mean 0.24 extra tests per participant). Twenty-six participants underwent PET-CT following WB-MRI.
Mean test costs per participant (bootstrapped 95% CIs) were £620 (95% CI £574 to £666) for
conventional imaging and £317 (95% CI £273 to £361) for WB-MRI.
TABLE 31 Mean per-participant staging cost (n= 187 participants) according to staging pathway: Streamline L
Investigation
Frequency (n)
Mean number of
tests per participant
Unit
cost (£)
Mean cost (£) per participant
(95% CI)
Standard
staging
pathway
WB-MRI
staging
pathway
Standard
staging
pathway
WB-MRI
staging
pathway
Standard
staging
pathway
WB-MRI
staging
pathway
PET-CT 181 26 0.97 0.14 484 469 (449 to 488) 67 (43 to 91)
WB-MRI 0 187 0.00 1.00 207 0 (0 to 0) 207 (207 to 207)
Head CT 25 0 0.13 0.00 120 16 (10 to 22) 0 (0 to 0)
Head MRI 16 6 0.09 0.03 180 15 (8 to 23) 6 (1 to 10)
US 8 4 0.04 0.02 52 2 (1 to 4) 1 (0 to 2)
Abdomen and
pelvis CT
11 0 0.06 0.00 112 7 (3 to 10) 0 (0 to 0)
EBUS/TBNA 6 4 0.03 0.02 1441 46 (10 to 83) 31 (0 to 61)
Radiography 9 0 0.05 0.00 19 1 (0 to 2) 0 (0 to 0)
Chest CT 8 0 0.04 0.00 97 4 (1 to 7) 0 (0 to 0)
US-guided biopsy 6 1 0.03 0.01 92 3 (1 to 5) 0 (0 to 1)
Liver CT 6 0 0.03 0.00 97 3 (0 to 6) 0 (0 to 0)
Chest and
abdomen CT
5 0 0.03 0.00 112 3 (0 to 6) 0 (0 to 0)
CT-guided biopsy 5 0 0.03 0.00 792 21 (3 to 39) 0 (0 to 0)
Neck, chest and
abdomen CT
3 0 0.02 0.00 123 2 (0 to 4) 0 (0 to 0)
Chest, abdomen
and pelvis CT
2 1 0.01 0.01 123 1 (0 to 3) 1 (0 to 2)
Other MRI 1 2 0.01 0.01 139 1 (0 to 2) 1 (0 to 2)
EUS 2 1 0.01 0.01 650 7 (0 to 17) 3 (0 to 10)
Bronchial washing 3 0 0.02 0.00 686 11 (0 to 23) 0 (0 to 0)
Adrenal MRI 2 0 0.01 0.00 180 2 (0 to 5) 0 (0 to 0)
MSK-MRI 2 0 0.01 0.00 139 1 (0 to 4) 0 (0 to 0)
Surgical biopsy 1 0 0.01 0.00 792 4 (0 to 12) 0 (0 to 0)
Total 1.61 1.24 620 (574 to 666) 317 (273 to 361)
MSK-MRI, musculoskeletal magnetic resonance imaging; TBNA, transbronchial needle aspiration.
Participants may undergo more than one of the same imaging test. Tests ranked by the most frequent across both arms.
All costs are 2016/17 Great British pounds, 95% CIs are derived from 1000 bootstrapped replications of the mean.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
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Chapter 6 WB-MRI and standard staging
pathways: comparison of participant experience,
perceived burden and preferences
Parts of this chapter are reproduced from Evans et al.33 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions and formatting
changes to the original text.
Parts of this chapter are reproduced from Evans et al.34 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions and formatting
changes to the original text.
Parts of this chapter are reproduced from Miles et al.35 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions and formatting
changes to the original text.
Introduction
Whole-body magnetic resonance imaging has the potential to replace current multimodality staging
strategies and improve patient outcomes by better triaging to optimal therapy and decreasing the time
between diagnosis and treatment. A single WB-MRI scan has the added advantage of reducing exposure
to ionising radiation, in theory reducing the risk of subsequent radiation-induced malignancies, particularly
in those diagnosed at a younger age. However, acquisition times for WB-MRI (between 45 minutes and
1 hour) are much longer than most standard imaging techniques, which take a matter of minutes or even
seconds. MRI machines are also noisier than standard imaging machines and WB-MRI requires full body
and head immersion into a relatively narrow ‘tube’. Between 5% and 30% of patients experience distress
associated with the anticipated and actual experience of undergoing MRI36–40 and severe claustrophobia
can lead to premature scan termination in 1–15% of attempts.41,42 Patient acceptability is crucial to the
successful uptake of any new technology, as poor tolerability could reduce patient adherence to WB-MRI
protocols, thereby reducing the impact, even if diagnostic accuracy is equivalent to or even better than
existing tests.
The aims of the three participant experience studies were therefore to assess the psychological burden and
acceptability of WB-MRI compared with standard staging scans (notably CT and PET-CT) and ascertain
drivers of participant preferences for one pathway over another. Although there has been some qualitative
work on patient experience during general MRI,43,44 there has been very little work on WB-MRI specifically,
particularly in cancer patients who have increased levels of psychological stress around the time of diagnosis.45
Study 1 was therefore a qualitative study that aimed to ascertain the challenges faced by participants
undergoing WB-MRI and standard tests via a series of detailed patient interviews. Study 2 then quantified the
level of burden experienced by participants undergoing staging investigations using a questionnaire design
and examined predictors of scan tolerance. Study 3 built on the findings of studies 1 and 2 and took the
form of a DCE to examine the relative importance of different scan attributes to participants, and the
trade-offs they were prepared to make between different attributes such as diagnostic accuracy and scan
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duration. The attributes required by a staging pathway based on initial WB-MRI to be favoured by patients
over standard staging were then identified.
Participant experience study 1: participant interview study to
examine WB-MRI burden and acceptability in comparison with
standard staging scans
Methods
A qualitative methodology was chosen given the lack of pre-existing research on patient experiences of
WB-MRI compared with standard staging investigations. Such a qualitative approach does not assume a
priori knowledge of patient responses and allows full capture of the range of patient experience without
the inhibition of a group setting.
Participants
Participants were recruited from 10 sites participating in Streamline C and/or Streamline L (see Chapter 2).
When consenting to participate in the main Streamline trials, participants could also opt into this
participant interview study. A health psychology researcher contacted consenting participants after they
had completed their staging investigations (including WB-MRI) and where possible before starting their
treatment. The a priori sample size was 25 participants with non-small-cell lung cancer and 25 participants
with colorectal cancer (as with 50 participants it was expected that the point of saturation would be
reached, after which little new information would be forthcoming with additional interviews). However,
the team was permitted to expand the recruitment number if they felt the point of saturation had not
been reached.33
Interviews
Interviews were conducted either face to face or by telephone by two trained and experienced psychology
researchers. A topic guide was created (see Appendix 69, Box 1) in collaboration with the Streamline
investigator team to gauge participants’ views on the experience of undergoing WB-MRI compared with
standard staging. However, participants were encouraged to discuss any issues that they felt were important
to them and all posed questions were deliberately open ended, with flexibility in the order of topics.
Interviews were digitally recorded and participants were paid £20 plus travel expenses for participation.
Data coding and analysis
NVivo version 10 (QSR International, Warrington, UK) was used to manage data. Interviews were transcribed
verbatim and analysed using thematic analysis.46 A coding structure was developed through a combination
of transcript reviews and a reflective log created by the interviewing researchers. This was an iterative
process and updated as the interviews were conducted. The code was reviewed and agreed by both
psychology researchers and enabled relevant themes to be identified, such as participants’ beliefs and
coping strategies during staging scans, and these were recorded using matrix tables.
Data were entered into SPSS version 20 (SPSS Inc., Chicago, IL, USA). Analysis of variance assessed
differences in mean ages between lung and colorectal participant groups, chi-squared tests assessed group
differences in sex and interview method and the Mann–Whitney U-test was used to assess differences in
the median time interval from WB-MRI scan to interview date, between participant groups.
Results
The first 123 trial participants were approached, of whom 91 (74%) initially agreed to participate. Of these
91, 51 participants (56%) underwent an interview (the additional interview was completed because a
participant expressed a strong wish to share their views even though their participation was no longer
required as the point of saturation was considered to have been reached after 50 participant interviews).
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Reasons participants were not interviewed included retracted consent (n = 8), participation in study 2
(questionnaire study) (n = 14), withdrawal from the main trial (n = 12) and interview quota reached before
completion of all staging imaging tests (n = 6).33 Interviews lasted between 12 and 86 minutes (mean
48 minutes). Overall, 39 participants (76%) were interviewed over the phone and the rest face to face.
In total, 47 of the 51 participants completed the WB-MRI, and the median interval between WB-MRI and
interview was 15 days (range 1–63 days). All Streamline C participants reported a cancer diagnosis
whereas around only half of Streamline L participants reported a cancer diagnosis at the time of interview;
others were still waiting for the outcome of test results. The full participant demographics of the
interviewed cohort are shown in Appendix 70, Table 107.
There were no significant differences in age or sex between those who initially agreed to take part in the
interviews (n = 91) and those who declined (n = 32) [mean age: 65 years vs. 64 years, F1,121 < 1, p = 0.527;
percentage male: 64% vs. 56%, χ2 = 0.562, degrees of freedom (df) = 1, p = 0.453]. There were also no
significant differences in demographics between the 51 (of the 91) participants who actually undertook
the interviews and the 40 who did not (mean age: 65 years vs. 64 years, F1,89 < 1, p = 0.579; percentage
male: 53.4% vs. 46.6%, χ2 = 0.437, df = 1, p = 0.508).
Participant experience of WB-MRI in comparison to standard staging investigations
Participants reported some challenges during standard staging scans, for example the use of intravenous
contrast agents: ‘you feel a bit, you know, woozy, funny [. . .] and it did make me feel slightly off’ (< 50
years of age, male, Streamline C). Concerns were also expressed about exposure to ionising radiation: ‘all
that radiation dye in my system and everything [. . .] And it just disturbed me. Because I couldn’t go near
my niece and she’s only 6 [years of age]’ (< 50 years of age, female, Streamline L).
Among the participants who completed the WB-MRI, there was variation in whether or not the experience
of WB-MRI was challenging and the intensity of difficulties encountered. WB-MRI was enjoyable for some:
‘I was very relaxed and quite enjoyed the sensations really of the hammer blows and stuff like that [. . .]
I was in a long time and it was fun’ (≥ 80 years of age, male, Streamline C). For others it elicited no
emotional response apart from happiness that it was being performed: ‘No nerves, no worries, no anxieties.
I feel happy’ (50–59 years of age, male, Streamline L). The ‘coping challenge’ created by WB-MRI formed
a continuum: some enjoyed it or experienced no difficulties, perceiving it to be ‘just another bit of kit that
they’re going to put me through. No worry, no apprehension’ (≥ 80 years of age, male, Streamline L);
however, many participants viewed WB-MRI as more challenging than standard scans, for example stating
‘I would say the most challenging of the MRI scans was the body scan [. . .] It’s quite different from the other
two [i.e. CT and PET-CT scans] [. . .] It’s different than what I would call the normal scans’ (60–69 years of
age, male, Streamline C). Indeed, some found WB-MRI to be very challenging, describing it as ‘torture –
medieval torture’ (50–59 years of age, male Streamline C), whereas CT was described as ‘a walk in the
park’ (60–69 years of age, male, Streamline C) and ‘very simple’ (50–59 years of age, female, Streamline L).
PET-CT was described by some as ‘so much easier’ (70–79 years of age, female, Streamline L) and ‘wasn’t
so unpleasant’ (50–59 years of age, male, Streamline C).
Challenges of WB-MRI
Among the cohort, the factors that were identified as difficult during the interviews were relatively
consistent, regardless of how challenging people found the scan. In particular, claustrophobia was often
cited as problematic, along with the physical discomfort, noise, scan duration and the challenge of
coping with emotions and negative thoughts elicited during the scan, including fear/panic and isolation.
The intensity of these problems was variable, but increased in those finding the scan more challenging
(Table 32).
Participants who found one aspect of the scan very problematic also appeared to find other aspects
difficult: ‘You’re kind of helpless and trapped in a tunnel [. . .] that was even before the noise started and
the noise is very kinda distressing really’ (50–59 years of age, male, Streamline C).
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TABLE 32 Problems and the diversity of challenge experienced related to WB-MRI
Problem
Challenge level
Did not complete WB-MRINone/enjoyable Low Medium/high
Enclosed space I’m not claustrophobic [. . .] that
[enclosed space] doesn’t
frighten me
50–59 years of age, male,
Streamline L
Maybe in the back of my mind
you’re worried about it
[enclosed space]
60–69 years of age, female,
Streamline C
Coffin came to mind [. . .]
initially, you feel like ‘Oh god,
it’s so close in here’
60–69 years of age, female,
Streamline L
I had this sense of being in
a sarcophagus
60–69 years of age, male,
Streamline L
Noise I thought it like music really [. . .]
and it relaxed me
≥ 80 years of age, male,
Streamline C
The noise was a bit [. . .]
disconcerting because it was
quite loud and quite sort of
clanking and banging [. . .] and
it took some time getting used
to it
< 50, years of age, male,
Streamline C
That’s one of the worst ones
that I’ve had to go through
with the noise [. . .] I felt like
something was going to fall
off and hit me
< 50 years of age, female,
Streamline L
Scan duration/discomfort It’s actually quite comfortable
in there
60–69 years of age, male,
Streamline L
It was not excruciatingly painful.
It just ached a bit, that is all
60–69 years of age, male,
Streamline C
My back was uncomfortable.
My, the back of my neck was
uncomfortable [. . .] My brain
was saying ‘You can’t go
much longer’
60–69 years of age, male,
Streamline C
Negative emotions
(e.g. anxiety, panic,
shock, distress)
I mean, there wasn’t, you know,
anything in particular to be
frightening
< 50 years of age, male,
Streamline C
When I first went in there, I was
quite shocked [. . .] I wondered
what the hell was going on [. . .]
After a while I quite enjoyed it
60–69 years of age, male,
Streamline C
When I first laid down in the
scan I was frightened
60–69 years of age, female, C
I’m lying there and all of a
sudden they put all these things
on top of me [. . .] And I’m
thinking, ‘Oh, my god! [. . .]
This is threatening’
60–69 years of age, male,
Streamline C
I don’t know whether the people
doing the scan knew I had lung
cancer. I didn’t feel any empathy
or any sort of friendly attitude.
I walked out of there feeling
quite upset actually
50–59 years of age, male,
Streamline L
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Claustrophobia
One reason offered by participants as to why the CT and PET-CT scans were ‘easier’ was because the
scanner construction was deemed ‘a lot more open’ (50–59 years of age, female, Streamline L) and
‘it was almost like going under a bridge [. . .] as opposed to going down a long dark tunnel underground’
(60–69 years of age, male, Streamline L), whereas participants often felt trapped or buried in the WB-MRI:
‘it was the feeling of being sort of trapped because you can feel the machine all around your body’
(50–59 years of age, male, Streamline C); ‘I had this sense of being in this sarcophagus’ (60–69 years of
age, male, Streamline L). Whereas some experienced intense reactions to being enclosed, only one participant
asked to terminate the scan early because of this.
Noise
The noise emitted by MRI machinery during image acquisition was thought to be unpleasant by some
participants: ‘Horrendous. It’s horrible! I think it’s one of the worst things there is’ (60–69 years of age,
female, Streamline L); ‘like having my head in a bucket with someone hitting a hammer’ (70–79 years of
age, female, Streamline L). However, for others it was not disconcerting, and some even compared it to
music: ‘There was some hammer noise. And, there was bell noises. And there were also some different
noises. And I thought it’s like music really, you know, disjointed a bit, but like music, isn’t it? And, it’s
relaxed me’ (80–89 years of age, Streamline C male). The unpredictability of noise was concerning for
some – ‘the sound was really irritating [. . .] it was very unpredictable and it changed quite a lot’
(50–59 years of age, male, Streamline C) – but engaging to others: ‘It was quite good [. . .] I would say,
“What’s coming next? What’s the next noise?” So, I enjoyed that. The not knowing what was coming
next’ (60–69 years of age, male, Streamline C). The inability to control noise exposure was also viewed
as difficult by some: ‘You wouldn’t have that much noise for an hour in any situation other than that because
you would move away from it’ (70–79 years of age, female, Streamline C). Certain sounds were sometimes
interpreted to indicate the presence of pathology – ‘I thought, “If the machine is clicking on, maybe
something is wrong there with me,” you know?’ (60–69 years of age, female, Streamline C) – or created
concern that the machine had a fault. Over time, some participants habituated to the noise – ‘You get
used to it in the end [. . .] I think the first, the first time you hear it, “oh goodness me” ’ (60–69 years of age,
female, Streamline L) – but others found their tolerance reduced as the scan progressed: ‘Right at the very
end, you get tired and then, you know, you get tired of the noise at the very end’ (60–69 years of age,
female, Streamline C).
Scan duration and physical discomfort
The longer time required to complete WB-MRI in comparison to CT and PET-CT was frequently noted:
‘The CT scan is very quick [. . .] you’re in and out. Whereas, the MRI scan was very long’ (60–69 years of
age, female, Streamline C). Scan duration was also linked to comfort: ‘CT scan is not as uncomfortable
as the WB-MRI scan because of the length of the scan’ (50–59 years of age, female, Streamline C);
‘My back was uncomfortable [. . .] the back of my neck was uncomfortable, maybe 15 minutes too long
to be comfortable’ (60–69 years of age, male, Streamline C). In contrast, other participants suffered no
discomfort and viewed the MRI scan duration as acceptable: ‘I think it’s over 1 and a half hours or
something like that, so it was alright for me [. . .] is comfortable’ (60–69 years of age, male, Streamline C).
One participant whose PET appointment immediately followed the WB-MRI drank large quantities of
water, as instructed, which resulted in numerous toilet trips prior to WB-MRI and led to panic in the last
10 minutes of the scan when she realised she needed to go again: ‘And that’s when a sense of panic
started to set in, because I thought [. . .] I’m thinking to myself, “I think I want to go to the toilet” ’
(70–79 years of age, Streamline L).
Emotions elicited
Some participants referred to negative emotions related to WB-MRI including panic and fear: ‘I could feel a
couple of times [. . .] I was going to have a sort of panic attack and have to be taken out of the machine’
(50–59 years of age, male, Streamline C). When asked what caused this, the participant said: ‘This
claustrophobia, the feeling of being [. . .] the feeling of being trapped, really’ (50–59 years of age, male,
Streamline C). The novelty of the WB-MRI experience prompted worry in some: ‘The oppression comes
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from the unknown’ (70–79 years of age, male, Streamline C). Some feared the scan result, specifically a
fear of finding that the cancer was advanced: ‘Whether they’d find [. . .] it has gone everywhere and you
know nothing you can do, I suppose that was the main worry’ (60–69 years of age, female, Streamline L);
‘when I first laid down in the scan I was frightened [. . .] I was thinking what if they find something the
other scan didn’t’ (60–69 years of age, female, Streamline C). However, while WB-MRI had the potential
to reveal bad news, there was acceptance that it was preferable to know if their cancer had spread: ‘but
that is a good thing, it will be dealt with’ (70–79 years of age, male, Streamline C). Dealing with feelings
of panic and fear was a challenge in itself and needed effort to overcome: ‘I was trying to put it [fear] out
of my head and think positively [. . .] I was sort of telling myself “this isn’t the end of the world, you just
have to think ahead, don’t think the worst” ’ (60–69 years of age, male, Streamline L).
Cancer context
As noted in some of the quotations above, the WB-MRI was perceived to have the potential reveal
additional findings associated with a poorer prognosis and treatment implications: ‘I was lying in there and
I was thinking, what if they say it’s cancer? Then, what?’ (< 50 years of age, female, Streamline L). One
participant reported relief when the scan confirmed that initial tumours were localised: ‘My biggest fear,
I know I’ve got the cancer in the bowels. And I was worried that they might, it might just disguise I’ve got
other cancers. So, when he said straight away, there was nothing else and I feel relieved’ (70–79 years of
age, male, Streamline C). One participant had a dilemma of whether or not to go ahead with the scan
because of the possibility that its findings might mean he was not offered treatment: ‘I was of two minds
about the trial scan because I didn’t want the trial scan to say the cancer’s spread and they wouldn’t
operate’ (50–59 years of age, male, Streamline L); but there was also appreciation of having the WB-MRI
even when it did reveal spread: ‘The MRI actually showed up even more of what’s going on with me and
I think if I hadn’t had it, they would [. . .] we still wouldn’t know. Because they found traces in five other
places I feel a lot better now having the MRI scan, knowing that they’ve picked up on all of it [. . .]
Without that, they would [. . .] I would just be having the chemo and not the full treatment that I need’
(< 50 years of age, female, Streamline L).
The underlying known or potential cancer diagnosis may have influenced how physical characteristics of
the scan where interpreted. One participant described the enclosed experience as follows: ‘It’s like being in
a coffin. You know, I did think that. It’s like being in a coffin. But I wasn’t. You just have to think that [. . .]
Because if you’ve got something really, really bad, it would be like being in a coffin. Just like thinking,
“My god. This is going to be me” ’ (60–69 years of age, male, Streamline C).
Coping
‘One has just got to face it and cope’ (60–69 years of age, male, Streamline C).
The thematic analysis identified two main coping strategies. (1) Strategies focused on coping with
distressing thoughts, emotional responses or physical sensations evoked by the scan, for example mental
distraction and relaxation: ‘Because I love Cyprus I was thinking of Cyprus the whole time. And it sort of
takes your mind off of what’s going on and how long you’re in there’ (60–69 years of age, female,
Streamline L); ‘Breathing, breathing, concentrating [. . .] And you know trying to sort of just to calm [. . .]
Because you can’t help but get anxious, you know, in a situation like that’ (60–69 years of age, female,
Streamline L). (2) Strategies related to motivation to complete the scan, such as focusing on benefit beliefs
and acceptance that the experience was part of the process to get better: ‘I was so fed up with pain that
I would have done [. . .] you know, any investigation was better [. . .] It [WB-MRI] was something to get me
better’ (60–69 years of age, female, Streamline C); ‘I was laying there and I was thinking, “Well, it’s for my
own benefit, so I can live with that” ‘ (60–69 years of age, male, Streamline C).
Staff contact
Interactions with staff were noted as important by many participants. Staff supported participants with
verbal reassurance and information provision as well as making them physically comfortable. For example:
‘They told me all about it so I didn’t get anxious. I knew what to expect’ (60–69 years of age, female,
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Streamline L); ‘They managed to find something to put under my neck [. . .] They did put it in the right
place under my neck and I was OK’ (60–69 years of age, male, Streamline C). Some participants spoke of
a sense of isolation when in the scanner and hearing a voice confirmed they were not alone: ‘You feel a
bit isolated because you’re in the scanner, on your own, and everybody else is behind a shielded glass in
a room’ (< 50 years of age, male, Streamline C); ‘Just made me feel a bit confident that you wasn’t on
your own, you know?’ (60–69 years of age, female, L). Staff communication also acted as distraction:
‘The person speaking keeps my mind occupied’ (60–69 years of age, female, Streamline L).
Explaining differences in people’s experiences
Site of cancer
Participants from both study cohorts described varied experiences. However, chest symptoms reported
by Streamline L participants were associated with discomfort – ‘I found lying flat on my back, yes, very
uncomfortable [. . .] I was coping OK for about 20, 25 minutes, and then that’s when this pressure or
aching or uncomfortable feeling on my chest began to kick in’ (50–59 years of age, male, Streamline L) –
particularly when there was a need to breath hold during sequence acquisition: ‘I was trying not to cough
because she was saying, “Please, no. If you can, please don’t” and when you’ve got to hold your breath
[. . .] was very difficult’ (60–69 years of age, female, Streamline L); ‘They had to make me do it a few times
because I couldn’t hold it for the length of time they wanted me to hold it [. . .] I’ve got COPD [chronic
obstructive pulmonary disease]; whether that made it worse, I don’t know’ (60–69 years of age, male,
Streamline L).
All four participants who did not complete the scan were recruited to Streamline L but their decisions to
stop the scan were not necessarily related to their symptoms. For example, for one participant it was the
discomfort arising from the head coil and for another it was claustrophobia.
Existing musculoskeletal problems
Sometimes participants reported that the WB-MRI exacerbated musculoskeletal problems: ‘I do suffer a
bit from back pain [. . .] My back started to sort of be pretty uncomfortable’ (60–69 years of age, male,
Streamline C); ‘I was worried about my neck being uncomfortable because I have got a very stiff neck
because of arthritis but they managed to sort me out and then I managed to last the hour, or whatever it
was, without too much pain’ (60–69 years of age, male, Streamline C).
Mental health comorbidities
Mental health issues increased the challenge of the scan for two participants. One participant with prior
anxiety found the scan difficult, describing their anxiety as causing feelings of claustrophobia: ‘I’m not
claustrophobic. I just felt that way because of the anxiety. When I get anxious, it feels like everything’s just
closing in on me’ (< 50 years of age, female, Streamline L). Several aspects of the scan evoked this anxiety,
such as wearing the helmet coil, the noise of the scan and the scan duration. Although the scan was
difficult, this participant had several methods of coping that enabled her to deal with the increased
anxiety, for example taking extra psychiatric medication, relaxing and mental distraction. Another
participant described himself as an alcoholic and found the scan experience difficult because he had to
abstain from food and alcohol: ‘But you see the only problem, I’m an alcoholic as well. And to be without
a drink all that time, I was getting really bad at the end [of the scan] [. . .] Because I normally have a few
pints about 8 or 9 [in the morning], you know’ (60–69 years of age, male, Streamline L).
Prior experiences
Prior experiences of claustrophobia, MRI and experiences outside medical contexts were linked with the
ability to cope. One participant who terminated the scan after 10 minutes did so because he did not like
being constrained and his aversion came as a surprise: ‘A sense of being constrained and being strapped
down which is a new one for me [. . .] I haven’t encountered that situation before’ (60–69 years of age,
male, Streamline L). In contrast, another participant (60–69 years of age, male, Streamline C) who knew he
suffered from severe claustrophobia requested a sedative and completed the scan with relative ease.
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Similarly, one participant who had several MRIs previously – which she reported as difficult – transformed
her experience by wearing an eye mask: ‘I put an eye mask on. So, you wouldn’t be tempted to sort of
peep; it would help you to sort of relax a bit more [. . .] I was fine with it, with the mask on’ (60–69 years
of age, female, Streamline C). Work experiences meant that other participants were used to confined
spaces and or loud noises and therefore the scan did not represent a new challenge for them: ‘It doesn’t
bother me. I’ve worked in pipes and tunnels and all sorts of places’ (60–69 years of age, male, Streamline L);
‘If I wasn’t in the trade that I was in [car mechanic], I suppose that that could really freak you out because
it’s quite loud’ (< 50 years of age, male, Streamline C). Vicarious experiences of friends and family were
sources of knowledge for participants with no personal prior experience: ‘Of course, when you haven’t
had it before, you’ve heard lots of stories from other people’ (60–69 years of age, female, Streamline L).
This led to expectations that were sometimes reassuring – ‘I have [a] few friends and relatives, my cousin,
they have already done MRI, so I had something from them. This is not that, you know, this [is not] painful
or anything like that. You will enjoy’ (60–69 years of age, male, Streamline C) – and sometimes contrary to
their own eventual experience: ‘It was not as intimidating as I thought because I had heard people talking
about going in to an MRI scanner, and they were telling me how nervous they were, and how they hated
it [. . .] And when I saw it, I thought, “That’s okay” ’ (60–69 years of age, male, Streamline C).
Staff contact
Participants varied in whether or not they felt that they received enough information and contact from
staff before and during the scan: ‘They told me everything I needed to know’ (< 50 years of age, male,
Streamline C) versus ‘There wasn’t any [information] to be honest, I think that was the lacking part’
(50–59 years of age, female, L) and ‘They talked all the way through it’ (60–69 years of age, female, L)
versus ‘They once asked me if I was OK but I didn’t really have any communication’ (60–69 years of age,
female, Streamline C). Participant preferences for information also varied: ‘[. . .] think that the less you
know the better’ (70–79 years of age, male, Streamline C) versus ‘Personally they could give as much
information as they could’ (60–69 years of age, male, Streamline C). Whether or not staff were perceived
to be reassuring also depended on the relationship established between staff and participants; a change
in staff mid-way through the scan lead to panic in two participants: ‘She was constantly talking to me,
I was fine. But then [. . .] another lady took over and she didn’t talk as much [. . .] So that last 10 minutes
or so was [. . .] when I panicked’ (60-69 years of age, female, Streamline L); ‘People I’ve been speaking
with beforehand, these are people I’ve actually built up the initial, you know, the trust [. . .] Then, suddenly,
a complete stranger is now telling me to breathe in and out. [. . .] That complete stranger then said, ”You
know, I should be coming down now to inject you with dye” [. . .] In my mind, I thought the absolutely
bizarre. You know, he killed everyone in the ward. Now, he’s out to kill the patients’ (60–69 years of age,
male, Streamline C). Failure to heed participant preference influenced one participant’s decision to terminate
the scan: ‘They told me that they’re going to inject dye. And once again I said to the person, “Don’t put that
cannula in my left arm”, but she did and the vein collapsed. And I said to them, ”I can’t do anymore now.
I told you not to use that vein but you had, the vein’s collapsed. And I think I’ve had enough” ’ (50–59 years
of age, male, Streamline L).
Generally, though, participants spoke positively about the caring attitude of staff in WB-MRI centres:
‘The staff were all very good. They’re very caring’ (60–69 years of age, female, Streamline C).
Willingness to have another WB-MRI scan
Participants were asked whether or not they would be prepared to have another WB-MRI scan if the
doctor recommended it and all said yes, even those who had requested termination of the trial scan.
However, this agreement was offered with varying enthusiasm; for example: ‘Only if absolutely necessary
[. . .] I want a good reason’ (50–59 years of age, male, Streamline C) and ‘Well, if I have to [. . .] I don’t like
it one bit but if it has to be done’ (60–69 years of age, male, Streamline L) versus ‘Yes, without hesitation’
(< 50 years of age, male, Streamline C) and ‘I’ll have the MRI any day’ (60–69 years of age, female,
Streamline L).
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Participant experience study 2: quantitative assessment of perceived
WB-MRI scan burden and acceptability – comparison with CT/PET-CT
Methods
When consenting to participate in the main Streamline trials, participants could also opt into this
participant questionnaire study, which was commenced as the interview study (study 1) was completing.
Questionnaires
The study utilised two questionnaires and participants were asked to complete both. The first questionnaire
was posted to participants within 2 days of being registered for the Streamline trials, to be completed
around the time participants were undergoing their staging investigations. This acted as the baseline
questionnaire. A second, follow-up questionnaire was completed after participants had undergone staging
investigations (post staging) and was posted 1 month after the baseline questionnaire. Both questionnaires
were returned using a stamped addressed reply envelope and participants were paid £20 for participation.
Recruitment continued until a minimum of 100 participants had returned both questionnaires (50 for
Streamline L and 50 for Streamline C) (see Power calculation).
Questionnaire content
The following data were collected in the baseline questionnaire.
l Emotional distress: psychological distress was measured using the General Health Questionnaire-12
items (GHQ-12).47
l Comorbidity: participants were asked to report (‘yes’ or ‘no’) whether or not they had any of the
following – heart or vascular disease, diabetes mellitus, epilepsy, a history of stroke, arthritis, asthma
and mental or emotional disorder. There was also an option to provide details of other illness.
l Demographics: participants were asked their age, sex and ethnicity. Missing demographic data on age
and sex as well as postcode data were supplied via the central trial database.
l Comparative experience of scans: part of the follow-up questionnaire asked participants about their
comparative experience of WB-MRI and chest, abdomen and pelvis CT (standard scan) if recruited to
Streamline C or PET-CT (standard scan) if recruited to Streamline L.
l Scan recovery, satisfaction and acceptability: participants rated their post-scan recovery on a 9-point
scale ranging from ‘immediate’ to ‘a week’. Participants also rated how satisfied they were with the
information received before scanning, communication and departmental facilities, as well as the overall
acceptability of scans, on a scale of 1 (‘very dissatisfied’/’not at all acceptable’) to 4 (‘very satisfied’/
’very acceptable’).
l Scan burden: we adapted a questionnaire previously used to assess acceptability of colonoscopy48
and CT colonography49 to measure scan burden. The questionnaire included 26 items and participants
completed it for both WB-MRI and standard scans. Participants scored their experience of the scans
for each item by ticking agreement on a 7-point Likert scale where 1 and 7 were anchored to bipolar
statements related to scan discomfort (13 items), worry (6 items) and satisfaction (7 items). An example
discomfort item was 1 (’the noise of the scanner was unbearable’) to 7 (’the noise of the scanner
was fine’).
Power calculation
Power (G*Power 3; Heinrich Heine University Düsseldorf, Düsseldorf) was based on rejecting the null
hypothesis that there was no significant difference in perceived burden of WB-MRI when compared with
standard staging (related t-test). Assuming a medium effect size (Cohen’s d = 0.5), a Cronbach’s alpha of
0.05 and 95% power, a minimum number of 90 participants were required across the two study cohorts
(45 in Streamline C and 45 in Streamline L). An effect size of 0.5 is considered the minimally important
difference (MID) in quality-of-life measures,50 where MID is defined as the smallest difference that
participants view as important (beneficial or harmful) and would result in a doctor considering a change in
the participant’s management.51
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Statistical analysis
Data handling
l Emotional distress: using the GHQ-12 binary coding method (0,0,1,1), a mean sum score (if ≥ 50% of
items were answered) was created ranging from 0 to 12. A score of ≥ 4 is considered indicative of
significant distress levels.52
l Comorbidity: a response of ‘yes’ to any illness was coded and a dichotomous ‘comorbidity’ variable was
created whereby the presence of one or more comorbid illness was reported (either ‘yes’ or ‘no’).
l Demographics: post code data were used to calculate an area-based deprivation score for each
individual using the 2010 Index of Multiple Deprivation (IMD) scale,53 categorised into quintiles from
1 (highest level of deprivation) to 5 (lowest).
l Scan recovery, satisfaction and acceptability: recovery data were collapsed into three categories –
‘immediate’, ‘up to 30 minutes’ and ‘over 30 minutes’ – for analysis.
l Scan burden: subscores for discomfort, worry and satisfaction scales were computed from the mean of
completed items (if < 50% of items were completed, the response was coded as missing). A total score
‘scan burden’ was computed by taking the mean of discomfort, worry and reverse scored satisfaction
subscales, with higher scores equating to greater scan burden.
Analysis was performed using SPSS version 22. Differences in demographic and psychological characteristics
between Streamline L and Streamline C cohorts were assessed using the Mann–Whitney U-test, and
chi-squared or Fisher’s exact test (if ≥ 20% of the cells in the contingency table had expected counts of < 5)
as appropriate. Related samples Wilcoxon signed-rank test were used to assess differences between WB-MRI
and CT/PET-CT in terms of scan recovery time, scan acceptability, satisfaction with scan-related information,
facilities, communication and scan burden. Linear regression tested the predictive value for WB-MRI scan
burden of data collected in the baseline questionnaire. Individual predictors were entered in unadjusted
analyses and those items achieving statistical significance were then entered into a multivariate analysis.
Statistical significance was assigned at the 5% level, two-tailed.34
Results
A total of 350 participants (89.3%) of the 392 recruited to the trials during the period that study 1
and study 2 were being performed consented to undergo the interview study (study 1) or the current
questionnaire study (study 2). None of the participants who took part in the present study took part in the
prior interview study.
The full recruitment pathway and reasons for exclusion are presented in Figure 7. In total, 214 participants
were sent both questionnaires. Ninety-nine were excluded. Reasons for exclusion were non-response
(n = 71), returned baseline questionnaire only (n = 27) and withdrawal from the trial (n = 1). Overall,
103 participants (median age, 66 years; male, n = 58) completed both questionnaires and 12 (median age,
60 years; male, n = 9) completed the post staging questionnaire only. A total of 115 participants completing
the follow-up questionnaires were included in the analyses. A total of 61 participants were recruited to
Streamline C and 54 participants to Streamline L. Participants were more likely to return the post-staging
questionnaire if they had lower levels of deprivation (linear χ2 = 7.113, df = 1; p = 0.008). There were no
differences in sex (p = 0.059), age (p = 0.676) or cancer type (linear χ2 = 0.442; df = 1; p = 0.506) between
those who did and did not return the post-staging questionnaire (see Appendix 71, Table 108).
Full demographics of the 115 participants are shown in Appendix 72, Table 109.
Female participants recruited to Streamline C (n = 24) were significantly younger than those recruited
to Streamline L (n = 24) (median age 60 vs. 73 years, respectively; p = 0.003), with no significant age
difference between males recruited to Streamline C (n = 37) and Streamline L (n = 30) (median age 66 vs.
66 years, respectively; p = 0.480).
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Participants recruited to Streamline L were significantly more likely to report additional comorbidity than
those recruited to Streamline C (66.7% vs. 40.4%; p = 0.008) (see Appendix 72, Table 109).
Post-scan participant recovery and scan acceptability
Table 33 shows participant scan recovery time and overall scan acceptability and Appendix 73, Table 110,
shows comparative scan information, communication and facilities.
There were no significant differences in recovery time after WB-MRI compared with CT/PET-CT, with
64% (n = 69) of participants who completed this item reporting ‘immediate’ recovery following WB-MRI,
compared with 65% following CT/PET-CT. However, in general, participants rated WB-MRI as less
Sent questionnaires at both 
time points
(n = 214)
[C, 118 (55.1%); L, 96 (44.9%)]
Completed baseline
questionnaire only
(n = 27)
Completed post-
staging questionnaire
only (no baseline data)
(n = 12)
(C, 9; L, 3)
Completed baseline
and post-staging
questionnaires
(n = 104) 
Did not consent to 
questionnaire study
(n = 42) 
Consented to interview (study 1)
and/or questionnaire study (study 2)
(n = 350)
Response rate 89.3%
(L, 93.1%; C, 85.8%) 
No response
(n = 71)
• Recruited to interview
   study, n = 91
• Not sent baseline
   questionnaires, n = 3
• Sent baseline
   questionnaire only, n = 42
Recruited to trials during the period
the questionnaire study was active
(n = 392)
• Included, n = 103 
• Withdrawn (did not
   undergo WB-MRI),
   n = 1 
Included in analyses
(n = 115)
[C, 61 (53%); L, 54 (47%);
54% sent both questionnaires]
Reasons for withdrawal/not sent
follow-up questionnaires
• Withdrew consent, n = 2
• Did not meet colorectal or
   non-small-cell cancer inclusion
   criteria, n = 12
• WB-MRI did not take place, n = 27
• Not recruited to questionnaire
   study in error, n = 3
• Lost to follow-up as moved
   abroad, n = 1
FIGURE 7 Flow diagram of participants through the studies 1 and 2. C, Streamline C; L, Streamline L. Reproduced
from Evans et al.34 This is an Open Access article distributed in accordance with the terms of the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
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acceptable than either CT/PET-CT. Participants’ satisfaction with information before the scan and facilities,
together with communication during the scan, were not significantly different between WB-MRI and either
CT or PET-CT (see Appendix 72, Table 109).
Scan burden
The comparative burden induced by WB-MRI and CT/PET-CT is shown in Table 34.
Mean ratings for scan discomfort and worry ranged from 1.63 to 2.65 (7 represents maximum discomfort
or worry). Mean satisfaction scores ranged from 6.25 to 6.53 (7 represents maximum satisfaction). In general,
therefore, the burden generated by all the scans was relatively low.
However, the overall burden induced by WB-MRI was significantly greater than both PET-CT and CT
(see Table 34). Specifically, both discomfort scores and satisfaction scores were worse for WB-MRI
TABLE 33 Comparative experience of WB-MRI vs. CT/PET-CT: recovery time and scan acceptability
Variable Overall, % (n) Streamline L,a % (n) Streamline C,b % (n)
Group differences
(Wilcoxon signed-rank test)
(p-value)
Recovery time
WB-MRIc 0.465,d 0.735e
Immediate 63.9 (69) 61.5 (32)d 66.1 (37)e
≤ 30 minutes 25.9 (28) 23.1 (12) 28.6 (16)
> 30 minutes 10.2 (11) 15.4 (8) 5.4 (3)
CT/PET-CTc
Immediate 65.1 (69) 58.8 (30)d 70.9 (39)e
≤ 30 minutes 21.7 (23) 23.5 (12) 20.0 (11)
> 30 minutes 13.2 (14) 17.6 (9) 9.1 (5)
Scan acceptability
WB-MRIc
Very 65.2 (73) 64.8 (35)d 65.5 (38)e 0.035,d 0.005e
Fairly 30.4 (34) 29.6 (16) 31.0 (18)
Slightly 3.6 (4) 3.7 (2) 3.4 (2)
Not at all 0.9 (1) 1.9 (1) 0.0 (0)
CT/PET-CTc
Very 77.8 (84) 75.0 (39)d 80.4 (45)e
Fairly 21.3 (23) 23.1 (12) 19.6 (11)
Slightly 0.0 (0) 0.0 (0) 0.0 (0)
Not at all 0.9 (1) 1.9 (1) 0.0 (0)
a WB-MRI vs. PET-CT
b WB-MRI vs. CT.
c Missing data > 5%.% is valid per cent.
d Comparison between WB-MRI and PET-CT (Streamline L).
e Comparison between WB-MRI and CT (Streamline C).
Reproduced from Evans et al.34 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes
minor additions and formatting changes to the original text.
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compared with those of both CT and PET-CT. By way of example, WB-MRI conferred significantly greater
feelings of claustrophobia than both CT (mean score 2.81 vs. 1.51; p < 0.001) and PET-CT (mean score
3.04 vs. 1.98; p < 0.001) and greater burden from scan-related noise compared with both CT (mean 2.84
vs. 1.73; p < 0.001) and PET-CT (mean 2.85 vs. 1.63; p < 0.001). In general, the intravenous injections
required for each of the three scan types resulted in low levels of discomfort that did not differ between
scan type (WB-MRI vs. CT: 1.59 vs. 1.56, p = 0.637; WB-MRI vs. PET-CT: 1.86 vs 1.73, p = 0.225).
Questionnaire items related to ‘worry’ did not differ for WB-MRI in comparison to PET-CT but were inferior
for WB-MRI in comparison to CT.
The WB-MRI burden was not rated differently between those recruited to Streamline C or Streamline L.
However, participants recruited to Streamline L reported significantly more worry and discomfort during
PET-CT compared with the equivalent ratings for CT by those recruited to Streamline C (worry 2.52 vs.
2.00, respectively, p < 0.001; discomfort 2.04 vs. 1.63, respectively, p < 0.001).
Predictors of WB-MRI scan burden
The presence of comorbidity, psychological distress and deprivation were significant predictors of WBI-MRI
burden in unadjusted analysis (β = 0.242, p = 0.015; β = 0.305, p = 0.002; β = –0.265, p = 0.005, respectively),
with age, sex, cancer type and ethnicity non-significant predictors (β = 0.059, p = 0.535; β = 0.083, p = 0.389;
β = –0.122, p = 0.201; β = –0.179, p = 0.081, respectively). In the adjusted analyses only psychological
distress and presence of comorbidities remained significantly predictive (β = 0.223, p = 0.025; β = 0.191,
p = 0.048, respectively).
TABLE 34 Comparative scan burden: WB-MRI vs. CT/PET-CT
Burden
Overall,
mean (SD)
Streamline L,a
mean (SD)
Streamline C,b
mean (SD)
Group differences
(Wilcoxon signed-rank test)
(p-value)
Total participant burden
WB-MRIc 2.21 (1.1) 2.33 (0.94)d 2.09 (1.18)e < 0.001d
CT/PET-CTc 1.87 (0.98) 2.05 (0.82)d 1.70 (1.1)e < 0.001e
Discomfort subscale
WB-MRIc 2.51 (1.26) 2.65 (1.14)d 2.30 (1.22)e < 0.001d
CT/PET-CTc 1.83 (1.05) 2.04 (.90)d 1.63 (1.15)e < 0.001e
Worry subscale
WB-MRIc 2.47 (1.32) 2.62 (1.15)d 2.23 (1.31)e 0.208d
CT/PET-CTc 2.24 (1.23) 2.52 (1.15)d 2.00 (1.28)e 0.041e
Satisfaction subscale
WB-MRIc 6.25 (1.06) 6.27 (0.85)d 6.26 (1.23)e 0.036d
CT/PET-CTc 6.49 (0.89) 6.43 (0.76)d 6.53 (1.01)e 0.001e
SD, standard deviation.
a WB-MRI vs. PET-CT.
b WB-MRI vs CT.
c Missing data > 5%.
d Comparison between WB-MRI and PET-CT (Streamline L).
e Comparison between WB-MRI and CT (Streamline C).
Reproduced from Evans et al.34 This is an Open Access article distributed in accordance with the terms of the Creative
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Participant experience study 3: participant preferences for whole body
MRI or conventional staging pathways in lung and colorectal cancer –
a discrete choice experiment
Study 3 built on the findings of study 1 and 2 and was designed to elicit overall participant preferences
for cancer staging pathways using a DCE. We followed international DCE guidelines for study design and
analysis.54,55
A DCE elicits preferences by asking individuals to indicate their choice between two or more options,
where each option contains characteristics or attributes that are varied and is differentiated by values or
levels of each attribute.35 By analysing the choices people make, the relative importance of different
attributes can be determined.35 In the case of cancer staging pathways, example attributes could include
exposure to ionising radiation or number of scans required to complete staging.
Study 3 was conducted after completion of studies 1 and 2. When consenting to participate in the main
Streamline trials, participants could also opt into this study. In total, 264 participants consented to take
part, of whom 126 did not respond to the DCE questionnaire. The final study cohort was therefore
148 participants (66 recruited to Streamline C and 72 to Streamline L).
The DCE questionnaires were posted to participants within 2 days of them consenting to the Streamline
trials and participants were asked to complete them during their staging process, returning them in a
stamped addressed envelope. Participating participants were paid £20 for completing the questionnaire.
Discrete choice experiment questionnaire attributes and levels
Attributes were selected by the trial team to capture known or potential important differences between
WB-MRI and standard staging pathways;35 these were informed by findings from the participant interview
study (study 1) and questionnaire study (study 2). Based in particular on the findings of these two studies,
the following attributes were included: scan duration, need for the whole body and head to be enclosed
by the scanner and increased cancer risk due to exposure to ionising radiation. In addition, and to align
with the main outcomes of the Streamlines trials (see Chapter 2), the following pathway attributes were
also included: pathway accuracy, scan number and time to diagnosis.
Credible levels for each attribute were chosen based on either known levels, such as scan duration,
or after appropriate literature review, for example radiation exposure and scan/pathway accuracy
(see Chapter 1).35,56 At the time of study design, actual pathway accuracy and scan number required to
reach a final diagnosis was not yet known (see Chapters 3 and 4).
Table 35 summarises the selected attributes and levels.
TABLE 35 Attributes and attribute levels
Attribute Attribute levels
Time in scanner 10 minutes 30 minutes 60 minutes
Time to reach a final diagnosis 1 week 3 weeks 5 weeks
Associated increase in cancer risk due to radiation exposure None 1 in 1000 patients 2 in 1000 patients
Number of additional staging scans before final diagnosis 0 1 2
Accuracy for metastatic disease (%) 85 90 95
Need for whole body and head to be in scanner No Yes –
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
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Discrete choice experiment questionnaire design
Of the six attributes, five had three levels and one had two levels. The total number of attribute combinations
was therefore 486 (35 × 21).35 By presenting each question to participants as a binary choice set (pathway A
vs. pathway B), there were a possible 235,710 choices (486 × 485). We reduced this choice set to 18 using
an orthogonal fractional main effects design for pathway A.57 Pathway B was generated by shifting the
attribute level up by one category for each attribute. We did not include an opt-out or ‘neither’ option as
participants are unlikely to choose not to undergo staging. The 18 choice sets were split into two blocks of
nine, and participants were randomly assigned to complete either choice sets 1 to 9 (questionnaire A) or
10 to 18 (questionnaire B).35 The choice sets were presented in a random order in each questionnaire.
Prior to administering the DCE questionnaire, its content was reviewed and modified for clarity by the Trial
Management Group (TMG), which included two patient representatives.
An example of a choice set is shown in Figure 8.
A range of demographic and health-related variables were also collected from participants including age,
sex, highest educational qualification, ethnicity, car and home ownership, employment and marital status
along with self-rated health, presence of comorbidities, and positive and negative mood (using the Positive
and Negative Affect Schedule,58 phrased to ask about current mood).35
Participants were also asked whether they preferred WB-MRI or standard tests (‘If you had to have JUST
ONE of the tests which one would you prefer?’).35
Choice 1 Scan A Scan B
You will be in the scanner for: 30 minutes 60 minutes
You will know your final full diagnosis after: 1 week 3 weeks
The lifetime chance of getting cancer because
you had a scan that exposed you to radiation is: 1 in 1000 patients 2 in 1000 patients
The number of additional scans after this one
that you will need before you know your final
full diagnosis is: 
2 0
The accuracy of the scans to tell you if the
cancer has or has not spread is: 
Correct in 95 out of
100 patients 
Correct in 85 out of
100 patients 
Your whole body including your head will
need to be inside the scanner: Yes No
Based on the descriptions above, which scan
would you prefer? (Tick one box only) 
Prefer Scan A

Prefer Scan B

FIGURE 8 Example of a choice set. Reproduced from Miles et al.35 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly
cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions and formatting changes to the
original text.
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Sample size calculation
Sample size calculations are difficult for DCEs and depend on the question format, the complexity of the
choice tasks, the desired precision of the results, the degree of heterogeneity in the target population, the
availability of respondents and the need to conduct subgroup analyses. Researchers commonly apply rules
of thumb, based on the number of attribute levels, to estimate sample size. Our calculations were based
on the formula:
(500 × c) διω (t × a), (1)
where t is the number of sets of choices (n = 9), a is the number of scenarios to choose between in each
choice (n = 2) and c is the largest number of levels for any one attribute (n = 3).59 Thus, our target sample
size was 84 in total, or 42 participants for each cancer type, which we comfortably exceeded.
Analysis
Descriptive statistics for participant characteristics were compared between colorectal and lung cancer
cohorts using chi-squared tests for categorical variables and independent t-tests for continuous variables.
Discrete choice experiment data were analysed using an alternative-specific regression model where the
outcome was test preference (scan A or B) and the variables in the equation were the individual attributes.35
Alternative-specific constant terms were not included. We ran the model on the whole sample, as well as
stratifying by recruitment to either Streamline L or Streamline C, and by participant characteristics. The
relative importance of each attribute was calculated as the difference in preference weights between the
best or most preferred level of each attribute and the worst or least preferred level of the same attribute.60
Preference weights for continuous measures were calculated as the product of the coefficient for each
attribute and the best and worst levels of the attribute. The resulting range for each attribute provides an
estimate of the relative importance of that attribute over the range of levels included in the experiment.
We used the regression coefficients to compute marginal rates of substitution (MRS). The MRS allow direct
assessment of the relative importance of each attribute by showing how much of one attribute participants
are willing to trade for one unit of another attribute. It therefore enables a comparison of how important
different attributes are to participants on a common scale.35
The choice of which attribute is used as the denominator allows different presentations of participants’
trade-offs to be made. Any of the attributes can be chosen as the denominator. We calculated the MRS
values using each attribute in turn as the denominator so that participants’ preferences and the trade-offs
could be compared in terms of (1) willingness to spend longer in the scanner (minutes), (2) willingness to
wait for diagnosis (weeks), (3) willingness for an extra 1/1000 risk of cancer due to radiation exposure,
(4) willingness to have an extra scan and (5) willingness for a 1% increase in accuracy for metastatic
disease.35 We also used the regression analysis results to calculate the predicted probabilities of choosing
alternative pathways (e.g. based on WB-MRI) compared with a standard staging pathway. The selected
default standard pathway was PET-CT plus one additional scan (Streamline L) or CT plus one additional
scan (Streamline C).
We compared default staging pathways to alternative pathways with varying attribute levels based around
PET-CT, CT and WB-MRI. We considered several scenarios for WB-MRI based pathways, although fixed
the following attributes: (1) 60 minutes in the scanner, (2) no risk of cancer from radiation exposure and
(3) requirement for the whole body and head to be enclosed. We then varied combinations of time to
diagnosis, number of additional scans and accuracy of WB-MRI individually and jointly. Non-traders were
included in the analysis.35
All data were analysed using SPSS version 24 and Stata 13.0.
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Study 3 results
Of the 138 participants recruited, 128 completed all nine choice sets. The full demographics of the cohort
is shown in Appendix 74, Table 111. Participants recruited to Streamline C were more likely to have
educational qualifications, own a home and be in employment than participants recruited to Streamline L.
They were also less likely to report comorbidities, more likely to rate their current health as good or very
good and more likely to report higher levels of positive mood than Streamline L participants.
The majority of participants had undergone WB-MRI by the time they completed the DCE [113/131
participants (86%) answering the question], with no significant difference between the cohorts [Streamline C:
55/64 participants (86%); Streamline L: 58/67 (87%)].35
Importance of attributes
Overall, participants preferred (1) to wait less time for a diagnosis, (2) a lower dose of radiation exposure,
(3) fewer additional scans and (4) greater test accuracy (Table 36).
Preferences across the combined cohort (Streamline C and Streamline L) were not influenced significantly
by time in the scanner or the need for the whole body and head to be enclosed. However, preferences
differed significantly between participants with lung cancer and those with colorectal cancer. Notably, time
in the scanner significantly influenced the preferences of lung cancer participants. Both cohorts preferred
TABLE 36 Results of conditional logit regression analysis by cohort
Attribute Levels
Participants
p-valuea
All Streamline L Streamline C
Coefficient
(95% CI) RI
Coefficient
(95% CI) RI
Coefficient
(95% CI) RI
Time in
scanner
Minutes –0.002
(–0.007 to 0.002)a
– –0.008
(–0.014 to –0.002)
0.04 0.005
(–0.002 to 0.012)b
– 0.01
Time to
diagnosis
Weeks –0.355
(–0.411 to –0.300)
1.42 –0.372
(–0.449 to –0.295)
1.49 –0.349
(–0.432 to –0.265)
1.40 0.70
Radiation
dose
Risk of
cancer
(/1000)
–0.421
(–0.521 to –0.320)
0.84 –0.413
(–0.551 to –0.274)
0.83 –0.436
(–0.587 to –0.286)
0.87 0.83
Number of
additional
scans
Number –0.192
(–0.299 to –0.084)
0.38 –0.179
(–0.330 to –0.028)
0.36 –0.224
(–0.382 to –0.067)
0.45 0.69
Accuracy Percentage 0.128
(0.107 to 0.150)
1.28 0.109
(0.079 to 0.138)
1.09 0.156
(0.122 to 0.190)
1.56 0.03
Need for
whole body
and head to
be in scanner
No – – – – – –
Yes 0.020
(–0.129 to 0.170)b
– 0.017
(–0.190 to 0.224)b
– –0.007
(–0.233 to 0.220)b
– 0.88
Observations/
respondents
– 2362/138 – 1230/72 – 1132/66 – 0.02
RI, relative importance.
a p-values are from chi-squared tests where coefficients are equal for lung cancer and colorectal cancer participants;
p < 0.05 indicates coefficients are significantly different between groups. The p-value in the bottom row is for joint test
across all coefficients.
b Coefficient not significantly different from zero; all other coefficients significant at p < 0.05.
Different attributes do not have the same unit of change so cannot be directly compared with one another. RI is calculated
for attributes with coefficients that were significantly different from zero.
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tests with higher accuracy, but the preference was significantly greater for participants with colorectal
cancer (p = 0.03). For the other attributes, preferences were not significantly different between the
two cohorts.
Relative importance of the attributes
Based on the relative importance weightings, for Streamline L participants time to diagnosis was the
attribute valued most highly, followed by accuracy, radiation dose, number of additional scans and time in
scanner (see Table 36). For Streamline C participants, accuracy was valued most highly, followed by time to
diagnosis, radiation dose and number of additional scans.
Within each cohort, there were no significant differences in preferences according to subgroups stratified
by sex, age, comorbidities, employment status, marital status and positive mood. For participants with lung
cancer (but not colorectal cancer) there were significant variations when participants were stratified by
home ownership, education and self-rated health (see Appendix 75, Table 112, Appendix 76, Table 113
and Appendix 77, Table 114). For example, the influence of diagnostic accuracy on preferences was
greater for lung cancer participants who were home owning or had higher self-rated health.
Overall, 32 out of 59 (54.2%) lung cancer participants and 45 out of 61 (73.8%) colon cancer participants
who answered the question selected WB-MRI over standard scans. For Streamline L participants, those
stating an overall preference for standard staging scans preferred less time in scanner and to not have their
whole body and head enclosed (see Appendix 78, Table 115). There were no significant differences in
attribute preferences between Streamline C participants who preferred WB-MRI and those who stated a
preference for standard staging scans.
Traders versus non-traders
A total of 37% (51/138) of participants were ‘non-traders’, with preferences determined by a single
attribute that they did not trade-off against any of the other attributes presented. The most common
attributes participants would not trade were higher accuracy, faster time to diagnosis and reduced cancer
risk due to scan-related radiation exposure (see Appendix 79, Table 116).
Marginal rates of substitution
Table 37 shows results of the MRS analysis. Lung cancer participants were willing to wait just over 1 extra
week (MRS –1.11) in return for a 1 in 1000 reduction in the risk of cancer from radiation exposure.
They were willing to wait around half an extra week (MRS –0.48) to avoid an additional scan and around
one-third of an extra week (MRS 0.29) for every 1% increase in accuracy (i.e. 1.45 weeks for a 5%
increase in accuracy). The willingness to wait longer for a diagnosis for a reduction in the time in scanner
was negligible (MRS –0.02). These figures were broadly similar for colorectal cancer participants. For example,
they were willing to wait just under half a week (MRS 0.45) for every 1% increase in accuracy (i.e. 2.25 weeks
for a 5% increase in accuracy).35
Predicted probabilities
Figures 9 and 10 detail the predicted probabilities of choosing alternative pathways, compared with a
default standard staging pathway, for Streamline L (PET-CT plus one additional scan) and Streamline C
(CT plus one additional scan), respectively. Lung cancer participants were more likely to prefer a WB-MRI-based
pathway (probability 0.64) if it was as accurate, required the same total number of scans and had the same
time to diagnosis as the default staging pathway. If the WB-MRI pathway was more accurate, reduced time
to diagnosis and/or required fewer scans than the default staging pathway, the preference for WB-MRI was
even stronger. For example, the probability of choosing WB-MRI if it was more accurate than the default
pathway was 0.76, rising to 0.89 if WB-MRI was more accurate, reduced time to diagnosis and meant fewer
scans. The same patterns were also found for colorectal cancer participants compared with their default
staging pathway.
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TABLE 37 Marginal rates of substitution across all attributes
Numerator of MRS
Participants
Streamline L Streamline C
Time in
scanner:
willingness
to wait
in scan
(minutes)
Time to
diagnosis:
willingness
to wait for
diagnosis
(weeks)
Radiation dose:
willingness to
have an additional
1/1000 cancer risk
due to radiation
exposure
Number of
additional
scans:
willingness
to have an
extra scan
Accuracy:
willingness
for a 1%
increase in
accuracy
Time to
diagnosis:
willingness
to wait for
diagnosis
(weeks)
Radiation dose:
willingness to
have an additional
1/1000 cancer risk
due to radiation
exposure
Number of
additional
scans:
willingness
to have an
extra scan
Accuracy:
willingness
for a 1%
increase in
accuracy
Time in the scanner – –0.02 –0.02 –0.05 0.08 NS NS NS NS
Time to diagnosis –45.23 – –0.90 –2.08 3.42 – –0.80 –1.55 2.23
Radiation exposure –50.20 –1.11 – –2.31 3.80 –1.25 – –1.94 2.79
Number of
additional scans
–21.77 –0.48 –0.43 – 1.65 –0.64 –0.51 – 1.44
Accuracy 13.21 0.29 0.26 0.61 – 0.45 0.36 0.70 –
NS, not significant.
NS indicates that the coefficient on time in scanner is non-significant, so the MRS is not computed. The MRS for willingness for time in the scanner for Streamline C participants is not
reported because the coefficient on time in scanner in this group is non-significant. The MRS for need for whole body and head to be in scanner is not reported for either Streamline C or
Streamline L participants because in both cases the coefficient is non-significant.
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions
and formatting changes to the original text.
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FIGURE 9 Predicted probabilities of choosing an alternative staging pathway in comparison to a default staging
pathway (PET-CT plus one additional scan): Streamline L. The comparison indicated by the dashed box (WB-MRI
scenario 2) is one in which WB-MRI differs from the default staging pathway according to established differences
(time in scanner, exposure to ionising radiation, need for the whole body and head to be inside the scanner) but for
which other attributes (time to diagnosis, number of additional scans, accuracy) are assumed to be the same between
the two pathways. Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and
build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. Includes minor additions and formatting changes to the original text.
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pathway (CT plus one additional scan): Streamline C. The comparison indicated by the dashed box (WB-MRI scenario 2)
is one in which WB-MRI differs from the default staging pathway according to established differences (time in scanner,
exposure to ionising radiation, need for the whole body and head to be inside the scanner) but for which other
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Description of tests in Streamline L
l Default staging pathway (PET-CT plus one additional scan) in every case: 30 minutes in scanner, 3 weeks
to diagnosis, 2/1000 increase in cancer risk due to radiation exposure, one additional scan, 90% accuracy
and no need for whole body and head to be in scanner.
l Worst possible test: 60 minutes in scanner, 5 weeks to diagnosis, 2/1000 increase in cancer risk due to
radiation exposure, two additional scans, 85% accuracy and need for whole body and head to be
in scanner.
l PET-CT plus two additional scans: 30 minutes in scanner, 5 weeks to diagnosis, 2/1000 increase in
cancer risk due to radiation exposure, two additional scans, 90% accuracy and no need for whole body
and head to be in scanner.
l CT plus two additional scans: 10 minutes in scanner, 5 weeks to diagnosis, 2/1000 increase in cancer
risk due to radiation exposure, two additional scans, 90% accuracy and no need for whole body and
head to be in scanner.
l WB-MRI scenario 1: longer scan time, no radiation, whole body enclosed, longer time to diagnosis,
more scans – 60 minutes in scanner, 5 weeks to diagnosis, 0/1000 increase in cancer risk due to
radiation exposure, two additional scans, 90% accuracy and need for whole body and head to be
in scanner.
l CT plus one additional scan: 10 minutes in scanner, 3 weeks to diagnosis, 1/1000 increase in cancer
risk due to radiation exposure, one additional scan, 90% accuracy and no need for whole body and
head to be in scanner.
l WB-MRI scenario 2: longer scan time, no radiation, whole body enclosed – 60 minutes in scanner,
3 weeks to diagnosis, 0/1000 increase in cancer risk due to radiation exposure, one additional scan,
90% accuracy and need for whole body and head to be in scanner.
l WB-MRI scenario 3: longer scan time, no radiation, whole body enclosed, more accurate – 60 minutes in
scanner, 3 weeks to diagnosis, 0/1000 increase in cancer risk due to radiation exposure, one additional
scan, 95% accuracy and need for whole body and head to be in scanner.
l WB-MRI scenario 4: longer scan time, no radiation, whole body enclosed, quicker time to diagnosis,
fewer scans – 60 minutes in scanner, 1 week to diagnosis, 0/1000 increase in cancer risk due to
radiation exposure, no additional scans, 90% accuracy and need for whole body and head to be
in scanner.
l WB-MRI scenario 5: longer scan time, no radiation, whole body enclosed, more accurate, quicker time
to diagnosis, fewer scans – 60 minutes in scanner, 1 week to diagnosis, 0/1000 increase in cancer risk
due to radiation exposure, no additional scans, 95% accuracy and need for whole body and head to be
in scanner.
l Best possible pathway: 10 minutes in scanner, 1 week to diagnosis, 0/1000 increase in cancer risk due
to radiation exposure, no additional scans, 95% accuracy and no need for whole body and head to be
in scanner.
Description of tests in Streamline C
l Default staging pathway (CT plus one additional scan) in every case: 10 minutes in scanner, 3 weeks to
diagnosis, 1/1000 increase in cancer risk due to radiation exposure, one additional scan, 90% accuracy
and no need for whole body and head to be in scanner.
l Worst possible pathway: 60 minutes in scanner, 5 weeks to diagnosis, 2/1000 increase in cancer risk
due to radiation exposure, two additional scans, 85% accuracy and need for whole body and head to
be in scanner.
l PET-CT plus two additional scans: 30 minutes in scanner, 5 weeks to diagnosis, 2/1000 increase in
cancer risk due to radiation exposure, two additional scans, 90% accuracy and no need for whole body
and head to be in scanner.
l CT plus two additional scans: 10 minutes in scanner, 5 weeks to diagnosis, 2/1000 increase in cancer
risk due to radiation exposure, two additional scans, 90% accuracy and no need for whole body and
head to be in scanner.
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l WB-MRI scenario 1: longer scan time, no radiation, whole body enclosed, longer time to diagnosis,
more scans – 60 minutes in scanner, 5 weeks to diagnosis, 0/1000 increase in cancer risk due to
radiation exposure, two additional scans, 90% accuracy and need for whole body and head to be
in scanner.
l PET-CT plus one additional scan: 30 minutes in scanner, 3 weeks to diagnosis, 2/1000 increase in
cancer risk due to radiation exposure, one additional scan, 90% accuracy and no need for whole body
and head to be in scanner.
l WB-MRI scenario 2: longer scan time, no radiation, whole body enclosed – 60 minutes’ time in scanner,
3 weeks to diagnosis, 0/1000 increase in cancer risk due to radiation exposure, one additional scan,
90% accuracy and need for whole body and head to be in scanner.
l WB-MRI scenario 3: longer scan time, no radiation, whole body enclosed, more accurate – 60 minutes’
time in scanner, 3 weeks to diagnosis, 0/1000 increase in cancer risk due to radiation exposure, one
additional scan, 95% accuracy and need for whole body and head to be in scanner.
l WB-MRI scenario 4: longer scan time, no radiation, whole body enclosed, quicker time to diagnosis,
fewer scans – 60 minutes’ time in scanner, 1 week to diagnosis, 0/1000 increase in cancer risk due to
radiation exposure, no additional scans, 90% accuracy and need for whole body and head to be
in scanner.
l WB-MRI scenario 5: longer scan time, no radiation, whole body enclosed, more accurate, quicker time
to diagnosis, fewer scans – 60 minutes’ time in scanner, 1 week to diagnosis, 0/1000 increase in cancer
risk due to radiation exposure, no additional scans, 95% accuracy and need for whole body and head
to be in scanner.
l Best possible pathway: 10 minutes in scanner, 1 week to diagnosis, 0/1000 increase in cancer risk due
to radiation exposure, no additional scans, 95% accuracy and no need for whole body and head to be
in scanner.
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Chapter 7 Influence of WB-MRI sequences on
diagnostic accuracy
Introduction
Whole-body magnetic resonance imaging is time intensive in terms of both acquisition and reporting.
This stems largely from the multiple sequences acquired as part of standard protocols. This multitude of
sequences allow the radiologist to not only detect abnormalities but also crucially characterise them to
maintain adequate diagnostic sensitivity and specificity. For example, sites of metastasis may be more
conspicuous on one sequence than another, although using a sequence with high sensitivity but lower
specificity alone risks false-positive diagnosis without other sequences to help characterise areas of
potential abnormality.
Although WB-MRI protocols may differ a little according to the primary cancer and the nature and usual
sites of metastatic disease, they usually consist of T1- and T2-weighted imaging supplemented with DWI.61
Intravenous contrast-enhanced sequences are also frequently employed, particularly to improve detection
and characterisation of metastasis in the liver, lung and bone.61 The addition of intravenous contrast,
however, adds to the length, cost and invasiveness of WB-MRI and for some cancer types such as prostate
may be omitted.62
There is interest in decreasing the number of sequences acquired as part of standard WB-MRI protocols
to reduce the overall scan acquisition time and, potentially, radiologist reporting time. For example, small
studies have suggested that protocols using DWI instead of contrast-enhanced sequences may achieve
similar sensitivity for extracranial metastatic disease in melanoma.63 However, in a single-centre explanatory
study of 203 participants with non-small-cell lung cancer, Ohno et al.22 reported that sensitivity for metastasis
detection of WB-MRI using only DWI sequences was 58% compared with 70% when DWI was added to
other sequences including post-contrast T1-weighted image acquisition. There are no such data on WB-MRI
protocol optimisation in staging colon cancer.
Given this existing evidence base, the Streamline WB-MRI protocol included whole-body axial DWI, whole-
body axial T2-weighted imaging, whole-body axial or coronal T1-weighted imaging pre contrast and axial
T1-weighted imaging post contrast of at least the liver, lungs and head (see Chapter 1 and Appendix 1).
This allowed us to investigate the impact of reduced sequence WB-MRI protocols on diagnostic accuracy.
Methods
As described in Chapter 2, all radiologists interpreting WB-MRI as part of the Streamline trials did so in
three blocks in the following order:
1. diffusion-weighted images and non-contrast-enhanced T1-weighted images
2. diffusion-weighted images and non-contrast-enhanced T1- and T2-weighted images
3. diffusion-weighted images, non-contrast-enhanced T1- and T2-weighted images and contrast-enhanced
T1-weighted images.
After viewing each sequence block (and before reviewing the next block) the radiologist completed a
WB-MRI imaging booklet CRF – available on the project web page [URL: www.journalslibrary.nihr.ac.uk/
programmes/hta/106801 (accessed 12 September 2019)] – documenting their findings. Items recorded on
the CRFs included the location and T and N stage of the local tumour (TNM 7th edition) and the presence,
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location and size of metastatic disease. The presence of metastatic disease was recorded for a range of
soft tissue and bony anatomical sites using six confidence levels grouped into normal (confidence levels 1
and 2), equivocal (levels 3 and 4) and abnormal (levels 5 and 6). If disease presence was recorded as
equivocal or abnormal (i.e. confidence level 3 or above), the size of the largest two metastatic deposits per
organ was recorded, along with the additional number of deposits sized < 6 mm, 6–9 mm and ≥ 10 mm.
Reporting radiologists were instructed to interpret the WB-MRI as they would in their routine clinical
practice, taking into account the known morphology and characteristics of potential metastatic disease
across the various sequences.22
Analysis
The primary outcome was the difference in per-patient sensitivity for metastatic disease based on the three
combinations of sequences, against the consensus reference standard. In participants for whom sequence
data were missing from sequence block 3, prior sequences were substituted. Analysis included participants
with complete data only. Sensitivity, specificity and differences between sequences were analysed using
the methods for the primary outcome. Influences of WB-MRI sequences on radiologists’ confidence and
diagnosis were summarised descriptively.
Results
A total of 187 (Streamline L) and 289 (streamline C) participants had full data for all sequences. In
10 Streamline C participants, data were missing from sequence block 3, so available MRI sequences were
substituted (sequence block 2 substitution in two participants and sequence block 2 in eight participants).
In Streamline L there were no missing sequence data.
Streamline C and Streamline L
Tables 38 and 39 show the sensitivity and specificity for participants with metastatic disease across the
three sequence blocks according to the participant cohort.
For both Streamline C and Streamline L cohorts, the combination of T1-weighted (pre and post gadolinium
contrast), DWI and T2-weighted imaging achieved significantly higher sensitivity for metastatic disease than
with a simple protocol of just pre-contrast T1-weighted imaging combined with DWI. Addition of contrast-
enhanced sequences to DWI and T2-weighted imaging sequences produced a small non-significant increase
in sensitivity for both cancers. There was no difference in specificity across the tested sequence combinations.
TABLE 38 Streamline C: sensitivity and specificity for metastatic disease according to WB-MRI protocol sequences
Diagnostic
accuracy
Diagnostic performance, % (95% CI)
Difference in sensitivity/specificity,a
% (95% CI)
S1: T1- and
diffusion-
weighted
imaging
S2: T1-, T2-
and diffusion-
weighted
imaging
S3: T1-, T2-, and
diffusion-weighted
and contrast-
enhanced imaging
S2 – S1: T1-, T2- and
diffusion-weighted
imaging – T1- and
diffusion-weighted
imaging
S3 – S1: T1-, T2- and
diffusion-weighted
and contrast-
enhanced imaging –
T1- and diffusion-
weighted imaging
Sensitivity 63 (51 to 73) 70 (58 to 80) 72 (60 to 81) 7 (–1 to 15) 9 (1 to 17)
Specificity 84 (78 to 88) 86 (81 to 90) 85 (80 to 89) 2 (–2 to 6) 1 (–2 to 5)
S1, sequence set 1; S2, sequence set 2; S3, sequence set 3.
a Participants with all sequence data available.
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TABLE 39 Streamline L: sensitivity and specificity for metastatic disease according to WB-MRI protocol sequences
Diagnostic
accuracy
Diagnostic performance, % (95% CI)
Difference in sensitivity/specificity,a
% (95% CI)
S1: T1- and
diffusion-
weighted
imaging
S2: T1-, T2-
and diffusion-
weighted
imaging
S3: T1-, T2-, and
diffusion-weighted
and contrast-
enhanced imaging
S2 – S1: T1-, T2- and
diffusion-weighted
imaging – T1- and
diffusion-weighted
imaging
S3 – S1: T1-, T2- and
diffusion-weighted
and contrast-
enhanced imaging –
T1- and diffusion-
weighted imaging
Sensitivity 42 (28 to 56) 48 (35 to 61) 52 (39 to 65) 6 (–3 to 15) 10 (1 to 19)
Specificity 82 (74 to 87) 84 (76 to 89) 86 (79 to 91) 2 (–3 to 6) 4 (–2 to 9)
S1, sequence set 1; S2, sequence set 2; S3, sequence set 3.
a Participants with all sequence data available.
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Chapter 8 Interobserver agreement in
WB-MRI interpretation
Introduction
Interobserver agreement is an important facet in the evaluation of any imaging technology. As noted in
Chapter 1, many WB-MRI studies use a consensus of two readers for interpretation, which does not reflect
how WB-MRI would be reported in NHS clinical practice. Where small single-site studies have tested
interobserver agreement, it is generally reported as good. For example, in a small study of 34 participants
with a mix of primary tumours, Grueneisen et al.64 reported very high interobserver agreement (κ = 0.96)
between two radiologists for lesion characterisation. In a similar study of 51 participants in which two
radiologists interpreted WB-MRI based on DWI only, Paruthikunnan et al.65 reported a kappa of 0.77,
0.89 and 0.93 for detection of lung, liver and bone metastasis, respectively. Blackledge et al.66 tested
interobserver agreement for manual segmentation of disease on diffusion weighted images, and again
reported good observer agreement for DWI-defined volume (intraclass correlation coefficient 1.0). In a
140-participant comparison of WB-MRI, PET-CT and PET-MRI in non-small-cell lung cancer, Ohno et al.67
reported that interobserver agreement across all three modalities for final TNM stage was high, with kappa
ranging from 0.63 to 0.97. However, in the calculation of kappa in these studies, if both readers are
incorrect in their interpretation, this counts as ‘agreement’.
To date, almost all the literature has tested interobserver agreement between pairs of readers, many of
whom are highly experienced in interpreting WB-MRI. To date, interobserver agreement has not been
formally tested across a large number of readers who are typical of those who would report WB-MRI in
NHS clinical practice. The Streamline trials afforded an opportunity to rectify this.
Methods
All participants recruited to the main Streamline trials gave permission for their imaging data sets to be
used for the interobserver variation substudy as part of the study consent process.
Seventeen radiologists took part in the study, 15 of whom had interpreted WB-MRI as part of the main
Streamline trials. Two invited Streamline trial radiologists were unable to participate in the current study
and were replaced by two radiologists fulfilling the original experience criteria for the main trials (see
Chapter 2). One radiologist who had interpreted WB-MRI as part of the Streamline trials did not undertake
the required reads for the current study and could not be replaced owing to study timelines.
The WB-MRI examinations of participants recruited to the Streamline trials were shared via upload to an
online viewing platform (3Dnet) (see Chapter 2). The platform has all the image viewing functionality
of a standard PACS system but can be accessed from any PC via the internet with appropriate password
credentials. The system allowed participating radiologists to access the WB-MRI examinations from any
geographical location without the need to receive copies on compact disc (CD) or hard drive, thus
facilitating study efficiency.
Data set selection
The interobserver study was planned during the recruitment phase of the main trials, although reads took
part after recruitment was complete in order to lock the 3Dnet platform so readers could not access
uploaded WB-MRI reports. Overall, 192 Streamline L and 193 Streamline C participants had complete data
for trial standard and WB-MRI reads by 21 July 2016. Of these, 70 data sets were identified for each
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interobserver study from which to select the final study data sets. Selection was undertaken to (1) enrich
for participants likely to have metastases to increase statistical power, against the expected mid-trial
prevalence of 21% and 22% for lung and colon cancer, respectively. Enrichment used available trial data
including consensus reference data (available for 21 Streamline L and 69 Streamline C participants at this
time) and also WB-MRI and standard imaging reads and participant follow-up data at 3, 6, 9 and 12 months
where available. Selection was also undertaken to (2) enrich for ‘stress’ data sets where trial readings of
WB-MRI and standard pathways disagreed on the presence of metastases, or conflicted with actual or
expected consensus reference.
Case reader randomisation used random sequence generation (random uniform distribution Stata 14.2)
to assign observers to data set reads. Readers were selected from two different centres or imaging hubs,
and were different from the radiologists who had interpreted the WB-MRI data set as part of the main trials
(i.e. no radiologist was given a data set they had already interpreted as part of the main trials). For the
current analysis, participant data sets were randomly selected to ensure an equivalent prevalence of ‘stress’
participants in the interobserver study to that in the main trials (13% and 18% for Streamline L and
Streamline C, respectively). ‘Stress’ participants were therefore not over- or under-represented in the
interobserver substudy. The prevalence of participants with metastases, however, remained enriched
(Streamline L prevalence 63%, compared with main trial prevalence 28%; Streamline C prevalence 63%,
compared with main trial prevalence 23%).
Once radiologists were allocated their cases, in their own time (but within 8 weeks) they interpreted the
examinations, noting their findings on a CRF based on that used for the main Streamline trials – available
on the project web page [URL: www.journalslibrary.nihr.ac.uk/programmes/hta/106801 (accessed
12 September 2019)]. Data sets were either interpreted using the 3Dnet platform or could be downloaded
onto the reader’s preferred workstation. Each reader was allocated between 10 and 15 data sets. For the
current interobserver study, reads were performed using all available WB-MRI protocol sequences.
Analysis
The primary outcome of the interobserver study was to determine agreement between two reads for
identification of participants either with or without metastases, based on the consensus panel at
12 months (see Chapter 2). Data were analysed for the Streamline L and C cohorts separately.
Analysis related to comparisons of the two reads within a participant (WB-MRI data set) and the outcomes
related to the agreement between two reads for the per-participant correct identification of metastasis (to
mirror the primary outcome of the Streamline trials; see Chapter 2). Equivocal results (confidence scores 3
and 4) were handled as for the primary outcome (see Chapter 2), with sensitivity analyses treating them as
either all positive or all negative (Streamline C) or all negative (Streamline L).
Interobserver variability was measured by agreement between two radiologists, grouping results by the
consensus reference as positive, negative and across all participants, with 95% CI based on paired
proportions. Agreement between the reads regardless of ‘correctness’ against the reference standard is
also reported to allow more direct comparison with the existing literature. Prevalence-adjusted bias-
adjusted kappa (PABAK) was also reported68 and interpreted as follows: 0.01–0.20 (slight agreement),
0.21–0.40 (fair agreement), 0.41–0.60 (moderate agreement), 0.61–0.80 (substantial agreement) and
0.81–0.99 (almost perfect agreement).69
Statistical analysis was performed using Stata version 14.2.
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Results
In total, 40 data sets from Streamline C and 43 data sets from Streamline L were included.
The level of agreement between both reads and the consensus reference standard according to Streamline C
and L is shown in Table 40, and between both reads (irrespective of agreement with the consensus
reference) is shown in Appendix 80, Table 117.
Overall, agreement was better for WB-MRI staging of colorectal cancer (Streamline C) than non-small-cell
lung cancer (Streamline L). For Streamline C, agreement between two reads against the reference standard
was 76% (95% CI 57% to 89%) and 87% (95% CI 62% to 96%) for participants with and without
metastatic disease, respectively (PABAK 0.60). For Streamline L, agreement between two reads against the
reference standard was 37% (95% CI 22% to 56%) and 56% (95% CI 33% to 77%) for participants
with and without metastatic disease, respectively (PABAK –0.12). This in part reflects the overall low
sensitivity of the two radiologist reads of 67% and 44% for the Streamline L datasets.
Agreement between reads for the presence or absence of metastatic disease regardless of agreement with
the reference standard was, as expected, higher than that when the reference standard was considered
(see Appendix 80, Table 117). For the primary outcome, overall reads agreed in 35 out of 40 (88%) data
sets for Streamline C and 28 out of 43 (65%) data sets for Streamline L. When equivocal lesions were
considered negative, agreement was unchanged for Streamline C but improved to 32 out of 43 (74%) for
Streamline L.
TABLE 40 WB-MRI interobserver variability against the consensus refence standard: Streamline C and Streamline L
Outcome
Streamline C participants (n= 40)
Participants with metastatic
diseasea (n= 25)
Participants without
metastatic diseasea
(n= 15)
% overall
agree κ
R1
(n)
R2
(n)
% positive agree
(95% CI)b
% negative agree
(95% CI)b
Primary outcomec 19 22 76 (57 to 89) 87 (62 to 96) 80 0.60
Equivocal lesions considered positive 19 23 76 (57 to 89) 73 (48 to 89) 75 0.50
Equivocal lesions considered negative 18 21 72 (52 to 86) 87 (62 to 96) 78 0.55
Outcome
Streamline L participants (n= 43)
Participants with metastatic
diseasea (n= 27)
Participants without
metastatic diseasea
(n= 16)
% overall
agree κ
R1
(n)
R2
(n)
% positive agree
(95% CI)b
% negative agree
(95% CI)b
Primary outcomec 18 12 37 (22 to 56) 56 (33 to 77) 44 –0.12
Equivocal lesions considered negative 10 10 26 (13 to 45) 69 (44 to 86) 42 –0.16
R1, first read; R2, second read.
a By consensus reference standard.
b Both reads agree with consensus reference standard.
c Per-participant sensitivity for metastatic disease. Equivocal results considered positive for colonic tumours and negative
for rectal tumours (Streamline C). Equivocal results considered positive (Streamline L).
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Chapter 9 Discussion
Parts of this chapter are reproduced from Taylor et al.25 This is an Open Access article distributed inaccordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Parts of this chapter are reproduced from Taylor et al.26 This is an Open Access article distributed in
accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is
properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes minor additions
and formatting changes to the original text.
Diagnostic accuracy
Whole-body magnetic resonance imaging is advocated as a replacement for current complex multimodality
cancer staging pathways. We prospectively tested its diagnostic accuracy, influence on staging efficiency
(in terms of time, number of tests and cost) and impact on the first major treatment decisions in the
two most common causes of cancer deaths in the UK: colorectal and non-small-cell lung cancer. Such
comprehensive evaluation of diagnostic tests, although recommended,24 is rarely performed. We also
investigated participant experience, influence of MRI sequences on diagnostic accuracy and interobserver
variation in the interpretation of WB-MRI.
At the time of writing and to the best of our knowledge, Streamline C and Streamline L are the largest
prospective multicentre trials of WB-MRI in cancer staging.
Multidisciplinary consensus panel review is standard methodology for diagnostic test accuracy studies for
which an independent reference standard does not exist or is impossible because of incorporation bias.23,28
We convened a number of consensus panels at recruitment sites that considered a full 12 months of
participant data including all imaging, histopathology and clinical outcomes. The panels were attended by
at least one radiologist external to the recruitment site to provide an independent review of all imaging,
as well as clinician representation. We a priori provided the panels with criteria for diagnosing metastatic
disease based on whether or not the primary tumour was left in situ, given its potential to seed metastatic
disease if not removed soon after diagnosis (thereby incorrectly penalising staging investigations). To the
best of our knowledge, seeding of metastatic disease from in situ primary tumours has not been considered
by imaging diagnostic accuracy studies to date. In the absence of hard evidence on which to base the
criteria, the trial investigators derived pragmatic definitions; any metastatic disease assumed as present
at diagnosis if the primary tumour was removed within 3 months, and for primary tumours left in situ,
metastatic disease appearing for the first time after 6-month follow-up was assumed to be seeded. Although
such criteria are arguably relatively arbitrary, they were applied equally to both staging pathways and, given
that our primary outcome was the difference between pathways rather than their absolute sensitivity, will
not affect our findings.
Overall, we found that the sensitivity and specificity of the WB-MRI staging pathway for identifying
participants with metastatic disease was not significantly different from standard staging pathways for
either colorectal or non-small-cell lung cancer. Based on a thorough literature review at the time of study
design (see Report Supplementary Material 1), we hypothesised that the WB-MRI pathway would have
higher sensitivity than standard pathways. For colorectal cancer this was mainly based on a higher
sensitivity for liver metastasis, and for non-small-cell lung cancer for brain and bone metastasis. Although
in Streamline L WB-MRI did detect more brain and pleural metastasis for example, overall it held no
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significant diagnostic accuracy advantage in either cancer. The Streamline trials are essentially the first
to compare complete staging pathways and our power calculations were informed mainly by the single
modality comparisons available in the literature. Indeed, it is owing to the known limitations of individual
cross-sectional imaging techniques that staging pathways are multimodality to maximise sensitivity for
metastatic disease. As part of our secondary analysis, we did replicate the existing literature and compared
WB-MRI with PET-CT alone (Streamline L) and with chest, abdomen and pelvis CT alone (Streamline C).
Interestingly, we did find WB-MRI alone had significantly higher sensitivity and lower specificity that chest,
abdomen and pelvis CT in staging colon cancer (76% vs. 50% and 86% vs. 99%, respectively), although
this was not significantly different from PET-CT in staging non-small-cell lung cancer. The Streamline trials
clearly demonstrate that it is overly simplistic to compare single imaging modalities and that true clinical
practice can be properly tested only by comparing complete staging pathways. For Streamline L, we
recruited sufficient numbers of participants with metastatic disease to meet the requirements of the power
calculation. However, for Streamline C, the prevalence of participants with metastatic disease according
to the 12-month consensus reference (23%) was lower than anticipated (40%) and the number of
participants with metastasis was less than that suggested as required by the pre-study power calculation.
The UK bowel screening programme has reduced the prevalence of advanced disease below that of
historical cohorts,70 which in part explains the lower prevalence of metastasis, and participants were
not preselected (e.g. based on age or primary tumour stage) to artificially boost the prevalence (other than
exclusion of polyp cancers). Instead, Streamline C recruited consecutive eligible participants who required
staging investigations, specifically to mimic clinical practice. The IDMC did perform an interim analysis to
look at both prevalence and other assumptions in the sample size calculation. The decision was made to
recruit to the number of evaluable participants in the original trial design, accounting for the increased
withdrawal rate. The number of participants recruited was not adjusted to account for the lower
prevalence, as this interim analysis showed no evidence that a difference in diagnostic accuracy between
pathways would be identified. The IDMC confirmed that the trial should be continued and would include
a sufficient number of participants for results to guide current practice. The study was designed to have
sufficient power to detect a clinically relevant sensitivity difference of 10% between WB-MRI and standard
staging pathways (predominantly chest, abdomen and pelvis CT). Interestingly, we did find that WB-MRI
alone has greater sensitivity than chest, abdomen and pelvis CT alone. Overall and to the best of our
knowledge, Streamline C is by far the largest trial of WB-MRI in staging pathways colon cancer to date.
In recent years, several meta-analyses have been published concerning the accuracy of WB-MRI in cancer
staging. Many combine disparate tumour types and, although several consider lung cancer in isolation, they
typically focus on one site of metastatic disease, usually bone or lymph node (see Chapter 1). Those combining
different primary tumours generally concur with our finding that the sensitivity of WB-MRI is similar to
conventional tests such as PET-CT. For example, Xu et al.9 analysed nine studies, including 1070 participants
with a range of primary cancers such as breast, lung, melanoma, nasopharyngeal and colorectal. Overall
sensitivity for participants with metastasis was 86% (95% CI 70% to 94%) for WB-MRI and 85% (95% CI
68% to 94%) for PET-CT. Li et al.11 also reported identical sensitivity (90%) for WB-MRI and PET-CT in their
2014 meta-analysis across a range of primary tumours and metastatic sites. Those meta-analyses concerning
lung cancer alone have mainly considered bone and nodal metastasis. Accuracy of bone metastases detection
was evaluated across a range of studies and participant cohorts by Qu et al.,15 who reported that WB-MRI
had lower sensitivity than PET-CT [77% (95% CI 65% to 87%) (in three studies of 252 participants) vs. 92%
[95% CI 88% to 95%] (in 17 studies, of which only two included WB-MRI), respectively]. Of note, only
Li et al.11 have directly compared the sensitivity and specificity of WB-MRI and PET-CT and reported that there
was no significant difference; the other meta-analyses and systematic reviews report only stand-alone data
from each test. Crucially, data were not reported for studies comparing the imaging methods in the same
participants (i.e. direct within-participant comparison). Furthermore, no study presents results stratified by the
largest lesion size, a key determinate of sensitivity in Streamlines L and C.
Overall, for both cancers we found the sensitivity of WB-MRI (and standard) pathways to be lower than
that reported in the literature. There are several probable reasons for this observation. Most studies to
date have been small single-site explanatory studies using a consensus of two experienced radiologists for
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WB-MRI interpretation. Such study design inflates the apparent diagnostic accuracy of any new technology.
Conversely, we tested WB-MRI as it would be used if disseminated in the NHS; images were acquired across
a range of MRI platforms and interpreted by radiologists representative of those who would report the
examination in clinical practice. It should be noted that detailed quality assurance review of WB-MRI data sets
was reassuring: just under half were judged to be of optimal quality, and although 43% were suboptimal they
remained fully diagnostic by our quality assurance criteria. Only 64 data sets were scored as degraded and
many (23) of these were because gadolinium could not be administered, meaning they still had T1-, T2- and
diffusion-weighted imaging sequences available (which achieve similar sensitivity as per our substudy in
Chapter 7). There were also few perceptual errors noted by the consensus panels on retrospective review of
the imaging that influenced the primary outcome (per-patient analysis). Interestingly, however, there were
more WB-MRI perceptual errors in Streamline L than in Streamline C. This probably reflects the conspicuity of
metastases according to their location. Most metastases in Streamline C participants were in the liver or lung,
with relatively few perceptual errors for either organ. This was mirrored in Streamline L, with few perceptual
errors in the lung or liver. Conversely, in Streamline L many metastases were located in the bone, where they
are more prone to being small, subtle and difficult to characterise. Indeed, there were perceptual errors in
seven of 15 bone metastases. It is important to stress that although the consensus panels suggested that some
missed lesions were perceptual errors, this does not necessarily imply that they should have been prospectively
reported. Many lesions although visible in retrospect and with the advantage of follow-up imaging are very
difficult to detect prospectively, particularly if reasonable specificity is to be maintained. Overall, in terms of the
primary outcome, there was no material difference in the number of perceptual errors in WB-MRI and standard
staging pathways. This suggests that WB-MRI was interpreted with at least the same competency as standard
imaging, justifying the stipulated experience criteria for radiologists. We of course acknowledge that diagnostic
sensitivity of WB-MRI may be higher if interpreted by highly experienced radiologists with large reporting
volumes. However, to restrict interpretation to these individuals would not be representative of a national
workforce. We also blinded radiologists to the patient history and, in the case of WB-MRI, to contemporaneous
imaging, which does not mirror usual clinical practice but was necessary to isolate diagnostic test accuracy as
far as possible. Indeed, we used novel cloud-based imaging interpretation software for WB-MRI to ensure full
blinding of WB-MRI reporters to standard imaging and to WB-MRI for those reporting standard imaging. Again,
to the best of our knowledge this approach is novel and added to the integrity of the trials. For both trials our
consensus reference standard considered a full 12 months of participant follow-up, and several participants
’developed’ metastasis during this follow-up period according to our criteria that was not visible even in
retrospect on any imaging modality (e.g. six participants in Streamline C). Such disease, almost certainly present
at diagnosis, is currently beyond the resolution of cross-sectional imaging and explains the large number of
colon cancer participants who relapse within 2 years of attempted curative resection and the relatively high rate
of ‘futile thoracotomy’ for apparently early-stage non-small-cell lung cancer.71 Most diagnostic accuracy studies
do not include such a prolonged period of participant follow-up, and, as such, the Streamline trials provide a
realistic reflection of cancer staging accuracy.
The trials were not powered to detect differences between pathways for metastasis detection in specific
organs, but although the ability of WB-MRI to detect lung metastasis has been questioned,21 we found no
strong evidence that it was inferior to standard pathways for either cancer type. Although WB-MRI pathways
diagnosed two additional participants with brain metastasis in Streamline L, we can conclude that WB-MRI
pathways are unlikely to significantly reduce the rates of unexpected relapse. In the case of Streamline L, we
excluded participants with locally advanced or metastatic disease on their diagnostic chest CT (which usually
includes the lower neck, liver and adrenal glands); such participants generally undergo treatment without
curative intent and detecting additional disease sites has limited therapeutic impact. Such exclusion is unusual
in the literature. In our cohort, metastases were therefore either occult on diagnostic chest CT or at remote
sites outside the chest and upper abdomen. This pre-selection of participants to only those in true clinical
need of detailed staging probably reduced overall diagnostic accuracy of both standard imaging and WB-MRI
in comparison to most trials in the literature in which such participants with metastatic disease at initial
diagnosis are included. In both trials, as would be expected, sensitivity for metastasis ≥ 1 cm in size was much
higher than for metastasis <1 cm in size. In the case of Streamline C, most (48/68) participants with metastatic
disease had liver involvement, and the dependence of imaging accuracy on lesion size is well established; in
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
87
their 2010 meta-analysis, Niekel et al.72 reported that sensitivity of even dedicated liver MRI is frequently < 50%
for liver metastasis < 1 cm in size. It is important to differentiate WB-MRI cancer staging protocols from those
specially designed to stage the liver. Our WB-MRI protocol complied with accepted international standards,62
including DWI and post-gadolinium-enhanced sequences, but by necessity had to compromise, for example on
slice thickness, to ensure reasonable scan times. A recent meta-analyses suggests 93% sensitivity for dedicated
liver MRI protocols with liver specific contrast agent, albeit with much heterogeneity between studies.73 As MRI
technology evolves, addition of sequences following liver-specific contrast agents to standard WB-MRI
protocols will be increasingly feasible, although would add to cost.
The Streamline trials were prospective real-world evaluations of staging pathways and the findings certainly
raise the possibility that diagnostic accuracy studies in the radiological literature tend to inflate the sensitivity
of cross-sectional imaging owing to participant selection bias, reading paradigms and applied standards of
reference. Indeed, recent data suggests the assumed accuracy of standard staging in non-small-cell lung
cancer is overly optimistic,74 reflected in the poor overall 5-year survival rate.
Overall, on a per-participant basis there was a moderate number of equivocal lesions (Streamline C, 11 and
21 participants for WB-MRI and standard pathways, respectively; Streamline L, two and six participants for
WB-MRI and standard pathways, respectively). The number of equivocal lesions was higher for WB-MRI
as a stand-alone test (Streamline C, n = 34; Streamline L, n = 19). WB-MRI generated several additional
staging investigations, probably as a result of equivocal findings, and these additional tests clarified their
nature, resulting in high specificity for the complete WB-MRI pathway. Again, this underlines the principle
that it is insufficient to compare stand-alone staging investigations, and that only full staging pathways are
relevant. In general, as part of the primary analysis we treated equivocal imaging findings as positive given
their impact on patient management, for example generating additional tests. On the advice of the IDMC,
however, equivocal findings were treated differently in the Streamline C cohort depending on whether the
primary tumour was rectal or non-rectal (in the case of rectal cancer they were considered negative). The
IDMC rationale was that many participants with rectal cancer undergo long-course chemotherapy radiation
and then restaging, giving time for equivocal lesions to ‘declare themselves’. However, we performed a
sensitivity analysis for both Streamline C and Streamline L, and there remained no significant difference
between WB-MRI and standard staging pathways when equivocal findings were either considered all
positive or all negative.
As part of the secondary analysis we also investigated the agreement of pathways for local T and N staging
against the consensus reference standard. Were WB-MRI pathways to replace current standard pathways, their
ability to stage the tumour locally as well as determining metastatic status is of importance. We found that for
Streamline C, the WB-MRI staging pathway had potentially lower agreement for T stage than standard staging
(54% vs. 60%, respectively, although this difference was not statistically significant) and that there was no
significant difference in nodal staging agreement or sensitivity to detect nodal disease (76% with both
imaging pathways). MRI is promising in its ability to assign the T stage of extrarectal colonic cancer,75 but
as yet there is no firm evidence that it will exceed the sensitivity of CT. WB-MRI protocols must compromise
on slice thickness to ensure that protocols can be completed in a reasonable time. Local staging of colonic
tumours would probably be improved by high-resolution T2-weighted images through the primary tumour
(akin to rectal cancer staging protocols), although this would require planning by radiographers and increased
scan time. In the case of Streamline L, agreement for T stage was no different between WB-MRI and standard
pathways, but agreement for N stage was higher in the standard pathway (75% in the standard pathway vs.
65% in the WB-MRI pathway). Sensitivity for nodal disease was also significantly higher [84% vs 71%,
respectively, a 13% (95% CI 3% to 22%) difference]. For MRI alone, the sensitivity to detect nodal disease
was 67% (95% CI 56% to 77%). In their 2016 meta-analysis, which included 1122 participants, Peerlings
et al.18 reported that thoracic MRI had 87% (95% CI 78% to 92%) sensitivity for per-patient nodal staging
in lung cancer, although Shen et al.19 reported a sensitivity of 68% (95% CI 63% to 73%), which is more
consistent with our findings. Indeed, in a study of 113 participants with a histological reference standard,
Kim et al.76 reported that morphological MRI observations had a per-patient sensitivity of 68% and a per-nodal
station sensitivity of 53%, again very similar to our findings. To date, there is little evidence that WB-MRI alone
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will increase the sensitivity for nodal disease compared with PET-CT. For example, in a recent meta-analysis,
Wu et al.20 reported MRI had a sensitivity of 72% (95% CI 63% to 80%) compared with 75% (95% CI
68% to 81%) for PET-CT, although only three studies included MRI, of which just one had a direct comparison
with PET-CT. Although MRI holds promise in nodal staging of non-small-cell lung cancer, our data suggest that
it is inferior to standard pathways, particularly PET-CT. The impact of this will probably be tempered by the
increasing use of EBUS to both diagnose and stage lung cancer77 (for the most part EBUS was considered a
diagnostic rather than staging test in the Streamline trials). As discussed in First major treatment decision, this
reduction in N stage agreement and sensitivity for the WB-MRI pathway did not appear to adversely influence
patient management.
First major treatment decision
The Streamline trials include a novel trial design where the first patient management decision was recorded
during the actual participant pathway. An important finding of the Streamline trials was that the level of
agreement between treatment decisions based on the WB-MRI pathway and both the final MDT treatment
decision and retrospective consensus panel optimal treatments was essentially identical to that between
standard staging pathways and both the final MDT treatment decision and retrospective consensus panel
optimal treatments.24 This suggests that the lower sensitivity of WB-MRI pathways for local staging
(particularly N stage in non-small-cell lung cancer) did not materially affect patient management, even in
retrospect. To date, there has been little study on the impact of WB-MRI on treatment decisions. For the
current study, we grouped the range of possible decisions into four major categories for Streamline C and
two major categories (curative and non-curative intent) for Streamline L. Such grouping was necessary for
analysis. Although the contemporaneous MDT first major treatment decision is arguably clinically the most
relevant when assessing staging pathways, it may ultimately be incorrect if WB-MRI and/or standard tests
are misleading and those findings were acted on by the MDT. We countered this by also collating the
optimum retrospective treatment decision based on the outcome of participants at 12 months. Perhaps
not surprisingly, agreement of both pathways was higher with the MDT treatment decision than with
the retrospective consensus decision, as the latter considers follow-up data, which would have influenced
initial treatment had it been known at the time, for example undiagnosed metastatic disease and
histopathological staging of resected tumours. For example, in 22 participants with (non-rectal) colon
cancer, where both WB-MRI and standard pathways agreed with the MDT treatment decision that
primary surgery without chemotherapy was recommended the consensus panel suggested that additional
chemotherapy would have been optimal, based on consideration of all follow-up data at 12 months.
Of course, such retrospective optimal treatment decisions are theoretical as much information would
often not be available at the time of the first major treatment decision. Overall, however, that the WB-MRI
staging pathway does not lead to a greater number of incorrect contemporaneous or retrospective optimal
treatment decisions than standard pathways is an important finding of the Streamline trials and suggests
that implementation would not have a detrimental impact on patient outcomes compared with current
practice. As noted in Main trial strengths and limitations, a limitation of our methods is that the MDT was
unblinded to the standard pathway tests and treatment decision prior to documenting the decision based
on the WBI-MRI pathway. However, it was important that the same individuals made the decision based on
WB-MRI to avoid contamination by the variability in treatment decisions due to differing opinions between
different clinicians.
In summary, the Streamline trials provide, to the best of our knowledge for the first time, a realistic
assessment of the accuracy of WB-MRI and standard staging pathways in NHS clinical practice. We can
conclude that WB-MRI pathways achieve similar diagnostic accuracy for identifying participants with
metastatic disease as current multimodality standard staging pathways, and result in very similar primary
treatment decisions.
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Staging pathway efficiency
Another important aspect of cancer staging pathways rarely addressed in the literature is pathway efficiency,
that is, the time to complete staging, the number of tests required and overall cost-effectiveness. The Streamline
trials identified that the WB-MRI pathway was more efficient than standard pathways. For both cancer types,
the WB-MRI pathway reduced the time taken to complete staging (by median 6 days for non-small-cell lung
cancer and median 5 days for colorectal cancer). The time saving was greater for participants with metastatic
disease. Although we were able to measure the actual time taken to complete standard staging pathways,
by necessity we modelled the timing of the WB-MRI staging pathway. However, this was based on real test
waiting times collated from recruitment sites as part of the trial, and so is probably an accurate reflection of
staging times, assuming local access to WB-MRI (which had been agreed upfront by imaging hubs). We defined
the end of staging as the date that the last staging investigation was performed, as this was a robust data point
easily collected. However, we did also record the length of time between this last staging investigation and the
final first major MDT treatment decision. This added a median 4 (95% CI 3 to 5) days for streamline C and 6
(95% CI 6 to 7) days for streamline L. Prolonged staging pathways increase participant anxiety8 and time to first
treatment is an important yardstick in assessing the quality of hospital cancer services. For example, accelerated
diagnostic pathways in participants with lung cancer are associated with a more rapid reduction in stress levels
over time.78 Furthermore, timeliness of lung cancer treatment is recognised as a care quality indicator, and
reducing time to treatment decisions by just 2 weeks is associated with improved survival.77 It is as yet unknown
if reduced staging times will have any meaningful effect on colorectal cancer outcomes, but reduction in
participant anxiety would perhaps be expected given the data from other cancer types.
The number of tests was also lower in the WB-MRI pathway for both cancers (significantly so for colorectal
cancer). We specifically excluded diagnostic tests, assuming that these would be common to both pathways,
and compared the tests undertaken as part of staging after a proven or highly suspected cancer diagnosis.
One of the potential advantages of WB-MRI is its ability to reduce the number of tests required to fully stage
the patient, thereby simplifying the staging pathway. The Streamline trials show this advantage to hold true
in the case of colorectal and non-small-cell lung cancer. Indeed, WB-MRI generated relatively few additional
tests (21 for Streamline C and 45 for Streamline L). We asked the MDT to state whether or not, after
reviewing the WB-MRI findings, they would request additional tests to complete staging. These decisions
were therefore made contemporaneously by the same clinical team that defined the content of the standard
staging pathway, and, outside a RCT design, this is the most robust way to define the content of staging
pathways utilising initial WB-MRI. Unsurprisingly, the vast majority (97%) of participants recruited to
Streamline L underwent PET-CT as part of standard staging, although just 14% would have required PET-CT
as part of the WB-MRI pathway. As discussed in Cost-effectiveness, this was a major component of the cost
savings of the WB-MRI pathway. For participants recruited to Streamline C, WB-MRI generated relatively few
additional tests and just six dedicated pelvic MRI scans. Overall, 130 recruited participants had rectal cancer,
for whom it would be expected that pelvic MRI would usually be performed for local staging. Indeed, 120
participants underwent a dedicated pelvic MRI as part of standard staging. It is of interest that the MDT were
for the most part content with the local staging provided by the WB-MRI protocol, although this included
relatively thick standard axial T2-weighted images, rather than high-resolution T2-weighted imaging angled
to the plane of the tumour (which forms the bedrock of dedicated rectal cancer staging protocols). In
Streamline C, the agreement for T and N staging of WB-MRI as a stand-alone investigation was lower than
that for standard pathways, which (as would be expected) suggests that dedicated rectal staging MRI has
superior accuracy than WB-MRI protocols. However, as noted in First major treatment decision, treatment
decisions were not adversely influenced by the inferior local staging provided by WB-MRI pathways. This
suggests that for most participants the staging information provided by WB-MRI (and additional tests
generated) was sufficient to guide the first major treatment decision. A similar observation can be made for
the need for dedicated liver MRI, utilised in 12% of participants as part of standard pathways.
Overall, the WB-MRI pathway was more efficient that standard pathways, reducing both the time needed
to complete staging and the number of tests performed. As discussed in Participant experience, with these
attributes, participants generally prefer the WB-MRI pathway to standard staging pathways.
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Cost-effectiveness
There was in excess of 90% concordance between the standard staging pathways and the WB-MRI staging
pathway for staging of both non-small-cell lung cancer and colorectal cancer. As a consequence, and based
on our study protocol,23 the economic analysis focused solely on the cost of the treatment decision pathways
for both cancers. We observed that the mean cost per patient in each trial was lower for WB-MRI pathways
than for conventional staging pathways, and that the 95% bootstrapped CIs did not overlap, leading us to
suggest that the differences in costs are significant. The WB-MRI staging pathway costs in Streamline C were
around three-quarters of the standard staging costs, and the WB-MRI pathway staging costs in Streamline L
were around half the standard staging pathways costs. The staging costs for non-small-cell lung cancer are
more expensive than for colorectal cancer. Assuming that there are no other differences in costs or effects
on patient management of using the different staging pathways, our conclusion is that WB-MRI is more
cost-effective than standard staging in both cancers. We note that an added consideration could be that the
use of WB-MRI could have a different impact on participants in the long term in that, theoretically, it could
be less harmful for them than the standard investigations (e.g. owing to no radiation exposure). However, no
data could be collected on this as all participants also received the standard battery of tests, so it would be
difficult to isolate the impact of reduced radiation exposure. Our costs were also based on standard NHS
reference costs, as this was considered the most robust and fair way of comparing pathways without undue
influence from local tariffs that may differ markedly between hospitals. For example, in the case of Streamline L,
the increased cost of standard pathways was mainly driven by the use of PET-CT. Our costings maintained
a 2 : 1 ratio of the cost of PET-CT and WB-MRI, which is consistent with local tariffs at most participating
hospitals, suggesting our comparisons were fair. Finally, we note that the WB-MRI pathway required fewer
tests than the standard pathway. As well as affecting the cost difference, this may also release capacity in
imaging departments, potentially allowing more participants to be scanned, and theoretically reducing
waiting times. The economic impact would depend on the availability and capacity of imaging equipment
and staff, together with the clinical demand for the imaging platforms (overall, not just for lung and
colorectal cancer participants). Consideration of this question would require a wider analysis, considering
these variables, but would be of interest.
Main trial strengths and limitations
A major strength of our study is its pragmatic design. We recruited from a representative range of district
general and teaching hospitals, with all imaging performed and interpreted according to usual local protocols,
to increase the generalisability of our results. The radiologists interpreting WB-MRI were representative of
those who would do so in daily NHS practice. We specifically avoided using a small number of highly
experienced radiologists as they do not represent the national workforce. We utilised MDT meetings to
mirror exactly how patient care is delivered in the NHS. Doing so captured the entirety of standard pathways,
including contemporaneous treatment decisions for both staging pathways. To facilitate this, we used a novel
cloud-based image repository to maintain blinding and control MDT access to WB-MRI until the appropriate
time in the decision-making process. We were then able to model the content and timing of the WB-MRI
staging pathway, and the potential impact on decision-making, which is a major strength of the Streamline
trials. Conversely, previous research usually reports head-to-head comparisons between single imaging
platforms, failing to capture pathway complexity. Previous studies have not measured staging pathway times
or effects on treatment decisions. We tested the alternative pathways in the same participants, who were
representative of those with the condition, which is the best methodology when testing diagnostic accuracy.
By including the standard staging pathway in its entirety, we were able to fully evaluate the impact of
replacement with WB-MRI. Such data are crucial to policy makers such as the NICE, and under-reported in
the literature.79 To the best of our knowledge, our trial design is unique.
The trials do have limitations in addition to those discussed in previous sections. We blinded radiologists to
patient history and, for WB-MRI, to contemporaneous imaging. This does not mirror daily practice but was
necessary to isolate diagnostic test accuracy as far as possible within a pragmatic setting. Participants were
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representative of those undergoing staging in daily practice, although we did exclude pregnant women and
participants with contraindications to MRI. We modelled timing of the WB-MRI staging pathway on real
waiting times collated from recruitment sites during the trial and imaging hubs that had agreed they had
capacity to perform WB-MRI. Treatment decisions based on WB-MRI pathways were made after the MDT
was unblinded to all standard imaging tests, which may introduce bias. However, this was unavoidable if
the full complexity of standard staging pathways was to be captured without interference from WB-MRI
findings, and treatment decisions (and changes) could be recorded contemporaneously. Furthermore,
alternative pathway agreement with a retrospective optimal treatment based on 12 months of follow-up
data remained essentially identical. Our costings reflect an English NHS perspective and may differ in other
settings, but full listing of the tests ordered for each pathway allows costing for alternative economic
settings. It is acknowledged that access to MRI platforms to perform WB-MRI examinations may be limited
in many health-care settings, which would influence the time of staging pathways. However, our data
suggest that investment in increased provision would ultimately reduce the cost and complexity of
colorectal and non-small-cell lung cancer staging.
Participant experience
We evaluated the comparative experience of the WB-MRI staging pathway and standard staging pathways
via a series of three connected studies.
Study 133 was a qualitative interview study. In general, participants reported that the challenge of WB-MRI
was different from standard investigations, although the extent of this challenge varied considerably
between individuals. Of note, among the cohort interviewed just four participants requested premature
termination and all were prepared to attempt a repeat WB-MRI in the future. To deal with the challenge
of undergoing WB-MRI, participants adopted a variety of coping strategies. These mainly focused on the
physical and emotional experiences while undergoing the examination, as well as focusing on beliefs that
bolstered motivation to complete the scan.33 Some strategies dealt with the immediate demands imposed
by the scan, whereas others addressed the contextual threat of what the scan might reveal about their
underlying condition. We found that hospital staff were often important in supporting participants; positive
interactions bolstered coping whereas negative interactions had the opposite effect. For example, verbal
contact from staff during the scan helped distract some participants from the physical challenges of being
in the scanner and provided emotional reassurance. However, this only appeared effective if a rapport was
established that was initiated at the start of the appointment before scanning started. If that trust was
absent, staff interactions could increase participants’ vulnerability.
Our data concur with previous qualitative work investigating patient experience during MRI scanning,43,44
although ours is the first to specifically investigate WB-MRI. Comparable with our findings, these two previous
studies report that many patients find MRI a unique experience, with references to isolation within the scanner
and of ‘being in another world’.44 The challenges described by participants in our study also feature in these
previous reports, particularly the enclosed space, scanner noise, physical discomfort, lying in the scanner and
long scan duration. The benefit of staff support is similarly conveyed. The themes identified by our participant
interviews also concur with previous quantitative work, particularly the negative impact of scanner noise and
confinement.37,41 We also found that comorbidity influenced tolerance, although unlike previous research41 we
also found that prior experience of MRI increased coping ability, even if this experience was relatively negative.
An important finding of our study was the greater impact of physical comorbidity on patient tolerance of
WB-MRI in participants with lung cancer than in those with colorectal cancer. For example, musculoskeletal
problems and difficulties with breath holding due to pre-existing chest disease were frequently cited. Participants
recruited to the Streamline trials were either suspected to have or newly diagnosed with underlying cancer
and this also affected their experience of WB-MRI. Some, for example, feared WB-MRI would reveal cancer
dissemination and several noted that the MRI machine magnet resembled a coffin or sarcophagus. Carlsson
et al.43 also reported that fear was greater when MRI was used to confirm suspicions of serious illness.
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Although the impact of comorbidities and the emotional vulnerability of cancer patients should be
acknowledged, it is important to note that many participants found WB-MRI to be acceptable, and most
tolerated scanning to completion.
Overall, study 1 suggested that good staff communication, both prior to and during the scan, is
undoubtedly beneficial, reducing anxiety and boosting coping efforts by acting as a source of distraction,
motivation and emotional reassurance.33 Staff training to build rapport and facilitate relaxation can reduce
the MRI non-completion rate and increase patient satisfaction.80 Participant experience during WB-MRI is
variable, but most employ some form of coping strategy and complete the scan.
Study 234 built on the findings of study 1, which suggested that for some participants WB-MRI is a greater
challenge than standard staging scans. We quantified participant experiences during staging pathways
using questionnaires and in particular compared WB-MRI with CT (Streamline C participants) and with
PET-CT (Streamline L participants).
Overall, study 2 suggested that in general participants tolerate WB-MRI well (96% rate it as very or fairly
acceptable) and, when quantified from one to seven, absolute discomfort and worry levels were low and
satisfaction was high. However, when compared with standard staging scans, the burden of WB-MRI was
significantly greater. This was particularly apparent when Streamline C participants compared WB-MRI with
CT, but also held true when Streamline L participants compared WB-MRI with PET-CT. Of the standard
staging scans, the burden of CT was less than that of PET-CT. However, as noted in study 1 and confirmed
by study 2, comorbidities in the lung cancer participant cohort may have influenced their tolerance of
PET-CT, so a direct comparison with Streamline C participants undergoing CT has limitations. Interestingly,
Adams et al.81 reported that lymphoma participants in general describe a better experience during WB-MRI
than during CT, although the latter required ingestion of oral contrast and an intravenous contrast
injection. An intravenous contrast injection was part of the Streamline WB-MRI protocol (see Chapter 2).
A high level of baseline distress was associated with subsequent higher WB-MRI burden, as was additional
comorbidity and high social deprivation (in the unadjusted analysis). It is known that the presence of
comorbidity is associated with suboptimal treatment and decreased cancer survival.82 Furthermore, higher
social deprivation is linked with worse outcomes, particularly in lung cancer.83 Our observation that both of
these factors increased the burden of WB-MRI is certainly interesting, and further research should explore
their association with WB-MRI image quality, which may affect diagnostic accuracy.
Study 2 found that although WB-MRI is generally reasonably well tolerated, it induces more participant
burden than CT and PET-CT. Study 335 used a DCE to investigate which attributes of staging pathways are
most important to participants, whether or not they are willing to trade between these attributes and what
criteria would need to be met for a WB-MRI staging pathway to be preferred to standard staging. We
found that both Streamline L and Streamline C participants rate time to diagnosis, diagnostic accuracy,
cancer risk from radiation exposure and the number of additional scans as important pathway attributes.
In addition, for participants with lung cancer, time in scanner was also rated as important. Streamline C
participants rated diagnostic accuracy as the most important pathway attribute, whereas Streamline L
participants rated time to diagnosis as most important (although diagnostic accuracy had a greater
influence on the preferences of lung cancer participants who were home owning or had higher self-rated
health). That time in the scanner is important for participants with lung cancer (but not colon cancer)
concurs with the findings in study 1 and 2 in which comorbidities (more prevalent in lung cancer
participants) influence the burden of WB-MRI. It is also interesting that both participant cohorts rated
exposure to ionising radiation as important. The doses received for staging scans such as CT and PET-CT
increase the theoretical cancer risk by a relatively small percentage in a cohort of participants who already
have a probable cancer diagnosis and the prognostic implications this entails. For example, radiotherapy
imparts much higher doses to participants than staging investigations. It is possible that improved
participant education about the potential influence of diagnostic radiation exposure on their long-term
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
93
prognosis would reduce the weighting of this attribute, but nevertheless it is important to acknowledge
that it is of importance to participants regardless of their underlying diagnosis.
Both study 1 and study 2 showed that claustrophobia was problematic for some participants. However, in
study 335 the need to enclose the whole body and head did not influence scan preferences when balanced
against other test attributes. By definition, participants recruited to the Streamline trials were willing to
undergoWB-MRI, so the prevalence of pre-existing claustrophobia may be lower than the general population.
Furthermore, the DCE methodology looks at relative weighting of attributes to each other rather than
absolute levels, and our study 3 sample may not have been fully representative of the whole cohort. It is of
note that Streamline L participants who chose standard staging over WB-MRI (when given a binary choice)
preferred less time in the scanner and not to have their whole body and head enclosed compared with those
preferring WB-MRI.
We found that around two-thirds of participants were willing to trade attributes against each other.
For example, both Streamline C and Streamline L participants were willing to wait additional time
and/or undergo additional scans to achieve greater pathway diagnostic accuracy. Of the ‘non-traders’
(i.e. those not willing to compromise on a particular attribute), diagnostic accuracy was the most
common ‘fixed’ attribute.
The final part of study 3 established the criteria that would need to be met for the WB-MRI staging pathway
to be preferred to standard staging. Participants from both cohorts were more likely to prefer the WB-MRI
pathway compared with default staging as long as it was as accurate and resulted in the same scan number
and time to diagnosis. As described in Chapters 3 and 4, the results of Streamline trials suggest that the
WB-MRI pathway is as accurate as standard staging pathways, but more efficient, actually reducing time
and number of tests required to complete staging. Overall, the DCE in study 3 suggests that, given these
findings, participants in general would prefer the WB-MRI staging pathway than standard pathways.
Our set of three participant experience studies has limitations. As noted above, by definition participants
recruited to the Streamline trials were willing to undergo WB-MRI and so may not be representative of the
population in general. Furthermore, the majority (86%) of participants had already undergone WB-MRI
when completing the DCE questionnaire, meaning that we were unable to investigate the influence of
prior experience of WB-MRI owing to the small number who had not yet experienced it. Future work
should investigate what attributes WB-MRI would need to possess to appeal to people who are more
reluctant to undergo it as part of cancer staging. The sample size for all three studies was based on the
established criteria (study 1) and on power calculations (studies 2 and 3). However, power was limited to
detect differences within each cancer type and our null findings for some predictors (e.g. age, sex and
cancer type) may be due to lack of statistical power to detect small effects. The proportion of participants
who completed the study 2 questionnaires was arguably quite low, at around 50%. However, this is in line
with postal survey completion rates observed in other similar studies.
In conclusion, the majority of participants are able to tolerate WB-MRI and view it as an acceptable
investigation. However, overall burden is greater than standard staging investigations, with the enclosed
scanner space, scanner noise, discomfort and scan duration particularly problematic. Most participants
develop coping strategies, which are aided by positive staff interactions both before and during the scan.
Participants with high levels of existing stress and with existing comorbidities have greater burden during
WB-MRI, and participants with lung cancer (but not participants with colon cancer) view time in the
scanner as a relatively important attribute. Participants rate time to diagnosis, diagnostic accuracy, cancer
risk from radiation exposure and the number of additional scans as important pathway attributes and around
two-thirds are willing to trade attributes. Based on the findings of the Streamline trial (see Chapters 3 and 4),
a DCE suggests that the majority of participants would prefer the WB-MRI staging pathway to standard
staging pathways for both cancer types.
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Influence of WB-MRI sequences on diagnostic accuracy
Although there is reasonable consensus as to the basic WB-MRI sequence protocol,61 optimised
approaches differ between cancer types, depending on the nature of metastatic disease and the specific
organ predilection, for example bone or soft tissue. The routine use of intravenous contrast for example
is currently not advocated in prostate cancer staging62 but probably has utility in staging myeloma.84
Ultimately, the optimal scan protocol is a compromise between acquisition time, cost, radiologist reporting
time and diagnostic accuracy. Recent data on potential retention in the brain have also highlighted the
need for judicious use of gadolinium.85
Colon cancer and lung cancer differ in their predilection for metastatic disease. Bone and brain metastasis
are frequent in lung cancer, whereas they are unusual in colorectal cancer, with liver and lung being the
most common sites for metastatic disease. DWI is increasingly part of WB-MRI protocols given its reported
high sensitivity for metastasis, particularly in bone and liver.13,61,63,86 However, in a large single-site study of
WB-MRI staging in non-small-cell lung cancer, DWI sequences alone had sensitivity of 58% for metastatic
disease compared with 70% when DWI was added to other sequences including post-contrast T1-weighted
image acquisition.22 This was predominantly caused by missed brain metastasis.
We prospectively tested the diagnostic accuracy of three WB-MRI sequence combinations across all
participating radiologists as part of their real-time interpretation of the Streamline WB-MRI data sets.
Overall, we found that the combination of T1-, T2-, diffusion-weighted sequences and post-contrast
T1-weighted sequences was significantly more sensitive for metastatic colorectal cancer than a combination
of non-contrast T1-weighted and diffusion-weighted sequences alone [72% (95% CI 60% to 81%) vs. 63%
(95% CI 51% to 73%), respectively], whereas specificity was no different. However, there was no significant
difference in sensitivity or specificity when using all available sequences compared with a combination of
T1-, T2- and diffusion-weighted imaging without post-contrast-enhanced images [70% sensitivity (95% CI
58% to 80%)].
Findings were similar for staging non-small-cell lung cancer. Again, the combination of T1-, T2- and
diffusion-weighted sequences and post-contrast T1-weighted sequences was significantly more sensitive
for metastasis than a combination of non-contrast T1-weighted and diffusion-weighted sequences alone
[52% (95% CI 39% to 65%) vs. 42% (95% CI 29% to 56%), respectively], whereas specificity was no
different. The combination of T1-, T2- and diffusion-weighted imaging without post-contrast-enhanced
images had 48% sensitivity (95% CI 35% to 61%).
The data suggest that, for both colorectal and non-small-cell lung cancer, time-efficient limited protocols
based on non-contrast T1-weighted and diffusion-weighted sequences alone are insufficient and cannot
be recommended. Addition of other anatomical (T2-weighted) sequences is required and thereafter there
does appear to be a small incremental (although non-statistically significant) advantage in the use of
intravenous gadolinium. Given the reported high sensitivity of DWI imaging in the bone and liver, we
perhaps may have expected that the additional sequences would have improved specificity rather than
sensitivity. This was not the case. However, there is evidence that non-contrast WB-MRI protocols have
lower sensitivity for lung metastasis than standard pathways87 and that detection of brain metastasis is also
improved by addition of gadolinium-enhanced sequences.22 Although the diagnostic advantage of adding
gadolinium to T1-, T2- and diffusion-weighted sequences was marginal in the Streamline cohorts, and did
not reach statistical significance, it should be remembered that the analysis was on a per-participant basis.
Given the major clinical importance of detecting metastatic disease (e.g. a solitary brain metastasis in a
participant with otherwise operable non-small-cell lung cancer), it seems prudent that WB-MRI protocols
should include T1-weighted imaging sequences pre and post gadolinium enhancement and T2- and
diffusion-weighted imaging sequences in both cancer types.
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Interobserver agreement in WB-MRI interpretation
As noted in Chapter 8, the existing literature suggests that interobserver agreement for WB-MRI
interpretation is high. However, most studies have been single-site studies and used highly experienced
radiologists. Conversely, we tested interobserver agreement across 17 radiologists, representative of those
who would report WB-MRI in daily clinical practice in the NHS. Our study is one of the largest in the
literature. We tested agreement in two ways: (1) against the final reference standard diagnosis and
(2) between reads regardless of the consensus reference standard adjudication of metastatic disease
presence or absence. Such analyses are important when evaluating true interobserver agreement in clinical
practice and its potential impact on patient management. Most studies ‘reward’ agreement between
radiologists by their use of simple percentage agreement and kappa, even when both readers are wrong.
Although this type of ‘technical’ agreement is of interest, it does not fully reflect the potential impact on
patient care. For our primary analyses, such ‘incorrect’ agreement was not considered as true agreement.
However, we also present simple agreement, which allows direct comparison with the existing literature.
Another strength of our study design was the deliberate selection of data sets to mirror the prevalence of
‘stress’ cases as in the main trials. Thus, our data sets were representative of what was encountered
(although we increased the prevalence of metastasis to increase statistical power). Not surprisingly,
agreement was lower in the first analysis as it incorporated the technical failures of WB-MRI technology as
well as interpretive differences. In both analyses, however, agreement was superior for colorectal cancer
than for lung cancer. Simple agreement between the two reads for the primary outcome (i.e. per-patient
detection of metastases) was 88% for colorectal cancer and 65% for non-small-cell lung cancer. This split
between cancer types mirrors the data on the number of perceptual errors in the trial and reinforces the
concept that metastases in non-small-cell lung cancer seem more subtle and less conspicuous than those
in colorectal cancer (predominantly affecting the liver and lung). There is no specific evidence that our
radiologists were more experienced in staging lung than colorectal cancer, but our data nonetheless
suggest that dedicated training in WB-MRI over and above that achieved in usual clinical practice may be
fruitful. This should perhaps focus on difficult disease organ sites such as bone. Further research into the
impact of organ site on perceptual error and observer agreement is also indicated. It is notable that the
way in which equivocal lesions were handled did affect agreement between radiologists, particularly for
non-small-cell lung cancer. When equivocal lesions were classified as negative, simple agreement between
the reads increased to 76%, suggesting that some of the disagreement was due to overdiagnosis of
potential lesions. The clinical implications of the data are unclear, but a suggested topic for future research
is the impact of dedicated radiologist training modules on the diagnostic accuracy of WB-MRI. The use of
computer-assisted detection software is also of interest and currently under investigation.
Overall conclusions
l When tested in a prospective multicentre trial setting, the WB-MRI staging pathway had similar
diagnostic accuracy to standard pathways for identifying patients with metastatic disease in newly
diagnosed colorectal and non-small-cell lung cancer, and precipitated similar treatment decisions.
l WB-MRI pathways are inferior to standard pathways for defining N stage in non-small-cell lung cancer,
although this does not adversely influence the first major treatment decision.
l The WB-MRI staging pathway was more efficient than standard pathways, reducing the time to staging
completion and, in the case of colorectal cancer, overall number of tests.
l When using English NHS reference costs, the WB-MRI staging pathway cost less than standard
staging pathways.
l Patients often find WB-MRI more challenging than standard staging investigations and devise coping
strategies to complete the examination. Positive staff interaction is important. The quantified burden of
WB-MRI, although relatively low, is greater than that of either CT or PET-CT. However, the majority of
patients prefer the WB-MRI staging pathway if it is as accurate as standard pathways and reduces
number of tests and/or staging time.
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l Time-efficient WB-MRI protocols based on DWI and non-contrast enhanced T1-weighted sequences are
insufficient and protocols including additional T2-weighted and post-gadolinium-enhanced T1-weighted
sequences significantly improve sensitivity for patients with metastatic disease. Addition of post-gadolinium-
enhanced T1 sequences has a small non-significant incremental advantage over protocols based on
non-enhanced T1-, T2- and diffusion-weighted imaging sequences.
l There is generally moderate agreement between radiologists interpreting WB-MRI. However,
interobserver agreement is inferior for non-small-cell lung cancer compared with colorectal cancer.
Implications for practice
In a NHS setting, the WB-MRI staging pathway is as accurate as current standard staging pathways for
detecting patients with metastasis in both newly diagnosed colorectal and non-small-cell lung cancer.
Sensitivity and overall agreement for N staging is lower in non-small-cell lung cancer but, for both cancers, the
WB-MRI pathway results in the same treatment decisions as standard staging pathways. The WB-MRI pathway
is more efficient, reducing time to complete staging and, in the case of colorectal cancer, the number of tests
in the staging pathway. For both colorectal and non-small-cell lung cancer, the WB-MRI staging pathway is less
costly than standard staging in an English NHS setting. Although patients find WB-MRI more challenging than
standard staging investigations, in general they prefer the WB-MRI staging pathway over standard staging if it
matches the diagnostic accuracy of standard pathways but reduces the time to staging and/or number of tests.
Time-efficient WB-MRI protocols using just T1- and diffusion-weighted sequences have lower sensitivity than
protocols that also include T2- and post-gadolinium-enhanced T1-weighted sequences. Radiologists must
receive adequate training in interpreting WB-MRI, and interobserver variation is inferior for non-small-cell lung
cancer compared with colorectal cancer when tested across NHS radiologists.
Recommendations for future research
Future research should investigate the following:
l The diagnostic accuracy, patient acceptability and cost-effectiveness of WB-MRI for staging and
treatment follow-up of other primary cancer sites, notably breast, prostate and myeloma, compared
with standard investigations. The NICE currently recommends WB-MRI in diagnosis, staging and
treatment follow-up of myeloma, but there are few data concerning its comparative accuracy and
cost-effectiveness with standard investigations such as CT. WB-MRI is used ad hoc in the NHS for staging
and treatment follow-up in breast and prostate cancer and the evidence base needs developing.
l The diagnostic accuracy, patient acceptability and cost-effectiveness of WB-MRI for investigating
patients with clinically suspected recurrence of colorectal and non-small-cell lung cancer compared with
standard investigations. Early detection of cancer recurrence may increase the chance of successful
treatment. Patients with suspected recurrence often undergo multiple testing and WB-MRI may be a
more efficient and cost-effective method.
l The diagnostic accuracy, patient acceptability and cost-effectiveness of WB-MRI in routine post-cancer
therapy surveillance in comparison with standard investigations. Surveillance of patients after
cancer therapy using cross-sectional imaging is routine. WB-MRI may be a more accurate and
cost-effective method.
l The impact on diagnostic accuracy and cost-effectiveness of adding liver-specific contrast agents to
WB-MRI protocols. Liver metastases are common, particularly in colorectal cancer, and their presence
usually drives treatment paradigms. There are good data suggesting that liver-specific contrast agents
increase the sensitivity of liver MRI for metastasis detection over conventional gadolinium contrast, but
the utility or otherwise and cost-effectiveness of adding such agents to WB-MRI protocols is unknown.
l The impact of formal WB-MRI training programmes on radiologist performance. Interobserver
agreement in WB-MRI interpretation is at best moderate, and there were a number of perceptual
errors. The impact of formal training programmes on radiologist performance is unknown.
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Appendix 1 WB-MRI acquisition: minimum
data set
MRI protocol
The aim is to complete the whole protocol in ≤ 60 minutes. Depending on the MRI technology available,
it may be possible to use the 5-mm slices for all axial imaging, although up to 7 mm is acceptable if time
constraints are problematic.
These specifications are a set of minimum requirements; where higher field strengths/scanner software
permits, the resolution/quality of sequences should be optimised (while keeping the maximum imaging
time limited to 1 hour).
Scanning may be performed at either 1.5 T or 3 T.
Whole-body coverage is defined as head to mid-thigh, optimised for detection of metastases.
Imaging procedure
1. A standard safety questionnaire should be completed.
2. For patients undergoing contrast enhancement, set up intravenous line in a vein in the antecubital
fossa, connected to an automated injector with two syringes (contrast and saline flush).
3. Unless contraindicated, administer 20 mg of buscopan or 1 mg of glucagon, to be given just before the
start of the scan.
Whole-body diffusion-weighted imaging
l Axial: using short T1 inversion recovery-echo planar imaging (or other fat saturation technique) DWI. Fixed
slice thickness of 5–7mm (to match T2- and T1-weighted axials as below), two b-values (b50 and b900).
A minimum acquisition matrix of 128 × 128 (or an interpolated equivalent) [rectangular field of view (FOV)
should be used if available and appropriate for the patient]; as a reference, a minimum signal-to-noise ratio
of 6 on b50 images (for liver) should be maintained if possible by increasing the number of averages. All
imaging should be performed in gentle respiration (recommended as four stations of 50 slices beginning
from the vertex to mid-thighs). Diffusion imaging through the brain is optional.
Whole-body T2-weighted imaging
l Axial: axial T2-weighted (without fat suppression) imaging should be performed from vertex to mid-thigh.
A 5- to 7-mm slice thickness should be used for all scanners. Where possible (within the 60-minute
imaging time), respiratory and electrocardiogram triggering should be used for the chest and respiratory
triggering alone for the upper abdomen. The head, neck, pelvis and legs should be scanned without any
triggering. The number of stacks should be adjusted to cover the imaging volume.
Pre-contrast T1-weighted imaging
Dixon technique to be applied if available.
l Axial: whole-body T1-weighted gradient echo (GRE) (e.g. fast low-angle shot two-dimensional) non-
contrast enhanced non-fat-saturation. Image resolution and slice thickness should be ideally matched to
T2-weighted imaging.
l Coronal: T1-weighted fat-saturated volume interpolated GRE imaging [e.g. three dimensional (3D)]
pre contrast.
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Post-contrast T1-weighted imaging (if gadolinium not contraindicated or refused)
Minimum data set.
Axial liver (60–70 seconds).
Axial lung (equilibrium phase).
Small field of view (SFOV) axial head.
Optional: coronal (organ specific or whole body).
l Axial: post contrast; for example T1-weighted fat-saturated volume interpolated GRE imaging (3D),
breath hold of the liver (60- to 70-second delay) and lungs. Multiple breath holds employed to provide
full volume coverage if required. A minimum of a 256 × 256 (rectangular FOV acquisition if possible and
appropriate for the patient) acquisition matrix should be employed. Slice thickness 5–7 mm.
l Coronal: post contrast, whole body, for example T1-weighted fat-saturated volume interpolated GRE
imaging (3D), and post contrast. Slice thickness 5 mm. Breath hold.
l Axial: fat-saturated T1-weighted imaging of the brain (SFOV). An acquisition matrix of 256 × 256 should
be employed.
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Appendix 2 Quality assurance grading score
definitions
TABLE 41 Quality assurance grading score definitions
Technical quality Definition
General
1 More than one sequence with substantial degradation of images severely limiting interpretation of
those sequences; not repeated
2 One sequence with substantial degradation of images severely limiting interpretation of that
sequence; not repeated
3 More than one sequence has minor artefacts, but all remain fully diagnostic; repeat, although
optimal, not necessary, or all sequences initially technically inadequate (score 1 or 2) correctly
repeated
4 One sequence has a minor artefact but remains fully diagnostic; repeat, although optimal,
not necessary
5 All sequences technically optimal with no artefacts or degradation
Anatomical coverage
1 Wrong examination performed
2 More than one sequence does not adequately cover the body (skull to mid-thigh) or designated
organ(s)
3 One sequence does not optimally cover the body or designated organ(s), but examination remains
fully diagnostic
4 All sequences optimally cover the body and designated organ(s)
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Appendix 3 Flow chart of multidisciplinary team
process recording the first major treatment decision
based on standard and WB-MRI pathways
MDT agree: sufficient information to
make the first major treatment
decision based on standard staging
tests performed
Further standard staging
investigations performed 
MDT first major treatment decision
based on standard staging tests
‘Standard staging pathway’
WB-MRI result and images revealed
to MDT
MDT agree: sufficient information to
make the first major treatment
decision based on WB-MRI 
MDT first major treatment decision
based on WB-MRI (and any
generated tests)
‘WB-MRI pathway’
Additional investigations
generated by WB-MRI
performed (or MDT notes results if
already performed as part of
standard staging pathway)
MDT first major treatment decision
based on all investigations in standard
and WB-MRI staging pathways 
NO
YES
NO
YES
FIGURE 11 Flow chart of MDT process recording the first major treatment decision based on standard and WB-MRI
pathways.
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Appendix 4 Summary of primary and
secondary outcomes
TABLE 42 Summary of primary and secondary outcomes
Aim/outcome Description
Overall aim To evaluate whether or not early WB-MRI increases detection rate for metastasis in colorectal cancer
or non-small-cell lung cancer compared with standard NICE-approved diagnostic pathways
Primary outcome l To evaluate whether or not early WB-MRI used as a replacement test increases detection rate
for metastasis in colorectal cancer or non-small-cell lung cancer compared with standard
diagnostic pathways
l Comparison to detect metastases between WB-MRI test strategy Aa and standard diagnostic
strategy test strategy Bb
l Difference in per-patient sensitivity
l Paired comparison of proportions of each strategy against the reference standard of full clinical
diagnosis and 12-month follow-up
l Patients without consensus reference standard are not included in analysis
l Imputation will be used to account for missing data and imperfect reference data
Secondary outcome
1 l To determine how WB-MRI influences time to and nature of first major treatment decision
following definitive staging compared with standard pathways and to determine whether or not
early WB-MRI could reduce or replace standard investigations
l In this secondary outcome, the following components will be measured up to the time of the first
major treatment decision:
¢ nature of first major treatment decision and number of patients with changed
management decision
¢ time taken for diagnostic pathways
¢ number of tests – average per patient; number of patients with fewer tests in pathway
l These will be compared for WB-MRI pathwaya in comparison to standard staging pathwaysb
l This information will be reported and discussed as a basis for whether or not early WB-MRI
(test strategy Aa) could replace or reduce standard investigations (test strategy Bb)
l No absolute pre-specified definition of the combination of these outcomes likely to be considered
clinically significant is attempted, although it is noted that an average decrease in diagnosis time
of 7 days is likely to be considered clinically significant if accuracy were similar
2 l Diagnostic accuracy of WB-MRI and standard staging pathways for local tumour staging and
detection of metastasis in comparison to an expert-derived consensus reference standard
l This secondary outcome will include per-patient analysis of:
¢ difference in specificity for test strategy Aa minus test strategy Bb (note primary outcome is
difference in sensitivity)
¢ difference in sensitivity for test strategy Cc minus test strategy Bb
¢ difference in specificity for test strategy Cc minus test strategy Bb
l This secondary outcome will include per-organ analysis of:
¢ difference in sensitivity for test strategy Aa minus test strategy Bb
¢ difference in specificity for test strategy Aa minus test strategy Bb
¢ difference in sensitivity for test strategy Cc minus test strategy Bb
¢ difference in specificity for test strategy Cc minus test strategy Bb
3 Lifetime incremental cost and cost-effectiveness of staging using WB-MRI compared with standard
diagnostic pathways
4 Patient experience of staging using WB-MRI in comparison to standard diagnostic pathways and
priorities placed by patients on differing attributes related to competing staging pathways
continued
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TABLE 42 Summary of primary and secondary outcomes (continued )
Aim/outcome Description
5 l Interobserver variability in WB-MRI analysis and the effect of diagnostic confidence on
staging accuracy
l A substudy conducted to look at interobserver variability between radiologists interpreting
WB-MRI images and the effect of diagnostic confidence on staging accuracy
l Each hub radiologist (n ≥ 5) interpreting a sample of WB-MRI data sets selected at random from
the other imaging hubs to define interobserver variation in the reported presence/absence of
metastatic disease
6 l Diagnostic accuracy of limited T1- and diffusion-weighted sequences compared with full
multisequence WB-MRI protocols
l Comparison of diagnostic accuracy of WB-MRI alone: (i) sequence block 1 (ii) sequence block 2
and (iii) sequence block 3
l Reference standard: WB-MRI plus standard tests with 12-month follow-up
l Methods and tables: as per secondary outcome 2
Additional analyses l Adverse events from WB-MRI
l Descriptive tables of WB-MRI reported, including quality of imaging based on technical quality
scored as (i) general properties and (ii) anatomical coverage
l Streamline C only: subgroup analysis for main trial outcomes – rectal cancer and non-rectal cancer
l Although this trial includes all colorectal cancers, descriptive analyses will be completed
separately for:
¢ rectal cancer
¢ non-rectal cancer
l Outcomes to be analysed include primary outcome – the difference in per-patient sensitivity to
detect metastases
l Additional outcomes: secondary outcome 3 (per-patient specificity, per-organ sensitivity
and specificity)
a WB-MRI pathway including additional tests requested as a result of WB-MRI findings.
b Standard pathway.
c WB-MRI pathway (plus additional tests generated), plus standard CT pathway tests (add-on test to test strategy B).
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Appendix 5 Streamline C: reasons for
non-inclusion of screened patients
TABLE 43 Streamline C: reasons for non-inclusion of screened patients
Reason for non-inclusion n (%)
Patients did not want extra visit 91 (14)
Did not want WB-MRI scan 77 (12)
Patients felt would delay potential treatment 70 (11)
Contraindications to WB-MRI 66 (10)
Polyp cancer 65 (10)
No WB-MRI slot available within 3 weeks of final staging 37 (6)
Evidence of severe or uncontrolled systematic disease 31 (5)
Not primary colorectal cancer 31 (5)
Too frail/not fit enough 24 (3)
Psychiatric or other condition likely to impact on informed consent 22 (3)
Language barrier 14 (2)
Other 122 (19)
Total 650
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Appendix 6 Streamline C: reasons for withdrawal
of recruited participants
TABLE 44 Streamline C: reasons for withdrawal of recruited participants
Reason for withdrawal n (%)
Participant withdrawal owing to failure to undergo WB-MRI 45 (63)
Participant withdrawal owing to non primary colorectal cancer diagnosis 18 (25)
Participant withdrew consent from trial 3 (4)
Participant lost to follow-up 3 (4)
Participant withdrew by consensus; not enough imaging 1 (2)
Participant had no consensus owing to administrative error 1 (2)
Total 71
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121

Appendix 7 Streamline C: primary tumour status
at the time of consensus review
TABLE 45 Streamline C: primary tumour status at the time of consensus review
Participant status n (%)
Participant died within 12 monthsa 17 (6)
Primary tumour removed within 3 months of diagnosis 219 (73)
Primary tumour in situ for > 3 months (or incomplete removal) – imaging capable of detecting metastatic
disease within 6 months of diagnosis
79 (26)
Primary tumour in situ for > 3 months (or incomplete removal) – no imaging capable of detecting
metastatic disease within 6 months of diagnosis
1 (1)
Other 0 (0)
a Participant death within 12-month follow-up recorded separately.
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Appendix 8 Streamline C: final T and N stage
based on consensus reference standard
TABLE 46 Streamline C: final T and N stage based on consensus reference standard
T stagea
N stagea (n)
N0 N1 N2
T1 11 0 0
T2 36 12 4
T3 76 62 39
T4 10 17 32
a 232 participants had histological proof for both T and N stage, six participants had histological proof for T stage only
and one participant for N stage only.
Reproduced from Taylor et al.25 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
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Appendix 9 Streamline C: local tumour spread
based on consensus reference
TABLE 47 Streamline C: local tumour spread based on consensus reference standard
Variable Yes, n (%) No, n (%) Histological proof, n (%)
Resection margin threatened 24 (8) 275 (92) 230 (77)
Extramural vascular invasiona 118 (40) 180 (60) 231 (77)
a Data unavailable for extramural vascular invasion in one participant.
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Appendix 10 Streamline C: detailed organ sites
of metastatic disease
TABLE 48 Streamline C: detailed organ sites of metastatic disease
Site
Participants
with
metastatic
disease,a,b n
Histological
proof, n (%)
Imaging diagnosis without histological proof, n (%)a
Characteristic imaging
appearances
Growth on
follow-up
Response to
therapy
Liver 48 12 (25) 33 (92) 26 (72) 19 (53)
Lung 20 0 (0) 19 (95) 13 (65) 11 (55)
Pleura 0 – – – –
Brain 0 – – – –
Spleen 0 – – – –
Adrenal 0 – – – –
Kidney 0 – – – –
Pancreas 0 – – – –
Mesentery/peritoneum 7 2 (29) 4 (80) 4 (80) 1 (20)
Bowel 0 – – – –
Neck/chest soft tissue 0 – – – –
Abdomen/pelvis soft
tissue
0 – – – –
Limbs soft tissue 0 – – – –
Nodal (metastatic) 11 2 (28) 8 (89) 7 (78) 3 (33)
Otherc 2 1 (33) 2 (100) 2 (100) 0 (0)
Skull 0 – – – –
Cervical spine 0 – – – –
Thoracic spine 0 – – – –
Lumbar spine 2 0 (0) 2 (100) 1 (50) 0 (0)
Pelvis 1 0 (0) 1 (100) 1 (100) 1 (100)
Sternum 0 – – – –
Clavicle/scapula 0 – – – –
Ribs 0 – – – –
Upper limb 0 – – – –
Lower limb 0 – – – –
a Metastasis may fulfil more than one criterion.
b Participants may have more than one site of metastatic disease.
c One participant has three additional sites of metastatic disease (i.e. skin, ovary and vagina).
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Appendix 11 Streamline C: number of metastatic
deposits per organ
TABLE 49 Streamline C: number of metastatic deposits per organ
Site
Number of participantsa
0 1 2 3 > 3 Unknown/not measurable
Liver 251 11 8 4 25 0
Lung 279 4 8 2 6 0
Bone 296 1 1 0 0 1
Mesentery/peritoneum 292 0 3 0 0 4
Nodal (metastatic) 288 2 4 1 4 0
Other 297 1 0 0 1 0
a Participants may have more than one site of metastatic disease.
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Appendix 12 Streamline C: maximum size of
metastatic deposits according to organ
TABLE 50 Streamline C: maximum size of metastatic deposits according to organ
Site
Number of
participants with
metastatic diseasea
Number of participantsa
< 1cm ≥ 1cm
Not visible on any initial
staging investigation
Unknown/not
measurable
Liver 48 5 37 6 0
Lung 20 12 5 3 0
Bone 3 1 0 1 1
Mesentery/peritoneum 7 0 1 2 4
Nodal (metastatic) 11 2 8 1 0
Otherb 2 0 1 2 0
a Each participant is categorised by their largest metastasis in each organ. Participants may have more than one site of
metastatic disease.
b One participant has two additional sites of metastatic disease (i.e. skin, ovary and vagina).
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Appendix 13 Streamline C: equivocal results for
metastatic disease
TABLE 51 Streamline C: equivocal results for metastatic disease
Location
Equivocal results (n,%)
Participants with metastatic diseasea Participants without metastatic diseasea
WB-MRI
staging
pathwayb
Standard
staging
pathway
Standard
staging
pathway
plus WB-MRIc
WB-MRI
aloned
WB-MRI
staging
pathwayb
Standard
staging
pathway
Standard
staging
pathway
plus WB-MRIc
WB-MRI
aloned
Per
participant
4 7 6 9 7 14 10 25
Non-skeletal
sitese
12 26 N/A 23 8 18 N/A 26
Skeletal sitese 2 0 N/A 0 2 0 N/A 7
N/A, data were not collected.
a Participants by consensus reference standard.
b WB-MRI plus additional generated tests.
c WB-MRI as an additional test to standard pathway.
d WB-MRI as a single staging investigation.
e Per organ as multiple sites can have equivocal results.
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135

Appendix 14 Streamline C: short-interval
follow-up for equivocal findings
TABLE 52 Streamline C: short-interval follow-up for equivocal findings
Test
Number of participants
WB-MRI staging
pathwaya
Standard staging
pathway
Standard staging
pathway plus WB-MRIb
Neck, chest and abdomen CT 0 0 0
Chest CT 1 2 2
Abdomen and pelvis CT 0 0 0
Chest and abdomen CT 0 0 0
Chest, abdomen and pelvis CT 2 2 2
Liver MRI 2 3 2
PET-CT 1 1 2
Biopsy 2 0 1
Other 8 5 9
a WB-MRI plus additional generated tests.
b WB-MRI as an additional test to standard pathway.
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Appendix 15 Streamline C: per-organ sensitivity
and specificity for metastatic disease – standard
staging pathways versus WB-MRI staging pathway
against the consensus reference standard
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TABLE 53 Streamline C: per-organ sensitivity and specificity for metastatic disease – standard staging pathways vs. WB-MRI staging pathway against the consensus
reference standard
Site
Sensitivitya Specificitya
Number of
participants with
metastatic diseaseb
WB-MRI
staging
pathway,c
% (95% CI)
Standard
staging
pathway,
% (95% CI)
Difference: WB-MRIc
vs. standard,
% (95% CI)
Number of
participants
without metastatic
diseaseb
WB-MRI
staging
pathway,c
% (95% CI)
Standard
staging
pathway,
% (95% CI)
Difference: WB-MRIc
vs. standard,
% (95% CI)
Liver 48 74 (60 to 84) 72 (57 to 83) 2 (–10 to 14) 251 99 (97 to 100) 99 (97 to 100) 0 (–2 to 2)
Lung 20 55 (34 to 74) 65 (43 to 82) –10 (–35 to 15) 279 99 (96 to 99) 99 (96 to 99) 0 (–2 to 2)
Bone 3 33 (6 to 79) 0 (0 to 56) 33 (–53 to 120) 296 99 (98 to 100) 99 (98 to 100) 0 (–2 to 1)
Mesentery/peritoneum 7 14 (3 to 51) 14 (3 to 51) 0 (–34 to 34) 292 99 (97 to 100) 99 (97 to 100) 0 (–2 to 2)
Nodal (metastatic) 11 45 (21 to 72) 27 (10 to 57) 18 (–13 to 49) 288 97 (94 to 98) 98 (95 to 99) –1 (–3 to 1)
Other 2 0 (0 to 66) 0 (0 to 66) 0 (–50 to 50) 297 98 (95 to 99) 98 (96 to 99) 0 (–3 to 2)
a Equivocal results considered positive for colonic tumours and negative for rectal tumours.
b Participants by consensus reference standard.
c WB-MRI plus additional generated tests.
Reproduced from Taylor et al.25 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes
minor additions and formatting changes to the original text.
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Appendix 16 Streamline C: per-participant
agreement for tumour T stage – standard staging
pathways versus WB-MRI staging pathway against
the consensus reference standard in participants with
histological proof
TABLE 54 Streamline C: per-participant agreement for tumour T stage – standard staging pathways vs. WB-MRI
staging pathway against the consensus reference standard in participants with histological proof
T stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRIb,c Standardc
T1 11 3 (27) 3 (27) 0 (–19 to 19)
T2 48 33 (69) 25 (52) 17 (3 to 31)
T3 134 69 (52) 83 (62) –10 (–20 to –1)
T4 43 7 (16) 10 (23) –7 (–18 to 4)
Total 236 112 (47) 121 (51) –4 (–10 to 3)
a 238 participants with histological proof by final consensus reference standard but two participants missing full data.
b WB-MRI plus additional generated tests.
c 11 and 6 participants staged Tx by WB-MRI and standard staging pathways, respectively.
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Appendix 17 Streamline C: per-participant
agreement for tumour N stage – standard staging
pathways versus WB-MRI staging pathway against
the consensus reference standard in participants with
histological proof
TABLE 55 Streamline C: per-participant agreement for tumour N stage – standard staging pathways vs. WB-MRI
staging pathway against the consensus reference standard in participants with histological proof
N stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRIb Standard
N0 120 73 (61) 71 (59) 2 (–6 to 10)
N1 64 30 (47) 28 (44) 3 (–8 to 14)
N2 46 23 (50) 20 (43) 7 (–7 to 20)
Total 230 126 (55) 119 (52) 3 (–3 to 9)
a 233 participants with histological proof by final consensus reference standard but three participants were missing full data.
b WB-MRI plus additional generated tests.
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Appendix 18 Streamline C: breakdown of the
primary treatment decision according to the standard
staging pathway compared with the retrospective
consensus panel optimal treatment decision
(non-rectal colon cancer)
TABLE 56 Streamline C: breakdown of the primary treatment decision according to the standard staging pathway
compared with the retrospective consensus panel optimal treatment decision (non-rectal colon cancer)
Standard pathway
Retrospective consensus panel optimal treatment decision (n)
Surgery for
the primary
tumour but no
chemotherapy
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
Chemotherapy
(and/or radiotherapy)
without surgery
Surgical
metastectomy
with or without
chemotherapy Total
Surgery for the
primary tumour but
no chemotherapy
83 25 3 2 113
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
8 23 2 1 34
Chemotherapy
(and/or radiotherapy)
without surgery
1 2 8 0 11
Surgical
metastectomy
with or without
chemotherapy
0 3 2 5 10
Total 92 53 15 8 168
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Appendix 19 Streamline C: breakdown of the
primary treatment decision according to the WB-MRI
staging pathway compared with the retrospective
consensus panel optimal treatment decision
(non-rectal colon cancer)
TABLE 57 Streamline C: breakdown of the primary treatment decision according to the WB-MRI staging pathway
compared with the retrospective consensus panel optimal treatment decision (non-rectal colon cancer)
WB-MRI pathway
Retrospective consensus panel optimal treatment decision (n)
Surgery for
the primary
tumour but no
chemotherapy
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
Chemotherapy
(and/or radiotherapy)
without surgery
Surgical
metastectomy
with or without
chemotherapy Total
Surgery for the
primary tumour but
no chemotherapy
82 23 3 2 110
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
9 25 2 1 37
Chemotherapy
(and/or radiotherapy)
without surgery
1 2 8 0 11
Surgical
metastectomy
with or without
chemotherapy
0 3 2 5 10
Total 92 53 15 8 168
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Appendix 20 Streamline C: breakdown of the
primary treatment decision according to the standard
staging pathway compared with the retrospective
consensus panel optimal treatment decision
(rectal cancer)
TABLE 58 Streamline C: breakdown of the primary treatment decision according to the standard staging pathway
compared with the retrospective consensus panel optimal treatment decision (rectal cancer)
Standard pathway
Retrospective consensus panel optimal treatment decision (n)
Surgery for
the primary
tumour but no
chemotherapy
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
Chemotherapy
(and/or radiotherapy)
without surgery
Surgical
metastectomy
with or without
chemotherapy Total
Surgery for the
primary tumour but
no chemotherapy
37 13 1 1 52
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
5 37 7 2 51
Chemotherapy
(and/or radiotherapy)
without surgery
1 9 6 4 20
Surgical
metastectomy
with or without
chemotherapy
0 2 1 2 5
Total 43 61 15 9 128
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Appendix 21 Streamline C: breakdown of the
primary treatment decision according to the WB-MRI
staging pathway compared with the retrospective
consensus panel optimal treatment decision
(rectal cancer)
TABLE 59 Streamline C: breakdown of the primary treatment decision according to the WB-MRI staging pathway
compared with the retrospective consensus panel optimal treatment decision (rectal cancer)
WB-MRI pathway
Retrospective consensus panel optimal treatment decision (n)
Surgery for
the primary
tumour but no
chemotherapy
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
Chemotherapy
(and/or radiotherapy)
without surgery
Surgical
metastectomy
with or without
chemotherapy Total
Surgery for the
primary tumour but
no chemotherapy
37 13 1 0 51
Surgery for the
primary tumour
and chemotherapy
(and/or radiotherapy)
5 36 7 3 51
Chemotherapy
(and/or radiotherapy)
without surgery
1 9 6 4 20
Surgical
metastectomy
with or without
chemotherapy
0 3 1 2 6
Total 43 61 15 9 128
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Appendix 22 Streamline C: time to complete
staging according to staging pathway:
interquartile range
TABLE 60 Time to complete staging according to staging pathway: interquartile range
Participants
Staging pathway, median days (IQR)
WB-MRI Standard
All participants 8 (4–13) 13 (8–25)
IQR, interquartile range.
Reproduced from Taylor et al.25 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
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Appendix 23 Streamline C: per-participant
sensitivity and specificity for metastatic disease –
standard staging pathway versus WB-MRI alone
against the consensus reference standard
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TABLE 61 Streamline C: per-participant sensitivity and specificity for metastatic disease – standard staging pathway vs. WB-MRI alone against the consensus reference standard
Outcome
Sensitivity Specificity
Number of
participants with
metastatic diseasea
WB-MRI alone,b
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Number of
participants
without
metastatic diseasea
WB-MRI alone,b
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Diagnostic
accuracyc
68 70 (59 to 80) 63 (51 to 74) 7 (–3 to 18) 231 86 (81 to 90) 94 (90 to 96) –8 (–13 to –3)
a Participants by consensus reference standard.
b WB-MRI as a single staging investigation.
c Equivocal results considered positive for colonic tumours and negative for rectal tumours.
Reproduced from Taylor et al.25 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes
minor additions and formatting changes to the original text.
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Appendix 24 Streamline C: per-organ sensitivity
and specificity for metastatic disease – standard
staging pathways versus WB-MRI alone against the
consensus reference standard
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TABLE 62 Streamline C: per-organ sensitivity and specificity for metastatic disease – standard staging pathways vs. WB-MRI alone against the consensus reference standard
Site
Sensitivity Specificity
Number of
participants with
metastatic diseasea
WB-MRI aloneb,
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Number of
participants
without metastatic
diseasea
WB-MRI aloneb,
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Liver 48 77 (63 to 87) 73 (59 to 83) 4 (–8 to 16) 251 98 (95 to 99) 99 (96 to 100) –1 (–4 to 1)
Lung 20 60 (39 to 78) 65 (43 to 82) –5 (–28 to 18) 279 98 (96 to 99) 98 (96 to 99) 0 (–3 to 2)
Bone 3 0 (0 to 56) 0 (0 to 56) 0 (–33 to 33) 296 99 (96 to 100) 100 (98 to 100) –1 (–2 to 1)
Mesentery/
peritoneum
7 14 (3 to 51) 14 (3 to 51) 0 (–34 to 34) 292 99 (96 to 99) 99 (97 to 100) 0 (–2 to 2)
Nodal
(metastatic)
11 54 (28 to 79) 27 (10 to 57) 27 (3 to 52) 288 92 (88 to 94) 98 (96 to 99) –6 (–10 to –3)
Other 2 0 (0 to 66) 0 (0 to 66) 0 (–50 to 50) 297 97 (95 to 99) 98 (96 to 99) –1 (–3 to 2)
a Participants by consensus reference standard.
b WB-MRI as a single staging investigation.
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Appendix 25 Streamline C: per-participant
agreement for tumour T stage – standard staging
pathways versus WB-MRI alone against the
consensus reference standard – all participants
TABLE 63 Streamline C: per-participant agreement for tumour T stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard – all participants
T stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standardc
T1 6 1 (16) 2 (33) –17 (–63 to 30)
T2 40 23 (57) 23 (57) 0 (–19 to 19)
T3 148 71 (48) 108 (73) –25 (–35 to –15)
T4 49 17 (35) 22 (45) –10 (–22 to 2)
Total 243 112 (46) 155 (64) –18 (–25 to –10)
a 54 and 3 participants missing data by WB-MRI alone and standard staging pathways, respectively.
b WB-MRI as a single staging investigation.
c 33 and 6 participants staged Tx by WB-MRI alone and standard staging pathways, respectively.
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Appendix 26 Streamline C: per-participant
agreement for tumour T stage – standard staging
pathways versus WB-MRI alone against the
consensus reference standard in participants with
histological proof
TABLE 64 Streamline C: per-participant agreement for tumour T stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard in participants with histological proof
T stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standardc
T1 6 1 (17) 2 (33) –17 (–63 to 30)
T2 37 21 (57) 20 (54) 3 (–17 to 23)
T3 114 48 (42) 76 (67) –25 (–37 to –13)
T4 37 7 (19) 10 (27) –8 (–23 to 7)
Total 194 77 (40) 108 (56) –16 (–25 to –7)
a 238 participants with histological proof by final consensus reference standard; 44 and one participants missing data for
T stage by WB-MRI alone and standard staging pathways, respectively.
b WB-MRI as a single staging investigation.
c 29 and one participants staged Tx by WB-MRI alone and standard staging pathways, respectively.
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Appendix 27 Streamline C: per-participant
agreement for tumour N stage – standard staging
pathways versus WB-MRI alone against the
consensus reference standard – all participants
TABLE 65 Streamline C: per-participant agreement for tumour N stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard – all participants
N stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standardc
N0 125 59 (47) 75 (60) –13 (–22 to –4)
N1 84 32 (38) 43 (51) –13 (–24 to –2)
N2 69 35 (51) 37 (54) –3 (–17 to 11)
Total 278 126 (45) 155 (55) –10 (–17 to –4)
a Information available for both standard pathway and WB-MRI alone pathway; three participants missing standard
pathway N stage and 18 participants missing WB-MRI alone pathway N stage.
b WB-MRI as a single staging investigation.
c 37 have staged Nx by WB-MRI alone.
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Appendix 28 Streamline C: per-participant
agreement for tumour N stage – standard staging
pathways versus WB-MRI alone against the
consensus reference standard in participants with
histological proof
TABLE 66 Streamline C: per-participant agreement for tumour N stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard in participants with histological proof
N stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standard
N0 114 52 (46) 66 (58) –12 (–22 to –3)
N1 61 21 (34) 27 (44) –10 (–22 to 2)
N2 45 18 (40) 20 (44) –4 (–22 to 13)
Total 220 91 (41) 113 (51) –10 (–17 to –3)
a 233 participants with histological proof by final consensus reference standard; 12 and one participant(s) missing data for
N stage by WB-MRI alone and standard staging pathways, respectively.
b WB-MRI as a single staging investigation.
c 28 participants have Nx stage by WB-MRI alone.
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Appendix 29 Streamline C: per-participant
sensitivity and specificity for metastatic disease:
chest, abdomen and pelvis CT versus WB-MRI alone
against the consensus reference standard
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TABLE 67 Streamline C: per-participant sensitivity and specificity for metastatic disease: chest, abdomen and pelvis CT vs. WB-MRI alone, against the consensus reference
standard
Outcome
Sensitivity Specificity
Number of
participants with
metastatic diseasea
WB-MRIb,
% (95% CI)
Chest, abdomen
and pelvis CT,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Number of
participants
without metastatic
diseasea
WB-MRIb,
% (95% CI)
Chest, abdomen
and pelvis CT,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Diagnostic accuracyc 50 76 (63 to 86) 50 (37 to 63) 26 (13 to 39) 188 86 (81 to 90) 99 (97 to 100) –13 (–18 to –9)
a Participants by consensus reference standard.
b WB-MRI as a single staging investigation.
c Equivocal results considered disease positive for non-rectal tumours and negative for rectal tumours.
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Appendix 30 Streamline C: per-participant
sensitivity and specificity for metastatic disease –
standard staging pathways versus standard staging
pathways plus WB-MRI against the consensus
reference standard
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TABLE 68 Streamline C: per-participant sensitivity and specificity for metastatic disease – standard staging pathways vs. standard staging pathways plus WB-MRI against the
consensus reference standard
Outcome
Sensitivity Specificity
Number of
participants with
metastatic diseasea
Standard staging
pathway plus
WB-MRI,
% (95% CI)b
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Number of
participants
without metastatic
diseasea
Standard staging
pathway plus
WB-MRI,
% (95% CI)b
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard
Diagnostic
accuracyc
231 71 (59 to 80) 63 (51 to 73) 7 (0 to 14) 68 95 (91 to 97) 94 (90 to 96) 1 (–2 to 5)
a Participants by consensus reference standard.
b WB-MRI as an additional test to standard pathway.
c Equivocal results considered positive for colonic tumours and negative for rectal tumours.
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Appendix 31 Streamline C: perceptual errors for
metastatic disease according to staging pathway
TABLE 69 Streamline C: perceptual errors for metastatic disease according to staging pathway
Location
Perceptual errorsa (n)
WB-MRI staging pathwayb Standard staging pathway WB-MRI alonec
Per participant 16 15 16
Non-skeletal sites 18 15 18
Skeletal sites 0 1 0
a Perceptual errors are by definition only in disease-positive participants.
b WB-MRI plus additional generated tests.
c WB-MRI as a single staging investigation.
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Appendix 32 Streamline C: perceptual errors for
metastatic disease according to staging pathway and
organ disease site
TABLE 70 Streamline C: perceptual errors for metastatic disease according to staging pathway and organ disease site
Site
Perceptual errorsa (n)
Number of
participants with
metastatic diseaseb
WB-MRI staging
pathwayc
Standard staging
pathway WB-MRI aloned
Liver 48 7 5 7
Lung 20 3 4 3
Bone 3 0 1 0
Mesentery/peritoneum 7 4 1 4
Nodal (metastatic) 11 5 4 5
Other 2 0 1 0
a Perceptual error are by definition only in disease-positive participants.
b Participants by consensus reference standard.
c WB-MRI plus additional generated tests.
d WB-MRI as a single staging investigation.
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Appendix 33 WB-MRI image quality scoring
TABLE 71 WB-MRI image quality scoring
Image quality score Streamline C, n (%) Streamline L, n (%) Overall, n (%)
Optimala 165 (51) 108 (39) 273 (46)
Suboptimalb 124 (39) 130 (47) 254 (43)
Degradedc 33 (10) 36 (13) 69 (11)
Total 322 274 596
a Technical quality score 5, anatomical coverage score 4.
b Technical quality score ≥ 3, anatomical coverage score ≥ 2.
c Technical quality score < 3, anatomical coverage score < 2.
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Appendix 34 Detailed image quality score
categories for scans rated as overall suboptimal
category
TABLE 72 Detailed image quality score categories for scans rated as overall suboptimal category
Image quality score Streamline C (n) Streamline L (n) Overall (n)
A4 T4 49 42 91
A4 T3 38 44 82
A3 T5 10 15 25
A3 T4 10 12 22
A3 T3 17 17 34
A, anatomical coverage score; T, technical quality score.
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Appendix 35 Detailed image quality score
categories for scans rated as overall degraded
category
TABLE 73 Detailed image quality score categories for scans rated as overall degraded category
Image quality score Streamline C (n) Streamline L (n) Overall (n)
A4 T2 3 1 4
A4 T1 3 1 4
A3 T2 0 1 1
A2 T5 5 4 9
A2 T4 0 7 7
A2 T3 8 2 10
A1 T5 5 6 11
A1 T4 2 2 4
A1 T3 6 4 10
A1 T2 0 2 2
A1 T1 4 3 7
A, anatomical coverage score; T, technical quality score.
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Appendix 36 Streamline L: reasons for
non-inclusion of screened patients
TABLE 74 Streamline L: reasons for non-inclusion of screened patients
Reason for non-inclusion n (%)
Evidence of severe or uncontrolled systematic disease 113 (18)
Unequivocal metastatic or N3 disease 110 (18)
Patients did not want extra visit for WB-MRI 86 (14)
Patients felt WB-MRI would delay potential treatment 62 (10)
Histology other than NSCLC 53 (8)
Did not want WB-MRI scan 52 (8)
Contraindications to WB-MRI 47 (8)
Site error/missed opportunity to undergo WB-MRI 29 (5)
Further staging work up not indicated in opinion of care team 27 (4)
Too frail/not fit enough to participate 20 (3)
Language barrier 14 (2)
Psychiatric or other conditions likely to impact on informed consent 10 (2)
Total 623
NSCLC, non-small-cell lung cancer.
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Appendix 37 Streamline L: reasons for withdrawal
of recruited participants
TABLE 75 Streamline L: reasons for withdrawal of recruited participants
Reason for withdrawal n (%)
Participant withdrawal owing to non-small-cell lung cancer diagnosis 84 (50)
Participant withdrawal owing to failure to undergo WB-MRI 75 (45)
Participant withdrew consent to follow-up 4 (2)
Participant lost to follow-up 1 (1)
Participant withdrawal owing to early release of WB-MRI findings 1 (1)
Participant died after registration 1 (1)
Total 166
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Appendix 38 Streamline L: primary tumour status
at the time of consensus review
TABLE 76 Streamline L: primary tumour status at the time of consensus review
Participant status n (%)
Participant died within 12 monthsa 31 (17)
Primary tumour removed within 3 months of diagnosis 93 (50)
Primary tumour in situ for > 3 months (or incomplete removal) – imaging capable of detecting metastatic
disease within 6 months of diagnosis
80 (43)
Primary tumour in situ for > 3 months (or incomplete removal) – no imaging capable of detecting
metastatic disease within 6 months of diagnosis
14 (7)
Other 0 (0)
a Participant death within 12-month follow-up recorded separately.
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Appendix 39 Streamline L: final T and N stage
based on consensus reference standard
TABLE 77 Streamline L: final T and N stage based on consensus reference standard
T stagea
N stagea (n)
N0 N1 N2 N3
T1a 29 1 1 0
T1b 12 2 4 1
T2a 33 7 10 2
T2b 15 2 5 1
T3 10 6 9 8
T4 11 3 7 8
a 87 participants with histological proof for both T and N stage, 13 participants with histological proof for T stage only
and 24 participants with histological proof for N stage only.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Includes minor additions and formatting changes to the original text.
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Appendix 40 Streamline L: final nodal disease
sites based on the consensus reference standard
TABLE 78 Streamline L: final nodal disease sites based on the consensus reference standard
Site
Number of participants
with metastatic disease,a n Histological proof, n (%)
Supraclavicular, low cervical and sterna notch 8 1 (13)
Upper paratracheal (right) 15 2 (13)
Upper paratracheal (left) 4 0 (0)
Pre vascular 3 0 (0)
Retrotracheal 1 0 (0)
Lower paratracheal (right) 22 10 (45)
Lower paratracheal (left) 10 0 (0)
Subaortic 10 4 (40)
Para-aortic 11 2 (18)
Subcarnal 27 12 (44)
Paraesophageal (below carina) 1 1 (100)
Pulmonary ligament 3 3 (100)
Hilar (right) 29 7 (24)
Hilar (left) 25 13 (52)
Interlobar (right) 3 2 (67)
Interlobar (left) 4 3 (75)
Lobar (right) 3 2 (67)
Lobar (left) 2 0 (0)
Segmental (right) 0 –
Segmental (left) 2 2 (100)
Subsegmental (left) 0 –
Subsegmental (right) 0 –
a Participants may have more than one site of metastatic disease.
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Appendix 41 Streamline L: detailed organs sites
of metastatic disease
TABLE 79 Streamline L: detailed organs sites of metastatic disease
Site
Number of
participants with
metastatic diseaseb
Histological
proof, n (%)
Imaging diagnosis without histological proof,a n (%)
Characteristic imaging
appearances
Growth on
follow-up
Response to
therapy
Liver 9 2 (22) 6 (86) 4 (57) 1 (14)
Lung 14 0 (0) 14 (100) 11 (79) 3 (21)
Pleura 5 1 (20) 4 (100) 2 (50) 1 (25)
Brain 14 1 (7) 13 (100) 8 (62) 4 (31)
Spleen 0 – – – –
Adrenal 7 0 (0) 6 (86) 5 (71) 1 (14)
Kidney 1 1 (100) – – –
Pancreas 2 0 (0) 2 (100) 1 (50) 0 (0)
Mesentery/
peritoneum
0 – – – –
Bowel 0 – – – –
Neck/chest soft
tissue
1 0 (0) 1 (100) 0 (0) 0 (0)
Abdomen/pelvis
soft tissue
3 0 (0) 3 (100) 1 (33) 0 (0)
Limbs soft tissue 1 0 (0) 1 (100) 0 (0) 0 (0)
Nodal (metastatic) 3 1 (33) 2 (100) 2 (100) 0 (0)
Otherc 2 0 (0) 3 (100) 1 (33) 0 (0)
Skull 1 0 (0) 1 (100) 1 (100) 0 (0)
Cervical spine 0 – – – –
Thoracic spine 9 0 (0) 9 (100) 5 (56) 1 (11)
Lumbar spine 8 1 (13) 7 (100) 3 (43) 0 (0)
Pelvis 5 0 (0) 5 (100) 2 (40) 0 (0)
Sternum 2 0 (0) 2 (100) 0 (0) 0 (0)
Clavicle/scapula 0 – – – –
Ribs 3 0 (0) 3 (100) 0 (0) 2 (67)
Upper limb 2 0 (0) 2 (100) 1 (50) 0 (0)
Lower limb 1 0 (0) 1 (100) 0 (0) 0 (0)
a Metastasis may fulfil more than one criterion for imaging diagnosis.
b Participants may have more than one site of metastatic disease.
c Two participants with metastasis in three other sites (right thyroid, left axilla and leptomeningeal).
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Appendix 42 Streamline L: number of metastatic
deposits per organ
TABLE 80 Streamline L: number of metastatic deposits per organ
Site
Number of participantsa
0 1 2 3 > 3
Unknown/not
measurable
Liver 178 5 3 0 1 1
Lung 173 6 3 1 4 0
Pleura 182 1 3 0 1 3
Brain 173 9 3 1 1 0
Adrenal 180 5 2 0 0 0
Bone 172 7 0 2 5 1
Other 178 4 3 1 1 1
a Participants may have more than one site of metastatic disease.
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Appendix 43 Streamline L: maximum size of
metastatic deposits according to organ
TABLE 81 Streamline L: maximum size of metastatic deposits according to organ
Site
Number of
participants with
metastatic diseasea
Number of participantsa
< 1 cm ≥ 1 cm
Not visible on any
staging investigation
Unknown/
not measurable
Liver 9 3 3 2 1
Lung 14 4 3 7 0
Pleura 5 1 1 0 3
Brain 14 3 7 4 0
Adrenal 7 1 3 3 0
Bone 15 3 11 0 1
Other 9 1 7 0 1
a Participants may have more than one site of metastatic disease.
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Appendix 44 Streamline L: equivocal results for
metastatic disease
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
197
TABLE 82 Streamline L: equivocal results for metastatic disease
Location
Equivocal results
Participants with metastatic diseasea Participants without metastatic diseasea
WB-MRI staging
pathwayb
Standard staging
pathway
Standard staging
pathway plus
WB-MRIc WB-MRI aloned
WB-MRI staging
pathway b
Standard staging
pathway
Standard staging
pathway plus
WB-MRIc WB-MRI aloned
Per participant 1 4 2 2 1 2 1 17
Non skeletal sitese 3 11 N/A 8 8 17 N/A 17
Skeletal sitese 4 4 N/A 2 1 0 N/A 4
N/A, data were not collected.
a Participants by consensus reference standard.
b WB-MRI plus additional generated tests.
c WB-MRI as an additional test to standard pathway.
d WB-MRI as a single staging investigation.
e Per organ as multiple sites can have equivocal results.
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Appendix 45 Streamline L: short-interval follow-up
for equivocal findings
TABLE 83 Streamline L: short-interval follow-up for equivocal findings
Test
Number of participants
WB-MRI plus additional tests Standard imaging All tests combined
Chest CT 0 0 0
Neck, chest and abdomen CT 0 0 0
Liver MRI 0 0 0
Bone scan 0 0 0
Spine and bone MRI 0 1 1
Other 2 3 2
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Appendix 46 Streamline L: per-organ sensitivity
and specificity for metastatic disease – standard
staging pathways versus WB-MRI staging pathway
against the consensus reference standard
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TABLE 84 Streamline L: per-organ sensitivity and specificity for metastatic disease – standard staging pathways vs. WB-MRI staging pathway against the consensus
reference standard
Site
Sensitivity Specificity
Number of
participants with
metastatic diseasea
WB-MRI staging
pathwayb,
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Number of
participants
without metastatic
diseasea
WB-MRI staging
pathwayb,
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Liver 9 44 (19 to 73) 33 (12 to 65) 11 (–23 to 46) 178 99 (97 to 100) 100 (98 to 100) –1 (–2 to 1)
Lung 14 36 (16 to 61) 36 (16 to 61) 0 (–22 to 22) 173 97 (94 to 99) 98 (95 to 99) –1 (–4 to 3)
Pleura 5 80 (38 to 96) 40 (12 to 77) 40 (7 to 73) 182 97 (94 to 99) 98 (95 to 99) –1 (–4 to 2)
Brain 14 57 (33 to 79) 44 (21 to 67) 13 (–5 to 33) 173 99 (97 to 100) 100 (98 to 100) –1 (–2 to 1)
Adrenal 7 28 (8 to 64) 57 (25 to 84) –29 (–71 to 14) 180 98 (95 to 99) 98 (95 to 99) 0 (–3 to 3)
Bone 15 60 (36 to 80) 67 (42 to 85) –7 (–31 to 18) 172 99 (96 to 100) 99 (96 to 100) 0 (–3 to 3)
Other 9 22 (6 to 55) 44 (19 to 73) –22 (–56 to 12) 178 97 (94 to 99) 93 (89 to 96) 4 (0 to 8)
a Participants by consensus reference standard.
b WB-MRI plus additional generated tests.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes
minor additions and formatting changes to the original text.
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Appendix 47 Streamline L: per-participant
agreement for tumour T stage – standard staging
pathways versus WB-MRI staging pathway against
the consensus reference standard in participants with
histological proof
TABLE 85 Streamline L: per-participant agreement for tumour T stage – standard staging pathways vs. WB-MRI
staging pathway against the consensus reference standard in participants with histological proof
T stage Number of participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRIb,c Standardc
T1a 21 20 (95) 20 (95) 0 (–16 to 16)
T1b 11 5 (45) 6 (54) –9 (–31 to 13)
T2a 37 10 (27) 14 (38) –11 (–26 to 5)
T2b 14 5 (36) 6 (43) –7 (–39 to 24)
T3 11 4 (36) 3 (27) 9 (–24 to 42)
T4 2 0 (0) 2 (100) –100 (–100 to –50)
Overall T stage 96 44 (46) 51 (53) –7 (–17 to 2)
a Participants with histological proof by final consensus reference standard.
b WB-MRI plus additional generated tests.
c One participant each staged Tx by WB-MRI and standard staging pathways.
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Appendix 48 Streamline L: per-participant
agreement for tumour N stage – standard staging
pathways versus WB-MRI staging pathway against
the consensus reference standard in participants with
histological proof
TABLE 86 Streamline L: per-participant agreement for tumour N stage – standard staging pathways vs. WB-MRI
staging pathway against the consensus reference standard in participants with histological proof
N stage Number of participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRIb Standardc
N0 70 56 (80) 60 (86) –6 (–15 to 4)
N1 19 3 (16) 6 (32) –16 (–41 to 9)
N2 15 6 (40) 10 (67) –27 (–61 to 8)
N3 5 3 (60) 3 (60) 0 (–46 to 46)
Overall N stage 109 68 (62) 79 (72) –10 (–19 to –1)
a Participants with histological proof by final consensus reference standard.
b WB-MRI plus additional generated tests.
c One participant staged Nx by standard staging pathway.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
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Appendix 49 Streamline L: nodal site agreement –
standard staging pathways versus WB-MRI staging
pathway against the consensus reference standard in
participants with histological proof
TABLE 87 Streamline L: nodal site agreement – standard staging pathways vs. WB-MRI staging pathway against
the consensus reference standard in participants with histological proof
Site
Number
of participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRIb Standard
Supraclavicular, low cervical
and sterna notch
2 1 (50) 1 (50) 0 (–57 to 57)
Upper paratracheal (right) 12 2 (17) 2 (17) 0 (–22 to 22)
Upper Paratracheal (left) 2 0 (0) 0 (0) 0 (–50 to 50)
Pre vascular 2 0 (0) 0 (0) 0 (–50 to 50)
Retrotracheal 2 0 (0) 1 (50) –50 (–169 to 69)
Lower paratracheal (right) 47 12 (25) 11 (23) 2 (–10 to 14)
Lower paratracheal (left) 3 0 (0) 1 (33) –33 (–120 to 53)
Subaortic 29 5 (17) 4 (14) 3 (–12 to 19)
Para-aortic 9 5 (56) 6 (67) –11 (–50 to 28)
Subcarinal 62 20 (32) 17 (27) –5 (–4 to 14)
Paraesophageal 21 4 (19) 3 (14) 5 (–12 to 21)
Pulmonary ligament 30 6 (20) 6 (20) 0 (–15 to 15)
Hilar (right) 40 7 (18) 3 (8) 10 (–3 to 23)
Hilar (left) 32 6 (19) 8 (25) –6 (–17 to 5)
Interlobar (right) 12 2 (17) 2 (17) 0 (–29 to 29)
Interlobar (left) 11 1 (9) 2 (18) –9 (–37 to 19)
Lobar (right) 6 0 (0) 0 (0) 0 (–17 to 17)
Lobar (left) 3 0 (0) 0 (0) 0 (–33 to 33)
Segmental (left) 1 0 (0) 0 (0) 0 (–100 to 100)
Segmental (right) 3 0 (0) 0 (0) 0 (–33 to 33)
Subsegmental (left) 1 0 (0) 0 (0) 0 (–100 to 100)
Subsegmental (right) 2 0 (0) 0 (0) 0 (–50 to 50)
a Participants with histological proof by final consensus reference standard.
b WB-MRI plus additional generated tests.
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Appendix 50 Streamline L: breakdown of the
primary treatment decision according to the standard
staging pathway compared with the retrospective
consensus panel optimal treatment decision
TABLE 88 Streamline L: breakdown of the primary treatment decision according to the standard staging pathway
compared with the retrospective consensus panel optimal treatment decision
Standard pathway
Retrospective consensus panel optimal treatment decision (n)
Curative intent Palliative intent Totala
Curative intent 123 25 148
Palliative intent 7 28 35
Totala 130 53 183
a Four participants were missing at least one type of participant management decision.
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Appendix 51 Streamline L: breakdown of the
primary treatment decision according to the WB-MRI
staging pathway compared with the retrospective
consensus panel optimal treatment decision
TABLE 89 Streamline L: breakdown of the primary treatment decision according to the WB-MRI staging pathway
compared with the retrospective consensus panel optimal treatment decision
WB-MRI pathway including
additional tests generated
Retrospective consensus panel optimal treatment decision (n)
Curative intent Palliative intent Totala
Curative intent 122 23 145
Palliative intent 8 30 38
Totala 130 53 183
a Four participants were missing at least one type of participant management decision.
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Appendix 52 Streamline L: time to complete
staging according to staging pathway
TABLE 90 Streamline L: time to complete staging according to staging pathway
Participants
Staging pathway, median days (IQR)
WB-MRI Standard
All participants 13 (7–19) 19 (13–31)
IQR, interquartile range.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for
commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
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Appendix 53 Streamline L: per-participant
sensitivity and specificity for metastatic disease-
standard staging pathway versus WB-MRI alone
against the consensus reference standard
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TABLE 91 Streamline L: per-participant sensitivity and specificity for metastatic disease-standard staging pathway vs. WB-MRI alone, against the consensus reference standard
Outcome
Sensitivity Specificity
Number of
participants with
metastatic diseasea
WB-MRI
aloneb, %
(95% CI)
Standard
staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Number of
participants
without metastatic
diseasea
WB-MRI
aloneb,
% (95% CI)
Standard
staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Diagnostic
accuracy
52 50 (37 to 63) 54 (41 to 67) –4 (–16 to 8) 135 85 (78 to 90) 95 (91 to 98) –10 (–17 to –4)
a Participants by consensus reference standard.
b WB-MRI as a single staging investigation.
Reproduced from Taylor et al.26 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text below includes
minor additions and formatting changes to the original text.
A
PPEN
D
IX
53
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
216
Appendix 54 Streamline L: per-organ sensitivity
and specificity for metastatic disease – standard
staging pathways versus WB-MRI alone against the
consensus reference standard
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TABLE 92 Streamline L: per-organ sensitivity and specificity for metastatic disease-standard staging pathways vs. WB-MRI alone against the consensus reference standard
Site
Sensitivity Specificity
Number of
participants with
metastatic diseasea
WB-MRI alone,b
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Number of
participants
without
metastatic diseasea
WB-MRI alone,b
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI)
Liver 9 33 (12 to 65) 33 (12 to 65) 0 (–38 to 38) 178 98 (94 to 99) 100 (98 to 100) –2 (–5 to 1)
Lung 14 21 (8 to 48) 35 (16 to 61) –14 (–37 to 9) 173 97 (93 to 98) 98 (95 to 99) –1 (–5 to 3)
Pleura 5 60 (23 to 88) 40 (12 to 77) 20 (–20 to 60) 182 95 (91 to 97) 98 (95 to 99) –3 (–7 to 0)
Brain 14 57 (33 to 79) 43 (21 to 67) 14 (–5 to 33) 173 99 (97 to 100) 100 (98 to 100) –1 (–2 to 1)
Adrenal 7 43 (16 to 75) 57 (25 to 84) –14 (–48 to 19) 180 97 (93 to 98) 98 (95 to 99) –1 (–4 to 2)
Bone 15 60 (36 to 80) 67 (42 to 85) –7 (–31 to 18) 172 98 (94 to 99) 99 (96 to 100) –1 (–4 to 2)
Other 9 33 (12 to 65) 44 (19 to 73) –11 (–38 to 16) 178 96 (92 to 98) 93 (89 to 96) 3 (–2 to 8)
a Participants by consensus reference standard.
b WB-MRI as a single staging investigation.
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Appendix 55 Streamline L: per-participant
agreement for tumour T stage – standard staging
pathways versus WB-MRI alone against the consensus
reference standard
TABLE 93 Streamline L: per-participant agreement for tumour T stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard
T stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standardc
T1a 26 23 (88) 24 (92) –4 (–22 to 14)
T1b 18 10 (55) 8 (44) 11 (–13 to 36)
T2a 50 16 (32) 24 (48) –16 (–33 to 1)
T2b 22 7 (32) 9 (41) –9 (–35 to 16)
T3 32 17 (53) 17 (53) 0 (–22 to 22)
T4 28 10 (36) 16 (57) –21 (–47 to 4)
Overall T stage 176 83 (47) 98 (56) –9 (–17 to 0)
a 11 participants were missing data.
b WB-MRI as a single staging investigation.
c 11 and one participant(s) staged Tx by WB-MRI alone and standard staging pathways, respectively.
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Appendix 56 Streamline L: per-participant
agreement for tumour T stage – standard staging
pathways versus WB-MRI alone against the
consensus reference standard in participants with
histological proof
TABLE 94 Streamline L: per-participant agreement for tumour T stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard in participants with histological proof
T stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standardc
T1a 19 17 (89) 19 (100) –11 (–29 to 9)
T1b 11 5 (45) 6 (54) –9 (–31 to 13)
T2a 36 8 (22) 15 (41) –19 (–38 to –1)
T2b 14 6 (43) 6 (43) 0 (–28 to 28)
T3 10 3 (30) 3 (30) 0 (–36 to 36)
T4 2 0 (0) 2 (100) –100 (–100 to –50)
Overall T stage 92 39 (42) 51 (55) –13 (–23 to –3)
a Participants with histological proof by final consensus reference standard.
b WB-MRI as a single staging investigation.
c Five and one participant(s) staged Tx by WB-MRI alone and standard staging pathways, respectively.
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Appendix 57 Streamline L: per-participant
agreement for tumour N stage – standard staging
pathways versus WB-MRI alone against the
consensus reference standard – all participants
TABLE 95 Streamline L: per-participant agreement for tumour N stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard – all participants
N stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standardc
N0 104 79 (76) 88 (85) –9 (–17 to 0)
N1 21 4 (19) 8 (38) –19 (–46 to 8)
N2 36 19 (53) 26 (72) –19 (–42 to 3)
N3 20 6 (30) 12 (60) –30 (–61 to 1)
Overall N stage 181 108 (60) 132 (74) –14 (–22 to –6)
a 6 participants missing data.
b WB-MRI as a single staging investigation.
c 10 and one participant(s) staged Nx stage by WB-MRI alone and standard staging pathways, respectively.
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Appendix 58 Streamline L: per-participant
agreement for tumour N stage – standard staging
pathways versus WB-MRI alone against the
consensus reference standard in participants with
histological proof
TABLE 96 Streamline L: per-participant agreement for tumour N stage – standard staging pathways vs. WB-MRI
alone against the consensus reference standard in participants with histological proof
N stage
Number of
participantsa
Staging pathway, n (%)
Difference: WB-MRIb vs.
standard, % (95% CI)WB-MRI aloneb,c Standard
N0 69 54 (78) 58 (84) –6 (–16 to 5)
N1 19 4 (21) 6 (32) –11 (–37 to 16)
N2 15 5 (33) 10 (66) –33 (–69 to 2)
N3 5 3 (60) 3 (60) 0 (–46 to 46)
Overall N stage 108 66 (61) 77 (71) –10 (–20 to 0)
a Participants with histological proof by final consensus reference standard.
b WB-MRI as a single staging investigation.
c Four and one participant(s) staged Nx by WB-MRI alone and standard staging pathways, respectively.
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Appendix 59 Streamline L: per-participant
agreement for metastatic disease – PET-CT
versus WB-MRI alone against the consensus
reference standard
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
227
TABLE 97 Streamline L: per-participant agreement for metastatic disease: PET-CT versus WB-MRI alone against the consensus reference standard
Outcome
Sensitivity Specificity
Number of
participants with
metastatic diseasea
WB-MRI
alone,b
% (95% CI)
PET-CT,
% (95% CI)
Difference: WB-MRIb
vs. PET-CT,
% (95% CI)
Number of
participants
without
metastatic diseasea
WB-MRI
alone,b
% (95% CI)
PET-CT,
% (95% CI)
Difference: WB-MRIb
vs. PET-CT,
% (95% CI)
Diagnostic accuracyc 47 47 (33 to 61) 53 (39 to 67) –6 (–20 to 8) 124 85 (78 to 91) 90 (84 to 94) –5 (–13 to 3)
a Participants by consensus reference standard.
b WB-MRI as a single staging investigation.
c Equivocal results considered disease positive.
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Appendix 60 Streamline L: per-participant
sensitivity and specificity for metastatic disease-
standard staging pathways versus standard staging
pathways plus WB-MRI against the consensus
reference standard
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TABLE 98 Streamline L: per-participant sensitivity and specificity for metastatic disease-standard staging pathways vs. standard staging pathways plus WB-MRI against the
consensus reference standard
Outcome
Sensitivity Specificity
Number of
participants
with metastatic
diseasea
Standard staging
pathway plus
WB-MRI,b
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI; p-value)
Number of
participants
without
metastatic
diseasea
Standard staging
pathway plus
WB-MRI,b
% (95% CI)
Standard staging
pathway,
% (95% CI)
Difference: WB-MRIb
vs. standard,
% (95% CI; p-value)
Metastatic disease 52 60 (46 to 72) 54 (41 to 67) 6 (–3 to 14; 0.375) 135 96 (91 to 98) 96 (91 to 98) 0 (–4 to 4; > 0.999)
a Participants by consensus reference standard.
b WB-MRI as an additional test to standard pathway.
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Appendix 61 Streamline L: perceptual errors for
metastatic disease according to staging pathway
TABLE 99 Streamline L: perceptual errors for metastatic disease according to staging pathway
Location
Perceptual errorsa (n)
WB-MRI staging pathwayb Standard staging pathway WB-MRI alonec
Per participant 18 7 19
Non skeletal sites 15 6 15
Skeletal sites 7 3 8
a Perceptual errors are by definition only in disease-positive participants.
b WB-MRI plus additional generated tests.
c WB-MRI as a single staging investigation.
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Appendix 62 Streamline L: perceptual errors for
metastatic disease according to staging pathway and
organ disease site
TABLE 100 Streamline L: perceptual errors for metastatic disease according to staging pathway and organ disease site
Site
Perceptual errorsa (n)
Number of participants
with metastatic diseaseb
WB-MRI staging
pathwayc
Standard staging
pathway
WB-MRI
aloned
Liver 9 3 1 3
Lung 14 2 0 2
Pleura 5 0 2 0
Brain 14 3 0 3
Adrenal 7 1 1 1
Bone 15 7 3 8
Other 9 6 2 6
a Perceptual error are by definition only in disease-positive participants.
b Participants by consensus reference standard.
c WB-MRI plus additional generated tests.
d WB-MRI as a single staging investigation.
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Appendix 63 Streamline C: concordance between
treatment decisions based on standard and WB-MRI
staging pathway (d1 and d2)
TABLE 101 Streamline C: concordance between treatment decisions based on standard and WB-MRI staging
pathway (d1 and d2)
WB-MRI staging
pathway (d2)
Standard staging pathway (d1) (%)
A B C D Total
A 10.47 0 0 0 10.47
B 0 26.69 3.04 0 29.73
C 0 1.69 52.7 0 54.39
D 0 0.34 0 5.07 5.41
Total 10.47 28.72 55.74 5.07 100
A, chemotherapy (and/or radiotherapy) without surgery; B, surgery for the primary tumour and chemotherapy (and/or
radiotherapy); C, surgery for the primary tumour but no chemotherapy; D, surgical metastectomy with or without chemotherapy.
Discordance = 1.69 + 0.34+ 3.04 = 5.07%.
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Appendix 64 Streamline L: concordance between
treatment decisions based on standard and WB-MRI
staging pathway (d1 and d2)
TABLE 102 Streamline L: concordance between treatment decisions based on standard and WB-MRI staging
pathway (d1 and d2)
WB-MRI staging pathway (d2)
Standard staging pathway (d1) (%)
X Y Total
X 78.69 0.55 79.23
Y 2.19 18.58 20.77
Total 80.87 19.13 100
X, treatments with curative intent; Y, treatments with non-curative intent.
Discordance = 2.19 + 0.55 = 2.74%.
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Appendix 65 Streamline C: discordance between
treatment decisions based on standard staging (d1) and
the consensus reference panel optimal decision (d4)
TABLE 103 Streamline C: discordance between treatment decisions based on standard staging (d1) and the
consensus reference panel optimal decision (d4)
Standard staging
pathway (d1)
Panel consensus decision (d4) (%)
A B C D Total
A 4.73 3.72 0.68 1.35 10.47
B 3.04 20.27 4.39 1.01 28.72
C 1.35 12.84 40.54 1.01 55.74
D 1.01 1.69 0.00 2.36 5.07
Total 10.14 38.51 45.61 5.74 100
A, chemotherapy (and/or radiotherapy) without surgery; B, surgery for the primary tumour and chemotherapy (and/or
radiotherapy); C, surgery for the primary tumour but no chemotherapy, D, surgical metastectomy with or without chemotherapy.
Discordance = 3.04 + 1.35+ 1.01+ 3.72 + 12.84+ 1.69 + 0.68+ 4.39+ 1.35 + 1.01+ 1.01 = 32.09%.
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Appendix 66 Streamline C: discordance between
treatment decisions based on WB-MRI staging
pathway (d1) and the consensus reference panel
optimal decision (d4)
TABLE 104 Streamline C: discordance between treatment decisions based on WB-MRI staging pathway (d1) and the
consensus reference panel optimal decision (d4)
WB-MRI staging
pathway (d2)
Panel consensus decision (d4) (%)
A B C D Total
A 4.73 3.72 0.68 1.35 10.47
B 3.04 20.61 4.73 1.35 29.73
C 1.35 12.16 40.20 0.68 54.39
D 1.01 2.03 0.00 2.36 5.41
Total 10.14 38.51 45.61 5.74 100
A, chemotherapy (and/or radiotherapy) without surgery; B, surgery for the primary tumour and chemotherapy (and/or
radiotherapy); C, surgery for the primary tumour but no chemotherapy; D, surgical metastectomy with or without chemotherapy.
Discordance = 3.04 + 1.35+ 1.01+ 3.72 + 12.16+ 2.03 + 0.68+ 4.73+ 1.35 + 1.35+ 0.68 = 32.10%.
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Appendix 67 Streamline L: discordance between
treatment decisions based on standard staging (d1) and
the consensus reference panel optimal decision (d4)
TABLE 105 Streamline L: discordance between treatment decisions based on standard staging (d1) and the
consensus reference panel optimal decision (d4)
Standard staging pathway (d1)
Panel consensus decision (d4) (%)
X Y Total
X 67.21 13.66 80.87
Y 3.83 15.3 19.13
Total 71.04 28.96 100
X, treatments with curative intent; Y, treatments with non-curative intent.
Discordance = 3.83 + 13.66 = 17.49%.
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Appendix 68 Streamline L: discordance between
treatment decisions based on WB-MRI staging
pathway (d1) and the consensus reference panel
optimal decision (d4)
TABLE 106 Streamline L: discordance between treatment decisions based on WB-MRI staging pathway (d1) and the
consensus reference panel optimal decision (d4)
WB-MRI staging pathway (d2)
Panel consensus decision (d4) (%)
X Y Total
X 66.67 12.57 79.23
Y 4.37 16.39 20.77
Total 71.04 28.96 100
X, treatments with curative intent; Y, treatments with non-curative intent.
Discordance = 4.37 + 12.57 = 16.94%.
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Appendix 69 Interview topic guide
BOX 1 Interview topic guide
I understand that you have been having a number of scans to investigate your symptoms; can you tell me
what’s been happening?
Can you describe what it feels like physically to have the scan?
How did you feel during/after/about the test?
What were the staff like?
What did you do to cope with [problem identified by patient, e.g. noise, keeping still, etc.]?
Would you have another WB-MRI if the doctor recommended it?
Reproduced from Evans et al.33 This is an Open Access article distributed in accordance with the terms of the
Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build
upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/. Includes minor additions and formatting changes to the original text.
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Appendix 70 Demographic characteristics of
interview participants by trial
TABLE 107 Demographic characteristics of interview participants by trial
Variable Streamline L (N= 25) Streamline C (N= 26) Group differences
Sex
Male, % (n) 60 (15) 61.5 (16) χ2 = 0.013, df 1; p = 0.910
Female, % (n) 40 (10) 38.5 (10)
Age (years), mean (SD) 65 (11) 64 (9) t = 0.261, df 49; p = 0.795
Area deprivation score (quintile)
1 (highest), % (n) 52.0 (13) 30.8 (8) χ2 = 5.459, df = 2; p = 0.065
2, % (n) 32.0 (8) 23.1 (6)
3–5 (mid to low), % (n) 16.0 (4) 46.2 (12)
Interview method
Face to Face, % (n) 20.0 (5) 26.9 (7) χ2 = 0.339, df = 1; p = 0.560
Phone, % (n) 80.0 (20) 73.1 (19)
Median interval between interview
and WB-MRI, days (range)
15 (6–43) 20 (1–63) U = 270.00; p = 0.299
Reproduced from Evans et al.33 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Includes minor additions and formatting changes to the original text.
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Appendix 71 Comparison of demographic
characteristics of participants sent both
questionnaires, who were or were not included in the
final analysis (study 2)
TABLE 108 Comparison of demographic characteristics of participants sent both questionnaires, who were or were
not included in the final analysis (study 2)
Variable
Sent both questionnaires
Group difference
Excluded from
analysis (n= 99)
Included in final
analysis (n= 115)
Age (years), mean (range) 65.0 (30–86) 66.3 (31–89) Mann–Whitney U-test; p = 0.676
Sex, % (n)
Male 37.7 (29) 51.1 (70) χ2 = 3.578, df 1; p = 0.059
Female 62.3 (48) 48.9 (67)
Cancer type, % (n)
Colorectal 48.3 (57) 43.8 (42) χ2 = 0.442, df 1; p = 0.506
Lung 56.3 (54) 51.7 (61)
Deprivation quintile, % (n)
1 (highest) 60.9 (42) 39.1 (27) χ2 = 10.370, df 4; p = 0.035
2 45.1 (23) 54.9 (28)
3 32.4 (12) 67.6 (25)
4 41.2 (14) 58.8 (20)
5 (lowest) 34.8 (8) 65.2 (15)
Reproduced from Evans et al.34 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Includes minor additions and formatting changes to the original text.
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Appendix 72 Demographic and characteristics
of participants who completed the post-staging
questionnaire
TABLE 109 Demographic and characteristics of participants who completed the post-staging questionnaire
Variable
Overall
(N= 115)
Participant cohort
Differences between
participant cohorts
Streamline L
(N= 54)
Streamline C
(N= 61)
Demographic characteristics
Age (years), median (range) 66.3 (31–89) 69.7 (50–89) 64.2 (31–85) Mann–Whitney U-test; p = 0.010
Male sex,a % (n) 58.3 (67) 55.6 (30) 60.7(37) χ2 = 0.306, df 1; p = 0.580
White ethnicity,b % (n) 91.8 (90) 93.8 (45) 90.0 (45) Fisher’s exact; p = 0.715
IMD deprivation,a % (n)
1 (highest) 23.5 (27) 25.9 (14) 21.3 (13) χ2 = 0.3875, df 4; p = 0.423
2 24.3 (28) 27.8 (15) 21.3 (13)
3 21.7 (25) 24.1 (13) 19.7 (12)
4 17.4 (20) 14.8 (8) 19.7 (12)
5 (lowest) 13.0 (15) 7.4 (4) 18.0 (11)
Physical and emotional well-being, % (n)
Comorbidity (at least one
comorbid illness reported)b
53.4 (55) 66.7 (34) 40.4 (21) χ2 = 7.147, df 1; p = 0.008
Emotional distress
(GHQ-12 score of ≥ 4)b
41.6 (42) 47.1 (24) 36.0 (18) χ2 = 1.271, df 1; p = 0.260
a No missing data.
b Missing data > 5%.
Reproduced from Evans et al.34 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Includes minor additions and formatting changes to the original text.
DOI: 10.3310/hta23660 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 66
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Taylor et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
253

Appendix 73 Comparative experience of WB-MRI
vs. CT/PET-CT: scan information, communication and
facilities
TABLE 110 Comparative experience of WB-MRI vs. CT/PET-CT: scan information, communication and facilities
Level of satisfaction Overall, % (n) Streamline L, % (n) Streamline C, % (n) Group differences, p-value
Satisfied with information received before scana
WB-MRIb 0.169,c 0.071d
Very satisfied 55.6 (60) 51.9 (27)a 58.9 (33)b
Satisfied 37.0 (40) 40.4 (21) 33.9 (19)
Dissatisfied 3.7 (4) 5.8 (3) 1.8 (1)
Very dissatisfied 3.7 (4) 1.9 (1) 5.4 (3)
CT/PET-CTb
Very satisfied 57.5 (61) 49.0 (25)a 65.5 (36)b
Satisfied 34.9 (37) 37.3 (19) 32.7 (18)
Dissatisfied 0.9 (1) 2.0 (1) 0 (0)
Very dissatisfied 6.6 (7) 11.8 (6) 1.8 (1)
Satisfied with communication during scana
WB-MRIb 0.637,c 0.059d
Very satisfied 56.1 (60) 57.7 (30)a 54.5 (30)b
Satisfied 39.3 (42) 34.6 (18) 43.6 (24)
Dissatisfied 2.8 (3) 5.8 (3) 0 (0)
Very dissatisfied 1.9 (2) 1.9 (1) 1.8 (1)
CT/PET-CTb
Very satisfied 64.2 (68) 62.7 (32)a 65.5 (36)b
Satisfied 32.1 (34) 31.4 (16) 32.7 (18)
Dissatisfied 1.9 (2) 3.9 (2) 0 (0)
Very dissatisfied 1.9 (2) 2.0 (1) 1.8 (1)
Satisfaction with facilitiesa
WB-MRIb 0.225,c 0.480d
Very satisfied 45.8 (49) 49.0 (25)a 42.9 (24)b
Satisfied 45.8 (49) 43.1 (22) 48.2 (27)
Dissatisfied 4.7 (5) 2.0 (1) 7.1 (4)
Very dissatisfied 3.7 (4) 5.9 (3) 1.8 (1)
continued
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TABLE 110 Comparative experience of WB-MRI vs. CT/PET-CT: scan information, communication and facilities
(continued )
Level of satisfaction Overall, % (n) Streamline L, % (n) Streamline C, % (n) Group differences, p-value
CT/PET-CTb
Very satisfied 54.7 (58) 62.7 (32)a 47.3 (26)b
Satisfied 38.7 (41) 33.3 (17) 43.6 (24)
Dissatisfied 4.7 (5) 2.0 (1) 7.3 (4)
Very dissatisfied 1.9 (2) 2.0 (1) 1.8 (1)
a Streamline L, WB-MRI vs. PET-CT; Streamline C, WB-MRI vs. CT.
b Missing data > 5%; % is valid %.
c Comparison between WB-MRI and PET-CT (Streamline L).
d Comparison between WB-MRI and CT (Streamline C).
Reproduced from Evans et al.34 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Includes minor additions and formatting changes to the original text.
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Appendix 74 Demographic and psychological
characteristics of the cohort completing the discrete
choice experiment
TABLE 111 Demographic and psychological characteristics of the cohort completing the DCE
All participants
Streamline L
participants
Streamline C
participants
Group
differences
(p-value)
Demographics
Age (years),a mean (SD); N 64.7 (10.9); 138 66.0 (10.8); 72 63.2 (10.9); 66 0.122
Male sex,a n (%); N 84 (60.9); 138 42 (59.2); 72 41 (62.1); 66 0.723
White ethnicity,b n (%); N 112 (84.2); 133 59 (85.5); 69 53 (82.8); 64 0.670
Educational qualifications,c N 124 63 61 < 0.001
None, n (%) 35 (28.2) 28 (44.4) 7 (11.5)
Below degree level, n (%) 39 (31.5) 17 (27.0) 22 (36.1)
Degree level or equivalent, n (%) 50 (40.3) 18 (28.6) 32 (52.5)
Home ownership (yes), n (%); N 82 (64.6); 127 34 (50.0); 68 48 (81.4); 59 < 0.001
Car ownership (yes), n (%); N 114 (87.0); 131 61 (88.4); 69 53 (85.5); 62 0.619
Marital status,b N 134 72 62 0.403
Married/cohabiting, n (%) 85 (63.4) 42 (58.3) 43 (69.4)
Single, n (%) 22 (16.4) 13 (18.1) 9 (14.5)
Divorced/separated/widowed, n (%) 27 (20.1) 17 (23.6) 10 (16.1)
Employment status,b N 135 71 64 0.018
Employed full-time/part-time/self-employed/
fulltime homemaker, n (%)
46 (34.1) 17 (23.9) 29 (45.3)
Retired, n (%) 74 (54.8) 43 (60.6) 31 (48.4)
Unemployed, disabled or too ill to work,
n (%)
15 (11.1) 11 (15.5) 4 (6.3)
Health
Self-rated health,b N 136 71 65 0.001
Very bad/bad/fair, n (%) 60 (44.1) 41 (57.7) 19 (29.2)
Good/very good, n (%) 76 (55.9) 30 (42.3) 46 (70.8)
Presence of comorbidities,a n (%); N 77 (55.8); 138 48 (66.7); 72 29 (43.9); 66 0.007
Psychological variables
Negative mood,b n (%); N 18.01 (7.45); 136 18.76 (7.62); 71 17.20 (7.23); 65 0.224
Positive mood,b n (%); N 27.32 (7.92); 137 25.73 (7.72); 71 29.03 (7.84); 66 0.014
a No missing data.
b Missing data < 5%.
c Missing data > 5%.
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Includes minor additions and formatting changes to the original text.
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Appendix 75 Results of conditional logit
regression analysis: Streamline L participants stratified
by home ownership
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TABLE 112 Results of conditional logit regression analysis: Streamline L participants stratified by home ownership
Attributes Levels
All participants,
coefficient (95% CI)
Home ownership, coefficient (95% CI)
p-valuebYes No
Time in scanner Minutes –0.008 (–0.014 to –0.002) –0.010 (–0.020 to 0.0003) –0.011 (–0.023 to 0.002) 0.89
Time to diagnosis Weeks –0.372 (–0.449 to –0.295) –0.469 (–0.603 to –0.334) –0.391 (–0.539 to –0.244) 0.45
Radiation dose Increased risk of cancer (/1000) –0.413 (–0.551 to –0.274) –0.582 (–0.809 to –0.354) –0.391 (–0.626 to –0.156) 0.25
Number of additional scans Number –0.179 (–0.330 to –0.028)a –0.063 (–0.191 to 0.318)a –0.354 (–0.654 to –0.054)a 0.03
Accuracy Percentage 0.109 (0.079 to 0.138)a 0.181 (0.129 to 0.233)a 0.077 (0.035 to 0.119)a 0.01
Need for whole body and head to be in scanner No – – – –
Yes 0.017 (–0.190 to 0.224) 0.026 (–0.316 to 0.367) 0.146 (–0.201 to 0.493) 0.63
Observations/respondents 1230/72 582/34 576/33 0.02
a Coefficient not significantly different from zero; all other coefficients significant at p values < 0.05.
b p-values are from chi-squared tests that coefficients are equal for the two subgroups; p-values < 0.05 indicate coefficients that are significantly different between groups the; p-value in
the bottom row is for a joint test across all coefficients.
Different attributes do not have the same unit of change so cannot be directly compared with one another.
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions
and formatting changes to the original text.
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Appendix 76 Results of conditional logit
regression analysis: Streamline L participants stratified
by education
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TABLE 113 Results of conditional logit regression analysis: Streamline L participants stratified by education
Attributes Levels
All participants,
coefficient (95% CI)
Education, coefficient (95% CI)
p-valuebDegree level or higher
No qualifications or
qualification below
degree level
Time in scanner Minutes –0.008 (–0.014 to –0.002) –0.002 (–0.014 to 0.011) –0.011 (–0.020 to –0.003) 0.24
Time to diagnosis Weeks –0.372 (–0.449 to –0.295) –0.369 (–0.541 to –0.198) –0.432 (–0.540 to –0.324) 0.56
Radiation dose Increased risk of cancer (/1000) –0.413 (–0.551 to –0.274) –0.522 (–0.834 to –0.210) –0.356 (–0.532 to –0.180) 0.36
Number of additional scans Number –0.179 (–0.330 to –0.028) –0.041 (–0.282 to 0.364) –0.271 (–0.479 to –0.064) 0.11
Accuracy Percentage 0.109 (0.079 to 0.138)a 0.190 (0.115 to 0.264)a 0.092 (0.054 to 0.130)a 0.01
Need for whole body and head to be in scanner No – – – –
Yes 0.017 (–0.190 to 0.224) –0.252 (–0.695 to 0.190) 0.208 (–0.070 to 0.486) 0.09
Observations/respondents 1230/72 310/19 776/44 0.04
a Coefficient not significantly different from zero; all other coefficients significant at p < 0.05.
b p-values are from chi-squared tests that coefficients are equal for the two subgroups; p < 0.05 indicate coefficients are significantly different between groups; p-value in bottom row is for
joint test across all coefficients.
Different attributes do not have the same unit of change so cannot be directly compared with one another.
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions
and formatting changes to the original text.
A
PPEN
D
IX
76
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
262
Appendix 77 Results of conditional logit
regression analysis: Streamline L participants stratified
by self-rated health
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TABLE 114 Results of conditional logit regression analysis: Streamline L participants stratified by self-rated health
Attributes Levels
All participants,
coefficient (95% CI)
Self-rated health, coefficient (95% CI)
p-valuebGood or very good Very poor, poor or fair
Time in scanner Minutes –0.008 (–0.014 to –0.002) –0.010 (–0.022 to 0.002) –0.009 (–0.016 to –0.001) 0.81
Time to diagnosis Weeks –0.372 (–0.449 to –0.295) –0.455 (–0.607 to –0.304) –0.342 (–0.445 to –0.238) 0.22
Radiation dose Increased risk of cancer (/1000) –0.413 (–0.551 to –0.274)a –0.119 (–0.348 to 0.109)a –0.613 (–0.810 to –0.415)a 0.01
Number of additional scans Number –0.179 (–0.330 to –0.028) –0.332 (–0.619 to –0.044) –0.095 (–0.291 to 0.100) 0.18
Accuracy Percentage 0.109 (0.079 to 0.138)a 0.151 (0.103 to 0.200)a 0.080 (0.043 to 0.116)a 0.02
Need for whole body and head to be in scanner No – – – –
Yes 0.017 (–0.190 to 0.224) 0.184 (–0.204 to 0.572) –0.055 (–0.323 to 0.212) 0.32
Observations/respondents 1230/72 534/29 678/37 0.01
a Coefficient not significantly different from zero; all other coefficients significant at p < 0.05.
b p-values are from chi-squared tests that coefficients are equal for the two subgroups; p < 0.05 indicate coefficients are significantly different between groups; p-value in bottom row is for
joint test across all coefficients.
Different attributes do not have the same unit of change so cannot be directly compared with one another.
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions
and formatting changes to the original text.
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Appendix 78 Results of conditional logit
regression analysis: Streamline L participants stratified
by test preference
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TABLE 115 Results of conditional logit regression analysis: Streamline L participants stratified by test preference
Attributes Levels
All participants,
coefficient (95% CI)
Test preference, coefficient (95% CI)
p-valuebWB-MRI Standard tests
Time in scanner Minutes –0.008 (–0.014 to –0.002)a 0.008 (–0.008 to 0.024)a –0.014 (–0.025 to –0.003)a 0.03
Time to diagnosis Weeks –0.372 (–0.449 to –0.295) –0.340 (–0.523 to –0.157) –0.262 (–0.409 to –0.115) 0.51
Radiation dose Increased risk of cancer (/1000) –0.413 (–0.551 to –0.274) –0.294 (–0.809 to 0.221) –0.251 (–0.692 to 0.190) 0.90
Number of additional scans Number –0.179 (–0.330 to –0.028) –0.512 (–1.029 to 0.004) –0.386 (–0.813 to 0.040) 0.71
Accuracy Percentage 0.109 (0.079 to 0.138) 0.092 (–0.020 to 0.204) –0.008 (–0.116 to 0.100) 0.21
Need for whole body and head to be in scanner No – – – –
Yes 0.017 (–0.190 to 0.224)a 0.359 (–0.152 to 0.870)a –0.722 (–1.269 to –0.176)a 0.01
Observations/respondents 1230/72 234/15 292/18 0.01
a Coefficient not significantly different from zero; all other coefficients significant at p < 0.05.
b p-values are from chi-squared tests that coefficients are equal for the two subgroups; p < 0.05 indicate coefficients are significantly different between groups; p-value in bottom row is for
joint test across all coefficients.
Different attributes do not have the same unit of change so cannot be directly compared with one another.
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to
distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. Includes minor additions
and formatting changes to the original text.
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Appendix 79 Participants unwilling to trade
attributes off against one another
TABLE 116 Participants unwilling to trade attributes off against one another
Attribute
Participants, n (%)
All Streamline L Streamline C
Accuracy: non-traders are those who always prefer more accurate tests 18 (13) 7 (10) 11 (17)
Time to diagnosis: non-traders are those who always prefer shorter time
to diagnosis
16 (12) 7 (10) 9 (14)
Radiation: non-traders are those who always prefer less radiation 11 (8) 7 (10) 4 (6)
Scan time: non-traders are those who always prefer shorter scan time 2 (1) 1 (1) 1 (2)
Scan number: non-traders are those who always prefer fewer scans 2 (1) 0 (0) 2 (3)
Enclosed: non-traders are those who always prefer non-enclosure of head
and body
2 (1) 1 (1) 1 (2)
All 51 (37) 23 (32) 28 (42)
Reproduced from Miles et al.35 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
Includes minor additions and formatting changes to the original text.
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Appendix 80 WB-MRI interobserver variability
(not considering agreement with the consensus
reference standard): Streamline C and Streamline L
TABLE 117 WB-MRI interobserver variability (not considering agreement with the consensus reference standard):
Streamline C and Streamline L
Outcome Disease status Total (n) Agree (n) Disagree (n)
Streamline C (N = 40)
Primarya Metastatic disease present 25 22 3
Metastatic disease absent 15 13 2
Overall 40 35 5
Equivocal lesions considered positive Metastatic disease present 25 21 4
Metastatic disease absent 15 11 4
Overall 40 32 8
Equivocal lesions considered negative Metastatic disease present 25 22 3
Metastatic disease absent 15 13 2
Overall 40 35 5
Streamline L (N = 43)
Primarya Metastatic disease present 27 17 10
Metastatic disease absent 16 11 5
Overall 43 28 15
Equivocal lesions considered negative Metastatic disease present 27 21 6
Metastatic disease absent 16 11 5
Overall 43 32 11
a Per-participant sensitivity for metastatic disease. Equivocal results considered positive for colonic tumours and negative
for rectal tumours (Streamline C). Equivocal results considered positive (Streamline L).
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